WO2012065057A2

WO2012065057A2 - Phosphatidylinositol 3-kinase inhibitors and methods of their use

Info

Publication number: WO2012065057A2
Application number: PCT/US2011/060361
Authority: WO
Inventors: Dana T. Aftab; Arthur Decillis
Original assignee: Exelixis, Inc.
Priority date: 2010-11-12
Filing date: 2011-11-11
Publication date: 2012-05-18
Also published as: WO2012065057A3

Abstract

The invention relates to methods, combinations, and formulations of a compound of Formula I, particularly Compound A.

Description

PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS AND METHODS OF

THEIR USE

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of priority to U.S. Provisional Application No. 61/413,345, filed November 12, 2010, which is incorporated herein by reference.

FIELD OF THE INVENTION

[0002] This invention relates to the field of protein kinases and inhibitors thereof. In particular, the invention relates to inhibitors of phosphatidylinositol 3-kinase (PI3K) signaling pathways, and methods of their use.

BACKGROUND OF THE INVENTION

[0003] The connection between abnormal protein phosphorylation and the cause or consequence of diseases has been known for over 20 years. Accordingly, protein kinases have become a very important group of drug targets. See Cohen, Nature, 1:309-315 (2002). Various protein kinase inhibitors have been used clinically in the treatment of a wide variety of diseases, such as cancer and chronic inflammatory diseases, including diabetes and stroke. See Cohen, Eur. J. Biochem., 268:5001-5010 (2001).

[0004] The protein kinases are a large and diverse family of enzymes that catalyze protein phosphorylation and play a critical role in cellular signaling. Protein kinases may exert positive or negative regulatory effects, depending upon their target protein. Protein kinases are involved in specific signaling pathways which regulate cell functions such as, but not limited to, metabolism, cell cycle progression, cell adhesion, vascular function, apoptosis, and angiogenesis. Malfunctions of cellular signaling have been associated with many diseases, the most characterized of which include cancer and diabetes. The regulation of signal transduction by cytokines and the association of signal molecules with

protooncogenes and tumor suppressor genes have been well documented. Similarly, the connection between diabetes and related conditions, and deregulated levels of protein kinases, has been demonstrated. See e.g., Sridhar et al. Pharmaceutical Research,

17(1 1):1345-1353 (2000). Viral infections and the conditions related thereto have also been associated with the regulation of protein kinases. Park et al. Cell 101 (7), 777-787 (2000).

[0005] Phosphatidylinositol 3-kinase (PI3K or PIK3CA) is composed of an 85 kDa regulatory subunit and a 1 10 kDa catalytic subunit. The protein encoded by this gene represents the catalytic subunit, which uses ATP to phosphorylate Ptdlns, PtdIns4P and PtdIns(4,5)P2. PTEN, a tumor suppressor which inhibits cell growth through multiple mechanisms, can dephosphorylate PDP3, the major product of PIK3CA. PIP3, in turn, is required for translocation of protein kinase B (AKT1, PKB) to the cell membrane, where it is phosphorylated and activated by upstream kinases. The effect of PTEN on cell death is mediated through the PIK3CA/AKT1 pathway.

[0006] PI3Ka has been implicated in the control of cytoskeletal reorganization, apoptosis, vesicular trafficking, proliferation and differentiation processes. Increased copy number and expression of PIK3CA is associated with a number of malignancies such as ovarian cancer (Campbell et al., Cancer Res 2004, 64, 7678-7681 ; Levine et al., Clin Cancer Res 2005, 11, 2875-2878; Wang et al., Hum Mutat 2005, 25, 322; Lee et al., Gynecol Oncol 2005, 97, 26-34), cervical cancer, breast cancer (Bachman, et al. Cancer Biol Ther 2004, 3, 772-775; Levine, et al., supra; Li et al., Breast Cancer Res Treat 2006, 96, 91-95; Saal et al., Cancer Res 2005, 65, 2554-2559; Samuels and Velculescu, Cell Cycle 2004, 3, 1221-1224), colorectal cancer (Samuels, et al. Science 2004, 304, 554; Velho et al. Eur J Cancer 2005, 41, 1649-1654), endometrial cancer (Oda et al. Cancer Res. 2005, 65, 10669-10673), gastric carcinomas (Byun et al., Int J Cancer 2003, 104, 318-327; Li et al., supra; Velho et al., supra; Lee et al., Oncogene 2005, 24, 1477-1480), hepatocellular carcinoma (Lee et al., id.), small and non-small cell lung cancer (Tang et al., Lung Cancer 2006, 57, 181-191 ; Massion et al., Am J Respir Crit Care Med 2004, 170, 1088-1094), thyroid carcinoma (Wu et al., J Clin Endocrinol Metab 2005, 90, 4688-4693), acute myelogenous leukemia (AML) (Sujobert et al., Blood 1997, 706^", 1063-1066), chronic myelogenous leukemia (CML) (Hickey and Cotter J Biol Chem 2006, 281, 2441-2450), and glioblastomas (Hartmann et al. Acta Neuropathol (Be ) 2005, 109, 639-642; Samuels et al., supra).

[0007] In view of the important role of PBKcc in biological processes and disease states, inhibitors and/or modulators of this protein kinase are desirable.

SUMMARY OF THE INVENTION

[0008] The following only summarizes certain aspects of the invention and is not intended to be limiting in nature. These aspects and other aspects and embodiments are described more fully below. All references cited in this specification are hereby

incorporated by reference in their entirety. In the event of a discrepancy between the express disclosure of this specification and the references incorporated by reference, the express disclosure of this specification shall control. [0009] The invention comprises compounds of Formula I and la that inhibit PI3K and pharmaceutical compositions thereof. The invention is also directed to methods of inhibiting PI3K in a cell, and methods for treating a disease, disorder, or syndrome.

[0010] A first aspect of the invention provides a compound of Formula I:

I

or a pharmaceutically acceptable salt or solvate thereof, where

W¹, W², W³, and W⁴ are -C(R')=; or one or two of W¹, W², W³, and W⁴ are independently - N= and the remaining are -C(R')=; and where each R¹ is independently hydrogen, alkyl, haloalkyl, nitro, alkoxy, haloalkoxy, halo, hydroxy, cyano, amino, alkylamino, or dialkylamino;

R⁵¹ is hydrogen or alkyl;

R⁵² is hydrogen or halo;

R⁵⁰, R⁵³, and R⁵⁴ are independently hydrogen, alkyl, alkenyl, halo, haloalkyl, haloalkenyl, hydroxy, alkoxy, alkenyloxy, haloalkoxy, nitro, amino, alkylamino, dialkylamino, -N(R⁵⁵)C(0)-C|-C₆-alkylene-N(R^55a)R^55b, alkylcarbonyl, alkenylcarbonyl, carboxy, alkoxycarbonyl, cyano, alkylthio, -S(0)₂ R⁵⁵R^55a, or alkylcarbonylamino and where R⁵⁵ and R^55b are indepedently hydrogen, alkyl, or alkenyl and R^55a is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy; or R⁵³ and R⁵⁴ together with the carbons to which they are attached form a 5- or 6-membered heteroaryl or 5- or 6-membered heterocycloalkyl;

B is phenyl substituted with R^3a and optionally further substituted with one, two, or three R³; or

B is heteroaryl optionally substituted with one, two, or three R³;

R^3a is cyano; hydroxyamino; carboxy; alkoxycarbonyl; alkylamino; dialkylamino;

alkylcarbonyl; haloalkoxy; alkylsulfonyl; aminoalkyloxy; alkylaminoalkyloxy;

dialkylaminoalkyloxy; or

a) -N(R⁷)C(0)-C|-C₆-alkylene-N(R^7a)(R^7b) where R⁷ is hydrogen, alkyl, or alkenyl and R^7a and R^7b are independently hydrogen, alkyl, alkenyl, hydroxyalkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyi, aryl, arylalkyl, or arylalkyloxy and where the aryl, cycloalkyl, heterocycloalkyl and heteroaryl rings in R^7a and R^7b (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyi) are independently optionally substituted with 1, 2, or 3 groups independently selected from alky I, amino, alkylamino, dialkylamino, hydroxy, halo, alkoxy, alkylthio, and oxo);

b) -C(0)NR⁸R^8a where R⁸ is hydrogen, hydroxy, alkoxy, alky], alkenyl, haloalkyl, or haloalkoxy and R^8a is hydrogen, alkyl, alkenyl, hydroxyalkyl, cyanoalkyl, alkoxyalkyl, alkylthioalkyl, heterocycloalkyl, heterocycloalkylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyi, aryl, or arylalkyl and where the aryl, cycloalkyl, heteroaryl, and heterocycloalkyl rings in R^8a (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyi) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, alkenyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, oxo, amino, alkylamino, dialkylamino, alkylcarbonyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxycarbonyl, and -C(0)H;

c) -NR⁹C(0)R^9a where R⁹ is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or haloalkoxy and R^9a is hydrogen, C₂.₆-alkyl, alkenyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyi, aryl, or arylalkyl; where the aryl, cycloalkyl, heteroaryl, and heterocycloalkyl rings in R^9a (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyi) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, alkenyl, alkoxy, hydroxy, hydroxyalkyl, halo, haloalkyl, haloalkoxy, oxo, amino, alkylamino, dialkylamino, alkylcarbonyl, alkoxycarbonyl, -C(0)H, aryl (optionally substituted with one or two halo), arylalkyl, heteroaryl, heteroarylalkyi, heterocycloalkyl, heterocycloalkylalkyl, cyloalkyl, cyloalkylalkyl, and cycloalkylcarbonyl;

d) -C(O)N(R¹⁰)-Ci-C₆-alkylene-N(R^10a)R^10b where R^10a is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, or hydroxyalkyl and R¹⁰ and R^10b are independently hydrogen, alkyl, alkenyl, haloalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, or hydroxyalkyl;

e) -NR " C(0)NR ¹¹ "R^{1 lb} where R^{1 la} is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy and R¹¹ and R^{l lb} are independently hydrogen, alkyl, alkenyl, aminoalkyl,

alkylaminoalkyl, or dialkylaminoalkyl; f) -C(0)R¹² where R¹² is heterocycloalkyl optionally substituted with 1, 2, or 3 groups selected from alkyl, oxo, amino, alkylamino, and heterocycloalkylalkyl;

g) -NR¹³C(0)OR^,3a where R¹³ is hydrogen, alkyl, or alkenyl and R^13a is aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aryl, or arylalkyl;

h) -C(0)N(R¹⁴)N(R^14a)(R^14b) where R¹⁴, R^l4a, and R^{1 b} are independently hydrogen, alkyl, or alkenyl;

i) -S(0)₂N(R¹⁵)-C,.C₆-alkylene-N(R^15a)R^15b where R¹⁵, R^15a, and R^15b are

independently hydrogen, alkyl, or alkenyl;

j) -C(0)N(R¹⁶)-C|.C₆-alkylene-C(0)OR^16a where R¹⁶ is hydrogen, alkyl, or alkenyl and R^l6a is alkyl or alkenyl;

k) heteroaryl optionally substituted with one or two aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl;

1) -N(R¹⁷)-C(=N(R^17b)(R^,7a))(NR^17cR^17d) where R¹⁷, R^17a, R^17b, R^17c, and R^17d are

independently hydrogen, alkyl, or alkenyl;

m) -N(R¹⁸)C(0)-C,-C₆-alkylene-N(R^18b)C(0)R^l8a where R^18a is hydrogen, alkyl,

alkenyl, or alkoxy and R¹⁸ and R^18b are independently hydrogen, alkyl, or alkenyl; n) -C(0)N(R¹⁹)-C,-C₆-alkylene-C(0)R^l9a where R¹⁹ is hydrogen, alkyl, or alkenyl and

R^l9a is amino, alkylamino, dialkylamino, or heterocycloalkyl;

o) -N(R²⁰)C(O)-C,-C₆-alkylene-C(O)R^20a where R²⁰ is hydrogen, alkyl, or alkenyl and

R ^0a is cycloalkyl or heterocycloalkyl;

p) -NR²¹S(0)₂R-C|.C₆-alkylene-N(R^21b)R^21a where R²¹ is hydrogen, alkyl, or alkenyl and R^21a and R^2lb are independently hydrogen, alkyl, or alkenyl;

q) -N(R²²)C(0)-C,.C₆-alkylene-N(R ^2b)-N(R^{2 c})(R^22a) where R²², R^22a and R^22b are independently hydrogen, alkyl, or alkenyl;

r) -Co-C6-alkylene-N(R²³)-Ci.C₆-alkylene-N(R²³ )R^23a where R²³, R^23a and R^23b are independently hydrogen, alkyl, or alkenyl; or

s) -NR² C(0)-Ci.C₆-alkylene-OR^24a where R²⁴ is hydrogen, alkyl, or alkenyl and R^24a is alkoxyalkyl or aryl optionally substituted with one or two halo or alkyl; and where each of the alkylene in R^3a is independently optionally further substituted with 1 , 2, 3, 4, or 5 groups selected from halo, hydroxy, amino, alkylamino, and dialkylamino; and

3 3

each R (when R is present) is independently alkyl; alkenyl; alkynyl; halo; hydroxy; oxo; alkoxy; cyano; hydroxyamino; carboxy; alkoxycarbonyl; amino; alkylamino;

dialkylamino; alkylcarbonyl; haloalkoxy; alkylsulfonyl; aminoalkyloxy;

alkylaminoalkyloxy; dialkylaminoalkyloxy; or a) -N(R⁷)C(0)-C C₆-alkylene-N(R^7a)(R^7b) where R⁷ is hydrogen, alkyl, or alkenyl and R^7a and R^7b are independently hydrogen, alkyl, alkenyl, hydroxyalkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, cycloalkyl, cycloalkylalkyi, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, arylalkyl, or arylalkyloxy and where the aryl, cycloalkyl, heterocycloalkyl and heteroaryl rings in R^7a and R^7b (either alone or as part of arylalkyl, cycloalkylalkyi, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, amino, alkylamino, dialkylamino, hydroxy, halo, alkoxy, alkylthio, and oxo);

b) -C(0)NR⁸R^8a where R⁸ is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or haloalkoxy and R^8a is hydrogen, alkyl, alkenyl, hydroxyalkyl, cyanoalkyl, alkoxyalkyl, alkylthioalkyl, heterocycloalkyl, heterocycloalkylalkyl, cycloalkyl, cycloalkylalkyi, heteroaryl, heteroarylalkyl, aryl, or arylalkyl and where the aryl, cycloalkyl, heteroaryl, and heterocycloalkyl rings in R^8a (either alone or as part of arylalkyl, cycloalkylalkyi, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, alkenyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, oxo, amino, alkylamino, dialkylamino, alkylcarbonyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxycarbonyl, and -C(0)H;

c) -NR⁹C(0)R⁹ where R⁹ is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or haloalkoxy and R^9a is hydrogen, C_2-6-alkyl, alkenyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyi, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, or arylalkyl; where the aryl, cycloalkyl, heteroaryl, and heterocycloalkyl rings in R^9a (either alone or as part of arylalkyl, cycloalkylalkyi, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, alkenyl, alkoxy, hydroxy, hydroxyalkyl, halo, haloalkyl, haloalkoxy, oxo, amino, alkylamino, dialkylamino, alkylcarbonyl, alkoxycarbonyl, -C(0)H, aryl (optionally substituted with one or two halo), arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, cyloalkyl, cyloalkylalkyl, and cycloalkylcarbonyl;

d) -C(O)N(R^l0)-Ci-C₆-alkylene-N(R^l0a)R^10b where R^10a is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or hydroxyalkyl and R¹⁰ and R^10b are independently hydrogen, alkyl, alkenyl, haloalkyl, or hydroxyalkyl; e) -NR^UC(0)NR' ^laR' ^lb where R^{1 l} is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy and R¹¹ and R^{l lb} are independently hydrogen, alkyl, alkenyl, aminoalkyl,

alkylaminooalkyl, dialkylaminoalkyl;

f) -C(0)R¹² where R¹² is heterocycloalkyl optionally substituted with 1, 2, or 3 groups selected from alkyl, oxo, amino, alkylamino, and heterocycloalkylalkyl;

g) -NR¹³C(0)OR^13a where R¹³ is hydrogen, alkyl, or alkenyl and R^13a is aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aryl, or arylalkyl);

h) -C(0)N(R¹⁴)N(R^14a)(R^14b) where R¹⁴, R^l4a, and R¹⁴ are independently hydrogen, alkyl, or alkenyl;

i) -S(0)₂N(R¹⁵)-C_1-C₆-alkylene-N(R^{1 a})R^15b where R¹⁵, R^l5a, and R^15b are

independently hydrogen, alkyl, or alkenyl;

1) -N(R¹⁷)-C(=N(R¹⁷ )(R^17a))( R^l7cR^17d) where R¹⁷, R^,7a, R^17b, R^17c, and R^17d are independently hydrogen, alkyl, or alkenyl;

m) -N(R¹⁸)C(0)-C,-C₆-alkylene-N(R^{l 8b})C(0)R^18a where R^18a is hydrogen, alkyl,

alkenyl, or alkoxy and R¹⁸ and R^l8b are independently hydrogen, alkyl, or alkenyl; n) -C(0)N(R¹⁹)-Ci-C₆-alkylene-C(0)R^19a where R¹⁹ is hydrogen, alkyl, or alkenyl and

R^l9a is amino, alkylamino, dialkylamino, or heterocycloalkyl;

o) -N(R²⁰)C(O)-Ci-C₆-alkyIene-C(O)R^20a where R²⁰ is hydrogen, alkyl, or alkenyl and

R^20a is cycloalkyl or heterocycloalkyl;

p) -NR²¹S(0)₂R-C,.C₆-alkylene-N(R^21b)R^21a where R²¹ is hydrogen, alkyl, or alkenyl and R^21a and R ^1b are independently hydrogen, alkyl, or alkenyl;

q) -N(R² )C(0)-C,.C₆-alkylene-N(R^22b)-N(R^22c)(R^{2 a}), where R²², R^22a and R^22b are independently hydrogen, alkyl, or alkenyl;

r) -Co-C6-alkylene-N(R²³)-C,.C₆-alkylene-N(R^{2 b})R ^3a where R²³, R^23a and R^23b are independently hydrogen, alkyl, or alkenyl; or

s) -NR²⁴C(0)-C|.C₆-alkylene-OR^24a where R²⁴ is hydrogen, alkyl, or alkenyl and R^24a is alkoxyalkyl or aryl optionally substituted with one or two halo or alkyl;

wherein each of the alkylene in R³ is independently optionally further substituted with 1 , 2, 3, 4, or 5 groups selected from halo, hydroxy, amino, alkylamino, and dialkylamino; provided that when R⁵⁰ and R⁵² are hydrogen, R⁵¹ is hydrogen or methyl, R⁵³ is hydrogen or methoxy, and R⁵⁴ is hydrogen or methoxy, then B is not 2,3-dihydro-l,4- benzodioxinyl, thien-2-yl, or thien-2-yl substituted with one R³ where R³ is halo.

[0011] A second aspect of the invention provides a compound of Formula Π:

II

or a pharmaceutically acceptable salt or solvate thereof, wherein

W¹, W², W³, and W⁴ are -C(R^la)=; or one or two of W¹, W², W³, and W⁴ are independently

-N= and the remaining are -C(R^la)=;

X¹ is -N(R^5a)-;

A is aryl, -S(0)₂-aryl, heteroaryl, cycloalkyl, heterocycloalkyi, halo, haloalkyl, haloalkoxy, alkyl, alkoxy, or -alkyl-N(R⁷)R^7a, where each of the aryl, heteroaryl, cycloalkyl, heterocycloalkyi, alkyl and alkoxy groups, each either alone or as part of another group within A, are independently optionally substituted with one, two, three, or four R^2a; or

B¹ is aryl, arylalkyl, alkyl, heteroaryl, or heteroaryalkyl, wherein each of the aryl, heteroaryl and alkyl groups are independently optionally substituted with one, two, three, or four R^3d;

each R^la is independently selected from hydrogen, alkoxy, alkyl, nitro, halo, cyano, and -Co- C₆-alkyl-N(R⁷)R^7a, wherein each of the alkyl and alkoxy groups is optionally substituted with 1, 2, 3, 4, or 5 groups selected from alkyl, alkoxy, halo, haloalkyl, haloalkoxy, nitro, cyano, hydroxy, -N(R⁸)R^8a, and -C(0)OR⁶;

each R^2a (when R²³ is present) is independently selected from alkyl, alkenyl, -alkenyl- C(0)OR⁶, -OR⁶, -N(R⁷)C(0)R⁶, -N(R⁷)C(O)-C₀-C₆ alkyl-N(R^7b)R^7a, -OC(O)-C₀-C₆ alkyl-N(R⁷)R^7a, -N(R⁷)C(0)-C_rC₆ alkylC(0)OR⁶, C₀-C₆-aIkyl-C(O)R⁶ oxo, dioxo, -S(0)₂-N(R⁷)R^7a, -C(0)OR⁶, -CH(R⁶)₂-C(0)OR⁶, -S(0)₂R⁶, cycloalkyl,

heterocycloalkyi, heteroaryl, -C(0)N(R⁷)-alkyl-OR⁶, -C₀-C₆ alkyl-C(O)N(R⁷)-C₀-C₆- alkyl-C(0)OR⁶, -C₀-C₆-alkyl-C(O)N(R⁷)R^7a, aryl, arylalkyl, -S-(d-C₆ alkyl), halo, oxo, nitro, -SCN, cyano, and -Co-C₆ alkyl-N(R⁷)R^7a, wherein each of the alkyl

(including, for example the alkyl within alkoxy), aryl, cycloalkyl, heterocycloalkyi, and heteroaryl groups, either alone or as part of another group within R , is independently optionally substituted with 1 , 2, 3, 4, or 5 groups selected from alkyl, halo, haloalkyl, haloalkoxy, oxo, nitro, cyano, hydroxy, -N(R⁸)R^8a, alkoxy, and -C(0)OR⁹;

each R^3d (when R^3d is present) is independently oxo, nitro, halo, cyano, alkyl, alkenyl,

alkynyl, alkoxy, C₃-C₆-cycloalkyl, -Co-C₆-alkyl-heterocycIoalkyl, -Co-C₆ alkyl- N(R⁷)C(O)-C₀-C₆-alkyl-N(R^7b)R^7a, -C C₆ alkyl-N(R⁷)C(O)-C₀-C₆-alkyl- N(R^7b)C(0)R^7a, -C₀.C₆ alkyl-C(O)-C_0-C₆-alkyl-N(R⁷)R^7a, -Co.C₆-alkyl-C(0)N(R⁷)-Co- C₆-alkyl-N(R^7b)R^7a, -C₀-C₆-alkyl-C(O)N(R⁷)-C,-C6alkylC(O)OR^7a, -C₀-C₆ alkyl- N(R⁷)C(O)-C₀-C₆-alkyl-(R^7a), -Co-C₆ alkyl-N(R⁷)-C₀-C₆-alkyl-N(R^7b)R^7a, -Co-C₆ alkyl- N(R⁷)C(0)-C₀-C6-alkyl-N(R^7b)-N(R^7c)R^7a, -Co.C₆ alkyl-N(R⁷)C(0)0-Co-C6-alkyl-aryl, -Co-C₆ alkyl-C(O)N(R⁷)-C₀-C₆-alky l-N(R^7b)R^7a, -Co-C₆ alkyl-N(R⁷)-C₀-C₆ alkyl- C(=N(R^7b)(R^7a))(NR^7cR^7d), -Co.C₆-alkyl-aryl, -C₀-C₆-alkyl-heteroaryl, -C₀-C₆ alkyl- heterocycloalkyl, -0-Co-C₆ alkyl-N(R⁷)R⁷ , -C₀-C₆ alkyl-OR₆, -C₀-C₆ alkyl-C(0)OR₆₎ C₀-C₆-alkyl-N(R⁷)R^7a, -C₀-C₆ alkyl-C(0)NR₇R^7a, -C₀-C₆ alkyl-C(0)R⁷, -SR₇, -S(0)₂R₇, -S(0)₃R₇, -S(0)R⁷, -S0₂N(R⁷)R^7a, -S0₂N(R⁷)-Co-C₆ alkyl-N(R^7b)R^7a, -C₀-C₆-alkyl- N(R⁷)-aryl, -C₀-C₆-atkyl-N(R⁷)-heteroaryl, -C₀-C₆-alkyl-N(R⁷)-heterocycloalkyl, -Co-C₆-alkyl-C(0)N(R⁷)-Co-C₆-alkyl-cycloalkyl, C₀-C₆-alkyl-C(O)N(R⁷)-C₀-C₆-aIkyl- aryl, C₀-C₆ alkyl-C(O)N(R⁷)-C₀-C₆ alkyl-heteroaryl, C₀-C₆ alkyl-C(O)N(R⁷)-C₀-C₆- alkyl-heterocycloalkyl, -C₀-C₆-alkyl-N(R⁷)C(O)-C₀-C₆-alkyl-cycloalkyl, -C₀-C₆-alkyl- N(R⁷)C(O)-C₀-C₆-alkyl-aryl, Co-C₆-alkyl-N(R⁷)C(0)-C₀-C₆-alkyl-heteroaryl, -Co-Ce- alkyl-N(R⁷)C(0)-Co-C₆-alkyl-heterocycloalkyl, Co-C₆-alkyl-N(R⁷)C(0)-Co-C₆-alkyl- heterocycloalkyl-aryl, -N(R⁷)C(0)OR⁶, or -NHC(0)H, wherein each of the alkyl, alkenyl, cycloalkyl, aryl, (including, for example the alkyl within alkoxy),

heterocycloalkyl, and heteroaryl groups, either alone or as part of another group within R^3d, is independently optionally substituted with 1, 2, 3, 4, or 5 groups selected from alkyl, alkenyl, -C₀-C₆-alkyl-OR⁹, cycloalkyl, halo, haloalkyl, haloalkoxy, -C(0)R⁹, nitro, cyano, oxo, -Co-C6-alkyl-N(R⁸)R^8a, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C(0)OR⁹, alkylthio, and hydroxyalkyl;

R⁴ is hydrogen, aryl, -C₀-C₆-alkyl-N(R⁷)R^7a, alkoxy, or Ci-C₆ alkyl, wherein each of the alkyl and aryl groups, either alone or as part of another group in R⁴, is independently optionally substituted with 1, 2, 3, 4, or 5 groups selected from alkyl, halo, haloalkyl, haloalkoxy, nitro, cyano, hydroxy, -N(R⁸)R^8a, alkoxy, and -C(0)OR⁶; or

R⁴ and X¹ together with the atoms to which they are attached form a heterocycloalkyl or heteroaryl group, wherein R^5a is absent when X is -N(R^5a)-, wherein each of the heterocycloalkyl or heteroaryl is optionally substituted with 1, 2, 3, 4, or 5 groups selected from alkyl, halo, haloalkyl, haloalkoxy, nitro, cyano, hydroxy, -N(R⁷)R^7a, alkoxy, and -C(0)OR⁶;

R^5a is hydrogen, -C_rC₆ alkyl-N(R⁷)R^7a, alkoxy, alkyl, or aryl, wherein each of the alkyl and aryl is optionally substituted with 1, 2, 3, 4, or 5 groups selected from alkyl, halo, haloalkyl, haloalkoxy, nitro, cyano, hydroxy, -N(R⁸)R^8a, C|-C₆ alkoxy, or -C(0)OR⁶; or

R^5a and R⁴ together with the atoms to which they are attached form a heterocycloalkyl or heteroaryl group, wherein the heterocycloalkyl and heteroaryl is optionally substituted with 1, 2, 3, 4, or 5 groups selected from alkyl, halo, haloalkyl, haloalkoxy, nitro, cyano, hydroxy, -N(R⁷)R^7a, C,-C₆ alkoxy, and -C(0)OR⁶;

R⁶ and R⁹ are independently hydrogen, hydroxy, alkyl, aryl, arylalkyl, cycloalkyl,

cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, or aryl, each alkyl, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl, either alone or as part of another group within R⁶ and R⁹, is independently optionally substituted with 1 , 2, 3, 4, or 5 groups independently selected from amino, hydroxy, alkoxy, alkyl, and halo; and

R⁷, R^7a R⁷ , R^7c, R^7d, R⁸, and R⁸ are independently hydrogen, alkyl, alkenyl, hydroxy, alkyloxy, alkenyloxy, -O-C₀-C₆ alkyl-aryl, -C₀-C₆ alkyl-C(0)OR⁶, -C₀-C₆ alkyl- C(0)R⁶, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, or heterocycloalkylalkyl, wherein each of the alkyl, aryl, heteroaryl, and heterocycloalkyl, either alone or part of another group within R⁷, R^7a R⁷ , R^7c, R^7d, R⁸, and R^8a is independently optionally substituted with 1, 2, 3, 4, or 5 groups selected from amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl,

dialkylaminoalkyl, -S-Ci-C₆ alkyl, cyano, nitro, hydroxy, C|-C₆ alkoxy, C|-C₆ alkyl, halo, aryl, heterocycloalkylalkyl, and heteroaryl optionally substituted with one or two Ci-C₆ alkyl.

[0012] The compounds of Formula I, la and II (including Compound A described below) are disclosed in WO 07/044729 and WO 08/127594, the entire contents of each of which are incorporated herein by reference.

[0013] In a third aspect, the invention is directed to a pharmaceutical composition which comprises a compound of Formula I or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, excipient, or diluent.

[0014] In a fourth aspect, the invention comprises a method of inhibiting PI3K in a cell, comprising contacting a cell with a compound of Formula I or Π or a pharmaceutically acceptable salt or solvate thereof, or with a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I and a pharmaceutically acceptable carrier, excipient, or diluent.

[0015] In a fifth aspect, the Invention provides a method for treating a disease, disorder, or syndrome which method comprises administering to a patient a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I or II or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, la, or II and a pharmaceutically acceptable carrier, excipient, or diluent.

[0016] A sixth aspect of the invention is directed to a process of preparing a compound of Formula I, comprising:

(a) reacting an intermediate of :

5

where LG is a leaving group such as chloro, and all other groups, are as defined in the Summary of the Invention, with an intermediate of formula NHR^aR^b or HO-C|-C₆- alkylene- HR^aR^b where R^a and R^b are independently hydrogen or alkyl to yield, respectively,

1(c) ; and

1(d); or

(b) reacting an intermediate of formula 8

8

where R^a is R⁷, R⁹, R¹¹, R¹³, R¹⁷, R¹⁸, R²⁰, R²¹, R²², or R²⁴, each as defined in the Summary of the Invention for a Compound of Formula I and all other groups are as defined in the Summary of the Invention;

with an intermediate of formula 9(a), 9(b), 9(c), 9(d), 9(e), 9(f), or 9(g):

9(a) HOC(0)-Ci-C₆-alkylene-N(R^7a)(R^7b) where R^a is R^7a or a N-protecting

group, such as Boc or Fmoc;

9(b) HOC(0)R^9a;

9(c) HOC(0)NR^{1 ,a}R^{l lb};

9(d) HOC(0)OR^13a;

9(e) HOC(0)-C_rC₆-aIkylene-N(R^18b)C(0)R^18a;

9(f) HOC(O)-Ci-C₆-alkylene-C(O)R^20a;

9(g) LG-S(0)₂R-C,.C₆-alkylene-N(R^21b)R^a where R^a is R^21a or a N-protecting group, such as Boc or Fmoc;

to yield

1(e)

where R¹⁰⁰ is -C(0)R^9a, -C(0)NR^UaR^nb, -C(0)OR^13a, -C(0)-C,-C₆-alkylene- N(R^18b)C(0)R^i8a, -C(O)-C,-C₆-alkylene-C(O)R^20a, or -S(0)₂R-C,.C₆-alkylene-N(R^21b)R^a; or (c) reacting an intermediate of formula 1 1

11

with one of the following intermediates NHR⁸R^8a, NH(R¹⁰)-Ci-C6-alkylene-N(R' a cyclic amine, NH(R¹⁴)N(R^14a)(R^l4b), NH(R¹⁶)-Ci-C₆-alkylene-C(0)OR¹⁶\ and

NH(R¹⁹)-Ci-C₆-alkylene-C(0)R^19a to yield a Compound of Formula I; or

(d) reacting an intermediate of formula 12:

12

with an intermediate of formula NH(R )R to yield a Compound of Formula 1(f):

1(f); or

(e) reacting an intermediate of formula 13 where LG is a leaving group, such as chloro, and all other groups are as defined in the Summary of the Invention:

13

with an intermediate of formula:

to yield a Compound of Form

1(h); and

(f) optionally further resolving individual isomers.

[0017] In an embodiment, Compound A is the Compound of Formula I in each of the above aspects.

[0018] An additional aspect relates to a method for treating a disease, disorder, or syndrome which method comprises administering to a patient a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I or II or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, la, or Π and a pharmaceutically acceptable carrier, excipient, or diluent, in combination with one or more agent. In an embodiment, Compound A is the Compound of Formula I in this aspect. The additional agent or agents are listed below:

Agent Name Source

(R)-(-)-Gossypol acetic acid (AT- 101) Ascenta Therapeutics

1 -Methyl-[D]-tryptophan NewLinkGenetics

506U78 GlaxoSmithKline

ABT-263 Abbott Laboratories

ABT-888 Abbott Laboratories

AFP464 (aminoflavone prodrug) Tigris Pharmaceuticals Inc

ARQ-197 Arqule

ATI 3387 Astex Agent Name Source

Azacitidine Celgene Corporation

AZD0530 AstraZeneca Pharmaceuticals

Belinostat (PXD 101) TopoTarget

BMS 247550 (ixabepilone, Ixempra) Bristol-Myers Squibb

Bortezomib (PS-341; Velcade) Millennium, a Takeda Company

CC-5013 (lenalidomide, Revlimid) Celgene Corporation ch 14.18 National Cancer Institute

Decitabine (5-aza-2'-deoxycytidine) Eisai Inc

E7389 (Halichondrin B Analog) Eisai Inc

EMD 121974 (Cilengitide) Merck KgaA

Entinostat (MS-275, SNDX-275) Syndax

FK228 (Depsipeptide; Romidepsin) Celgene Corporation

Flavopiridol (alvocidib) Sanofi Aventis

GDC-0449 *** Genentech Inc

J C-A12 Imclone

MDX-010 (MDX-CTLA4; Hybridoma- Medarex Inc

derived and Transfectoma-derived)

MK-2206 Merck and Company Inc

O-6-Benzylguanine NCI

Obatoclax mesylate (GX15-070MS) GeminX Pharmaceuticals

OSI-906 OSI Pharmaceuticals

Pertuzumab Genentech Inc

Rl 15777 (tipifarnib, Zarnestra) Johnson & Johnson

Reolysin Oncolytics Biotech Inc

RO4929097 Roche

SB-715992 (ispinesib) Cytokinetics

SCH727965 Schering-Plough

SJG-136 Spirogen

Thalidomide (Thalomid) Celgene Corporation

Triapine

UCN-01 Kyowa Hakko Kirin

VEGF-Trap (aflibercept) Sanofi Aventis

Vorinostat (suberoylanilide hydroxamic Merck and Company Inc acid; SAHA)

XK469R National Cancer Institute

17-AAG BMS

17-DMAG BMS

Alemtuzumab (Campath) Genzyme

AZD2171 (cediranib; Recentin™) AstraZeneca Pharmaceuticals

AZD6244 AstraZeneca Pharmaceuticals

BAY 43-9006 tosylate (BAY 54-9085; Bayer Corporation

sorafenib tosylate)

Bevacizumab (rhuMAb VEGF, Avastin) Genentech Inc

BMS-354825 (dasatinib, Sprycel) Bristol-Myers Squibb

CCI-779 (temsirolimus, Torisel) Pfizer, inc

Erlotinib (OSI-774; Tarceva) OSI Pharmaceuticals

Gefitinib (ZD 1839, Iressa) AstraZeneca Pharmaceuticals

GM-CSF (sargramostim, Leukine) Genzyme Agent Name Source

GW572016 (lapatinib) GlaxoSmithKline

GW786034 (pazopanib) GlaxoSmithKline

MLN 518 Millennium Pharmaceuticals

Oxaliplatin (Eloxatin) Sanofi Aventis

Perifosine Keryx Biopharmaceuticals

Rituximab (MoAb C2B8 anti CD20, Biogen Idee

chimeric)

STI571 (imatinib, Gleevec) Novartis Pharmaceuticals

Corporation

Sunitinib malate (SUOl 1248 L-malate; Pfizer Inc

Sutent)

Trastuzumab (Herceptin) Genentech Inc

More preferably, the additional agent or agents are selected from the following

Agent Name Source

(RM-)-Gossypol acetic acid (AT- 101) Ascenta Therapeutics

1 -Methy l-[D]-tryptophan NewLinkGenetics

506U78 GlaxoSmithKline

ABT-263 Abbott Laboratories

ABT-888 Abbott Laboratories

AFP464 (aminoflavone prodrug) Tigris Pharmaceuticals Inc

ARQ-197 Arqule

AT13387 Astex

Azacitidine Celgene Corporation

AZD0530 AstraZeneca Pharmaceuticals

Belinostat (PXD 101) TopoTarget

BMS 247550 (ixabepilone, Ixempra) Bristol-Myers Squibb

Bortezomib (PS-341; Velcade) Millennium, a Takeda Company

CC-5013 (lenalidomide, Revlimid) Celgene Corporation

ch 14.18 National Cancer Institute

Decitabine (5-aza-2'-deoxycytidine) Eisai Inc

E7389 (Halichondrin B Analog) Eisai Inc

EMD 121974 (Cilengitide) Merck KgaA

Entinostat (MS-275, SNDX-275) Syndax

FK228 (Depsipeptide; Romidepsin) Celgene Corporation

Flavopiridol (alvocidib) Sanofi Aventis

GDC-0449 *** Genentech Inc

IMC-A12 Imclone

MDX-010 (MDX-CTLA4; Hybridoma- Medarex Inc

derived and Transfectoma-derived)

MK-2206 Merck and Company Inc

O-6-Benzylguanine NCI

Obatoclax mesylate (GX1 -070MS) GeminX Pharmaceuticals

OSI-906 OSI Pharmaceuticals

Pertuzumab Genentech Inc

Rl 15777 (tipifarnib, Zarnestra) Johnson & Johnson Agent Name Source

Reolysin Oncolytics Biotech Inc

RO4929097 Roche

SB-715992 (ispinesib) Cytokinetics

SCH727965 Schering-Plough

SJG-136 Spirogen

Thalidomide (Thalomid) Celgene Corporation

Triapine

UCN-01 Kyowa Hakko Kirin

VEGF-Trap (aflibercept) Sanofi Aventis

Vorinostat (suberoylanilide hydroxamic Merck and Company Inc

acid; SAHA)

XK469R National Cancer Institute

17-AAG BMS

[0020] More preferably, the additional agent or agents are selected from ABT-888, AZD6244, CCI-779, erlotinib, gefitinib, GW572016, GW786034, pertuzumab, or sunitinib.

[0021] An additional aspect relates to a method for treating a disease selected from anaplastic thyroid cancer, chronic lymphocytic leukemia, mantel cell lymphoma, non- Hodgkins lymphoma, glioblastoma multiforme, pediatric brain tumors, pontine glioma, HPV-related head and neck cancer, Hormone Receptive positve (HR+) breast cancer, and HER-2 overexpressing breast cancer, comprising adminstering a therapeutically effective amount of a compound of Formula I or II or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, la, or lit. In an embodiment, Compound A is the Compound of Formula I in this aspect.

[0022] An additional aspect relates to a method for treating a disease selected from anaplastic thyroid cancer, chronic lymphocytic leukemia, mantel cell lymphoma, non- Hodgkins lymphoma, glioblastoma multiforme, pediatric brain tumors, pontine glioma, HPV-related head and neck cancer, Hormone Receptive positve (HR+) breast cancer, and HER-2 overexpressing breast cancer, comprising adminstering a therapeutically effective amount of a compound of Formula I or II or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, la, or II and a pharmaceutically acceptable carrier, excipient, or diluent, in combination with another agent. In an embodiment, Compound A is the Compound of Formula I in this aspect. In another embodiment, Compound A is the Compound of Formula I and the additional agent or agents is selected from the group consisting of ABT-888, AZD6244, CCI-779, erlotinib, gefitinib, GW572016, GW786034, pertuzumab, and sunitinib. [0023] An additional aspect relates to a tablet formulation of a compound of formula I. The tablet formulation is the following formulations or an equivalent thereof. Compound A is the Compound of Formula I in this aspect.

Ingredient Theoretical Quantity (mg unit dose)

100 mg 150 mg 200 mg

Com ound A 100.0 150.0 200.0

Silicified 29.5 44.3 59.0

miciOcrystalline

cellulose

Partially pregelatmized 40.0 60.0 80.0

maize starch

Sodium starch glycolate 14.0 21.0 28.0

Hypromellose 2910 12.0 18.0 24.0

Colloidal silicon dioxide 2.0 3.0 4.0

Stearic acid 2.0 3.0 4.0

Magnesium stearate 0.5 0.75 1.0

a 3 a

Purified water

a Means essentially removed during manufacture

[0024] In one embodiment, the pharmaceutical composition is a tablet solid dosage form such as one of the above, as a 100, 150, 200, or 400 mg tablet. In one embodiment, the Compound A dosage form is a 400 mg tablet qd.

[0025] An additional aspect relates to a capsule formulation as, for instance a powder- in-capsule (PiC) formulation comprising a compound of formula I. The tablet formulation can be one of the following formulations or an equivalent thereof. Compound A is the Compound of Formula I in this aspect.

Gray Opaque White Opaque Swedish Orange Capsule Capsule Capsule

Component (for 5 mg strength) (far 25 mg strength) (for 100 ing strength)

FDA/El 71 Titanium Dioxide 2.7074% 2.9079% 0.4902%

FDA/ El 72 Black Iron Dioxide 0.3075% — —

FDA/E 172 Red Iron Dioxide — — 1.4706%

Gelatin qsp 100% qsp 100% qsp 100% qsp. quantity sufficient for preparation DETAILED DESCRIPTION OF THE INVENTION

Abbreviations and Definitions

The following abbreviations and terms have the indicated meanings throughout:

Abbreviation Meaning

br broad

°C degrees Celsius

CBZ CarboBenZoxy = benzyloxycarbonyl

d doublet

dd doublet of doublet

dt doublet of triplet

EI Electron Impact ionization

Et Ethyl

g gram(s)

GC gas chromatography

h or hr hour(s)

HPLC high pressure liquid chromatography

L liter(s)

M molar or molarity

m Multiplet

mg milligram(s)

MHz megahertz (frequency)

Min minute(s)

mL milliliter(s)

mM Millimolar

mmol millimole(s)

mol mole(s)

MS mass spectral analysis

N normal or normality

nM Nanomolar

NMR nuclear magnetic resonance spectroscopy

q Quartet

RT Room temperature Abbreviation Meaning

[0027] The symbol "-" means a single bond, "=" means a double bond, "≡" means a triple bond, and " means a single bond and optionally a double bond. When chemical structures are depicted or described, unless explicitly stated otherwise, all carbons are assumed to have hydrogen substitution to conform to a valence of four.

[0028] "Administration" and variants thereof (e.g., "administering" a compound) in reference to a compound of the invention means introducing the compound or a prodrug of the compound into the system of the animal in need of treatment. When a compound of the invention or prodrug thereof is provided in combination with one or more other active agents (e.g., surgery, radiation, and chemotherapy, etc.), "administration" and its variants are each understood to include concurrent and sequential introduction of the compound or prodrug thereof and other agents.

[0029] "Alkenyl" or "lower alkenyl" means a straight or branched hydrocarbon radical having from 2 to 6 carbon atoms and at least one double bond and includes ethenyl, propenyl, l-but-3-enyl, l-pent-3-enyl, l-hex-5-enyl and the like.

[0030] "Alkenylcarbonyl" means a C(0)R group where R is alkenyl, as defined herein.

[0031] "Alkenyloxy" or "lower alkenyloxy" means an -OR group where R is alkenyl, as defined herein. Representative examples include methoxy, ethoxy, 1-methoxyprop-l-en-

3-yl, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy and the like.

[0032] "Alkoxy" or "lower alkoxy" means an -OR group where R is alkyl, as defined herein. Representative examples include methoxy, ethoxy, l-methoxyprop-l-en-3-yl, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy and the like.

[0033] "Alkoxyalkyl" means an alkyl group, as defined herein, substituted with one, two, or three alkoxy groups, as defined herein. [0034] "Akoxycarbonyl" means a -C(0)OR group where R is alkyl as defined herein.

[0035] "Alkoxyycarbonylalkyl" means an alkyl group, as defined herein, substituted with one, two, or three alkoxycarbonyl groups, as defined herein.

[0036] "Alkyl" or "lower alkyl" means a linear or branched hydrocarbon group having one to six carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, s-butyl, ί-butyl, isobutyl, pentyl, hexyl and the like. A "Co" alkyl (as in "Co-Ce-alkyl") is a covalent bond. "C₆ alkyl" refers to, for example, n-hexyl, wo-hexyl, and the like.

[0037] "Alkylamino" means a -NHR radical where R is alkyl as defined herein, or an N-oxide derivative thereof, e.g., methylamino, ethylamino, n-, wo-propylamino, n-, iso-, tert-butylamino, or methylamino-N-oxide, and the like.

[0038] "Alkylaminoalkyl" means an alkyl group substituted with one or two alkylamino groups, as defined herein.

[0039] "Alkylaminoalkyloxy" means an -OR group where R is alkylaminoalkyl, as defined herein.

[0040] "Alkylcarbonyl" means a C(0)R group where R is alkyl, as defined herein.

[0041] "Alkylcarbonylamino" means a -NRC(0)R' group where R is hydrogen or alkyl, as defined herein, and R' is alkyl, as defined herein.

[0042] "Alkylene" refers to straight or branched divalent hydrocarbon, containing no unsaturation and having from two to eight carbon atoms. Examples of alkylene include eth- diyl (-CH₂CH₂-), prop- l,3-diyI (-CH₂CH₂CH₂-), 2,2-dimethylprop- l,3-diyl (-CH₂C(CH₃)₂CH₂-), and the like.

[0043] "Alkylsulfonyl" means a -S(0)₂R group where R is lakyl, as defined herien.

[0044] "Alkylthio" means a -SR group where R is alkyl, as defined herein. Examples of alkylthio include methylthio and ethylthio, and the like.

[0045] "Alkylthioalkyl" means an alkyl group substituted with one or two alkylthio groups, as defined herein, e.g. 2-(methylthio)-ethyl and 2-(ethylthio)-ethyl.

[0046] "Alkynyl" or "lower alkynyl" means a straight or branched hydrocarbon radical having from 2 to 6 carbon atoms and at least one triple bond and includes ethynyl, propynyl, butynyl, pentyn-2-yl and the like.

[0047] "Amino" means a - H₂.

[0048] "Aminoalkyl" means an alkyl group substituted with at least one, specifically one, two, or three, amino groups. [0049] "Aminoalkyloxy" means an -OR group where R is aminoalkyl, as defined herein.

[0050] "Aryl" means a monovalent six- to fourteen-membered, mono- or bi-carbocyclic ring, wherein the monocyclic ring is aromatic and at least one of the rings in the bicyclic ring is aromatic. Representative examples include phenyl, naphthyl, and indanyl, and the like.

[0051] "Arylalkyi" means an alkyl group, as defined herein, subsituted with one or two aryl groups, as defined herein. Examples include benzyl, phenethyl, phenylvinyl, phenylallyl and the like.

[0052] "Aryloxy"means a -OR group where R is aryl as defined herein.

[0053] "Arylalkyloxy" means a -OR group where R is arylalkyi as defined herein.

[0054] "Arylsulfonyl" means a -S0₂R group where R is aryl as defined herein.

[0055] "Carboxyalkyl" means an alkyl group, as defined herein, substituted with one, two, or three -C(0)0H groups.

[0056] "Carboxy ester" means a -C(0)OR group where R is lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, aryl or arylalkyi, each of which is defined herein. Representative examples include methoxycarbonyl, ethoxycarbonyl, and benzyloxycarbonyl, and the like.

[0057] "Cyanoalkyl" means an alkyl, alkenyl, or alkynyl radical, as defined herein, substituted with at least one, specifically one, two, or three, cyano groups.

[0058] "Cycloalkyl" means a monocyclic or polycyclic hydrocarbon radical having three to thirteen carbon atoms. The cycloalkyl can be saturated or partially unsaturated, but cannot contain an aromatic ring. Cycloalkyl includes fused, bridged, and spiro ring systems. Examples of such radicals include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

[0059] "Cycloalkylalkyl" means alkyl group substituted with one or two cycloalkyl group(s), as defined herein. Representative examples include cyclopropylmethyl and 2- cyclobutyl-ethyl, and the like.

[0060] "Cycloalkylcarbonyl" means a -C(0)R group where R is cycloalkyl as defined herein.

[0061] "Dialkylamino" means a -NRR' radical where R and R' are independently alkyl as defined herein, or an N-oxide derivative, or a protected derivative thereof, e.g., dimethylamino, diethylamino, N,N-methylpropylamino or N,N-methylethylamino, and the like. [0062] "Dialkylaminoalkyl" means an alkyl group substituted with one or dialkylamino group(s), as defined herein.

[0063] "Dialkylaminoalkyloxy" means an -OR group where R is dialkylaminoalkyl, as defined herein.

[0064] "Fused ring system" and "fused ring" refer to a polycyclic ring system that contains bridged or fused rings; that is, where two rings have more than one shared atom in their ring structures. In this application, fused-polycyclics and fused ring systems are not necessarily all aromatic ring systems. Typically, but not necessarily, fused-polycyclics share a vicinal set of atoms, for example naphthalene or 1,2,3,4-tetrahydro-naphthalene. A spiro ring system is not a fused-polycyclic by this definition, but fused polycyclic ring systems of the invention may themselves have spiro rings attached thereto via a single ring atom of the fused-polycyclic. In some examples, as appreciated by one of ordinary skill in the art, two adjacent groups on an aromatic system may be fused together to form a ring structure. The fused ring structure may contain heteroatoms and may be optionally substituted with one or more groups. It should additionally be noted that saturated carbons of such fused groups (Le. saturated ring structures) can contain two substitution groups.

[0065] "Haloaloxy" means an -OR' group where R' is haloalkyl as defined herein, e.g., trifluoromethoxy or 2,2,2-trifluoroethoxy, and the like.

[0066] "Haloalkoxyalkyl" means an alkyl group, as defined herein, substituted with one, two, or three haloalkoxy, as defined herein.

[0067] "Halogen" or "halo" means fluoro, chloro, bromo and iodo.

[0068] "Haloalkenyl means an alkenyl group, as defined herein, substituted with one or more halogens, specifically one to five halo atoms.

[0069] "Haloalkyl" means an alkyl group, as defined herein, substituted with one or more halogens, specifically one to five halo atoms. Representative examples includes 2,2- difluoroethyl, trifluoromethyl, and 2-chloro-l-fluoroethyl, and the like.

[0070] "Heteroaryl" means a monocyclic, fused bicyclic, or fused tricyclic, monovalent radical of 5 to 14 ring atoms containing one or more, specifically one, two, three, or four ring heteroatoms independently selected from -0-, -S(0)„- (n is 0, 1, or 2), -N-, -N(R^X)-, and the remaining ring atoms being carbon, wherein the ring comprising a monocyclic radical is aromatic and wherein at least one of the fused rings comprising a bicyclic or tricyclic radical is aromatic. One or two ring carbon atoms of any nonaromatic rings comprising a bicyclic or tricyclic radical may be replaced by a -C(O)-, -C(S)-, or -C(=NH)- group. R^x is hydrogen, alkyl, hydroxy, alkoxy, acyl, or alkylsulfonyl. Fused bicyclic radical includes bridged ring systems. Unless stated otherwise, the valency may be located on any atom of any ring of the heteroaryl group, valency rules permitting. In particular, when the point of valency is located on the nitrogen, R^x is absent. More specifically, the term heteroaryl includes, but is not limited to, 1 ,2,4-triazolyl, 1,3,5-triazolyl, phthalimidyl, pyridinyl, pyrrolyl, imidazolyl, thienyl, furanyl, indolyl, 2,3-dihydro- lH-indolyl (including, for example, 2,3-dihydro- lH-indol-2-yl or 2,3-dihydro- lH-indol-5-yl, and the like), isoindolyi, indolinyl, isoindolinyl, benzimidazolyl, benzodioxol-4-yl, benzofuranyl, cinnolinyl, indolizinyl, naphthyridin-3-yl, phthalazin-3-yl, phthalazin-4-yl, pteridinyl, purinyl, quinazolinyl, quinoxalinyl, tetrazoyl, pyrazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, isooxazolyl, oxadiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl,

tetrahydroisoquinolinyl (including, for example, tetrahydroisoquinolin-4-yl or

tetrahydroisoquinolin-6-yl, and the like), pyrrolo[3,2-c]pyridinyl (including, for example, pyrrolo[3,2-c]pyridin-2-yl or pyrrolo[3,2-c]pyridin-7-yl, and the like), benzopyranyl, thiazolyl, isothiazolyl, thiadiazolyl, benzothiazolyl, benzothienyl, and the derivatives thereof, or N-oxide or a protected derivative thereof.

[0071] "Hetereoarylalkyl" means an alkyl group substituted with one or two heteroaryl group(s) as defined herein.

[0072] "Heterocycloalkyl" means a saturated or partially unsaturated monovalent monocyclic group of 3 to 8 ring atoms or a saturated or partially unsaturated monovalent fused bicyclic group of 5 to 12 ring atoms in which one or more, specifically one, two, three, or four ring heteroatoms independently selected from -0-, -S(0)_n- (n is 0, 1 , or 2), -N=, -N(R^y)- (where R^y is hydrogen, alkyl, hydroxy, alkoxy, acyl, or alkylsulfonyl), the remaining ring atoms being carbon. One or two ring carbon atoms may be replaced by a -C(O)-, -C(S)-, or -C(=NH)- group. Fused bicyclic radical includes bridged ring systems. Unless otherwise stated, the valency of the group may be located on any atom of any ring within the radical, valency rules permitting. In particular, when the point of valency is located on a nitrogen atom, R^y is absent. More specifically the term heterocycloalkyl includes, but is not limited to, azetidinyl, pyrrolidinyl, 2-oxopyrrolidinyl, 2,5-dihydro-lH- pyrrolyl, piperidinyl, 4-piperidonyl, morpholinyl, piperazinyl, 2-oxopiperazinyl, tetrahydropyranyl, 2-oxopiperidinyl, thiomorpholinyl, thiamorpholinyl, perhydroazepinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, dihydropyridinyl, tetrahydropyridinyl, oxazolinyl, oxazolidinyl, isoxazolidinyl, thiazolinyl, thiazolidinyl, quinuclidinyl, isothiazolidinyl, octahydroindolyl, octahydroisoindolyl, decahydroisoquinolyl, tetrahydrofuryl, and tetrahydropyranyl, and the derivatives thereof and N-oxide or a protected derivative thereof.

[0073] "Heterocycloalkylalkyl" means an alkyl group, as defined herein, substituted with one or two heterocycloalkyl group(s), as defined herein.

[0074] "Hydroxyalkyl" means an alkyl radical, as defined herein, substituted with at least one, specifically one, two, or three, hydroxy group(s), provided that if two hydroxy groups are present they are not both on the same carbon atom. Representative examples include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 2-hydroxypropyl,

3- hydroxypropyl, 1 -(hydroxy methyl)-2-methylpropyl, 2-hydroxybutyl, 3-hydroxybutyl,

4- hydroxybutyl, 2,3-dihydroxypropyl, l-(hydroxymethyl)-2-hydroxyethyl, 2,3- dihydroxybutyl, 3,4-dihydroxybutyl and 2-(hydroxymethyl)-3-hydroxypropyl, specifically 2-hydroxyethyl, 2,3-dihydroxypropyl, or l-(hydroxymethyl)-2-hydroxyethyl, and the like.

[0075] "Hydroxyamino" means a -NH(OH) group.

[0076] "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. One of ordinary skill in the art would understand that with respect to any molecule described as containing one or more optional substituents, only sterically practical and/or synthetically feasible compounds are meant to be included. "Optionally substituted " refers to all subsequent modifiers in a term. So, for example, in the term "optionally substituted arylC j .s alkyl," both the "Ci.g alkyl" portion and the "aryl" portion of the molecule may or may not be substituted. A list of exemplary optional substitutions is presented below in the definition of "substituted."

[0077] "Optionally substituted alkyl" means an alkyl radical, as defined herein, optionally substituted with one or more group(s), specifically one, two, three, four, or five groups, independently selected from alkylcarbonyl, alkenylcarbonyl, cycloalkylcarbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, amino, alkylamino, dialkylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cyano, cyanoalkylaminocarbonyl, alkoxy, alkenyloxy, hydroxy, hydroxyalkoxy, carboxy, alkylcarbonylamino, alkylcarbonyloxy, alkyl-S(0)o-2-, alkenyl-S(0)o-2-, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, alkyIsulfonyl-NR^c- (where R^c is hydrogen, alkyl, optionally substituted alkenyl, optionally substituted alkynyl, hydroxy, alkoxy, alkenyloxy, or cyanoalkyl), alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkylaminoalkyloxy, dialkylaminoalkyloxy, alkoxycarbonyl, alkenyloxycarbonyl, alkoxycarbonylamino, alkylaminocarbonylamino,

dialkylaminocarbonylamino, alkoxyalkyloxy, and -C(0)NR^aR^b (where R^a and R^b are independently hydrogen, alkyl, optionally substituted alkenyl, optionally substituted alkynyl, hydroxy, alkoxy, alkenyloxy, or cyanoalkyl).

[0078] "Optionally substituted alkenyl" means an alkenyl radical, as defined herein, optionally substituted with one or more group(s), specifically one, two, or three groups, independently selected from alkylcarbonyl, alkenylcarbonyl, cycloalkylcarbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, amino, alkylamino, dialkylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cyano, cyanoalkylaminocarbonyl, alkoxy, alkenyloxy, hydroxy, hydroxyalkoxy, carboxy, alkylcarbonylamino, alkylcarbonyloxy, alkyl-S(0)o-2-, alkenyl-S(0)o-₂-, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonyl-NR^c- (where R^c is hydrogen, optionally substituted alkyl, optionally substituted alkynyl, hydroxy, alkoxy, or alkenyloxy), alkylaminocarbonyloxy,

dialkylaminocarbonyloxy, alkylaminoalkyloxy, dialkylaminoalkyloxy, alkoxycarbonyl, alkenyloxycarbonyl, alkoxycarbonylamino, alkylaminocarbonylamino,

dialkylaminocarbonylamino, alkoxyalkyloxy, and -C(0)NR^aR^b (where R^a and R^b are independently hydrogen, optionally substituted alkyl, alkenyl, optionally substituted alkynyl, hydroxy, alkoxy, or alkenyloxy).

[0079] "Optionally substituted aryl" means an aryl group, as defined herein, which is optionally substituted with one, two, three, four, of five groups selected from halo, haloalkyl, haloalkoxy, hydroxy, lower alkyl, lower alkenyl, lower alkynyl, alkoxy, carboxy, carboxy ester, amino, alkylamino, dialkylamino, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, -C(0)NR'R" (where R' is hydrogen or alkyl and R" is hydrogen, alkyl, aryl, heteroaryl, or

heterocycloalkyl), -NR'C(0)R" (where R' is hydrogen or alkyl and R" is alkyl, aryl, heteroaryl, or heterocycloalkyl), and -NHS(0)₂R' (where R' is alkyl, aryl, or heteroaryl).

[0080] "Optionally substituted heteroaryl" means a heteroaryl group, as defined herein, optionally substituted with one, two, three, four, or five groups selected from halo, haloalkyl, haloalkoxy, lower alkyl, lower alkenyl, lower alkynyl, alkoxy, hydroxy, oxo (valency rules permitting), carboxy, carboxy ester, amino, alkylamino, dialkylamino, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, heteroaryl, optionally substituted aryl, -C(0)NR'R" (where R' is hydrogen or alkyl and R" is hydrogen, alkyl, aryl, heteroaryl, or heterocycloalkyl), -NR'C(0)R" (where R' is hydrogen or alkyl and R" is alkyl, aryl, heteroaryl, or heterocycloalkyl), and -NHS(0)₂R' (where R' is alkyl, aryl, or heteroaryl). [0081] "Optionally substituted heterocycloalkyl" means a heterocycloalkyl, as defined herein, optionally substituted with one, two, three, four, or five groups selected from halo, haloalkyl, haloalkoxy, hydroxy, oxo, lower alkyl, lower alkenyl, lower alkynyl, alkoxy, optionally substituted cycloalkyl, heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, alkylaminoalkyl, dialkylaminoalkyl, carboxy, carboxy ester, -C(0)NR'R" (where R' is hydrogen or alkyl and R" is hydrogen, alkyl, aryl, heteroaryl, or heterocycloalkyl), -NR'C(0)R" (where R' is hydrogen or alkyl and R" is alkyl, aryl, heteroaryl, or heterocycloalkyl), amino, alkylamino, dialkylamino, and -NHS(0)₂R' (where R' is alkyl, aryl, or heteroaryl).

[0082] "Saturated bridged ring system" refers to a bicyclic or polycyclic ring system that is not aromatic. Such a system may contain isolated or conjugated unsaturation, but not aromatic or heteroaromatic rings in its core structure (but may have aromatic substitution thereon). For example, hexahydro-furo[3,2-b]furan, 2,3,3a,4,7,7a-hexahydro- lH-indene, 7-aza-bicyclo[2.2.1]heptane, and l,2,3,4,4a,5,8,8a-octahydro-naphthalene are all included in the class "saturated bridged ring system."

[0083] "Spirocyclyl" or "spirocyclic ring" refers to a ring originating from a particular annular carbon of another ring. For example, as depicted below, a ring atom of a saturated bridged ring system (rings C and C), but not a bridgehead atom, can be a shared atom between the saturated bridged ring system and a spirocyclyl (ring D) attached thereto. A spirocyclyl can be carbocyclic or

[0084] "Patient" for the purposes of the present invention includes humans and other animals, particularly mammals, and other organisms. Thus the methods are applicable to both human therapy and veterinary applications. In a specific embodiment the patient is a mammal, and in a more specific embodiment the patient is human.

[0085] "Kinase-dependent diseases or conditions" refer to pathologic conditions that depend on the activity of one or more protein kinases. Kinases either directly or indirectly participate in the signal transduction pathways of a variety of cellular activities including proliferation, adhesion, migration, differentiation and invasion. Diseases associated with kinase activities include tumor growth, the pathologic neovascularization that supports solid tumor growth, and associated with other diseases where excessive local vascularization is involved such as ocular diseases (diabetic retinopathy, age-related macular degeneration, and the like) and inflammation (psoriasis, rheumatoid arthritis, and the like). [0086] While not wishing to be bound to theory, phosphatases can also play a role in "kinase-dependent diseases or conditions" as cognates of kinases; that is, kinases phosphorylate and phosphatases dephosphorylate, for example protein substrates. Therefore compounds of the invention, while modulating kinase activity as described herein, may also modulate, either directly or indirectly, phosphatase activity. This additional modulation, if present, may be synergistic (or not) to activity of compounds of the invention toward a related or otherwise interdependent kinase or kinase family. In any case, as stated previously, the compounds of the invention are useful for treating diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth.

"Compound A," which is a compound of Formula I and of Table

Compound A is disclosed in WO

07/044729 and WO 08/127594, the entire contents of each of which are incorporated herein by reference.

[0088] "Therapeutically effective amount" is an amount of a compound of the invention, that when administered to a patient, ameliorates a symptom of the disease. The amount of a compound of the invention which constitutes a "therapeutically effective amount" will vary depending on the compound, the disease state and its severity, the age of the patient to be treated, and the like. The therapeutically effective amount can be determined routinely by one of ordinary skill in the art having regard to their knowledge and to this disclosure.

[0089] "Cancer" refers to cellular-proliferative disease states, such as those disclosed hereinabove and including but not limited to: Cardiac: sarcoma (angiosarcoma,

fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Lung: bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hanlartoma, mesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel

(adenocarcinoma, lymphoma, carcinoid tumors, Karposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma); Genitourinary tract: kidney

(adenocarcinoma, Wilm's tumor [nephroblastoma], lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma,

teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma); Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma; Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors; Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain

(astrocytoma, medulloblastoma, glioma, ependymoma, germinoma [pinealoma], glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma); Gynecological: uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian carcinoma [serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma], granulosa-thecal cell tumors, SertoliLeydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma], fallopian tubes (carcinoma); Hematologic: blood (myeloid leukemia [acute and chronic], acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma [malignant lymphoma]; Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Karposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis; and Adrenal glands: neuroblastoma. Thus, the term "cancerous cell" as provided herein, includes a cell afflicted by any one of the above- identified conditions.

[0090] A "pharmaceutically acceptable salt" of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. It is understood that the pharmaceutically acceptable salts are non-toxic. Additional information on suitable pharmaceutically acceptable salts can be found in Remington's Pharmaceutical Sciences, 17^th ed., Mack Publishing Company, Easton, PA, 1985, which is incorporated herein by reference or S. M. Berge, et al., "Pharmaceutical Salts," J. Pharm. Sci., 1977;66:1-19 both of which are incorporated herein by reference.

[0091] Examples of pharmaceutically acceptable acid addition salts include those formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; as well as organic acids such as acetic acid, trifluoroacetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, 3-(4-hydroxybenzoyl)benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, glucoheptonic acid, 4,4'-methylenebis-(3-hydroxy-2-ene-l-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, p-toluenesulfonic acid, and salicylic acid and the like.

[0092] Examples of a pharmaceutically acceptable base addition salts include those formed when an acidic proton present in the parent compound is replaced by a metal ion, such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Specific salts are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include, but are not limited to, salts of primary, secondary, and ternary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins. Examples of organic bases include isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine,

2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, tromethamine, N-methylglucamine, polyamine resins, and the like. Exemplary organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine.

[0093] "Prodrug" refers to compounds that are transformed (typically rapidly) in vivo to yield the active ingredient of the above formulae, for example, by hydrolysis in blood. Common examples of a prodrug include, but are not limited to, ester and amide forms of a compound having an active form bearing a carboxylic acid moiety. Examples of pharmaceutically acceptable esters of the compounds of this invention include, but are not limited to, alkyl esters (for example with between about one and about six carbons) the alkyl group is a straight or branched chain. Acceptable esters also include cycloalkyl esters and arylalkyl esters such as, but not limited to benzyl. Examples of pharmaceutically acceptable amides of the compounds of this invention include, but are not limited to, primary amides, and secondary and tertiary alkyl amides (for example with between about one and about six carbons).

[0094] "Metabolite" refers to the break-down or end product of a compound or its salt produced by metabolism or biotransformation in the animal or human body; for example, biotransformation to a more polar molecule such as by oxidation, reduction, or hydrolysis, or to a conjugate (see Goodman and Gilman, "The Pharmacological Basis of Therapeutics" 8.sup.th Ed., Pergamon Press, Gilman et al. (eds), 1990 for a discussion of

biotransformation). As used herein, the metabolite of a compound of the invention or its salt may be the biologically active form of the compound in the body. In one example, a prodrug may be used such that the biologically active form, a metabolite, is released in vivo. In another example, a biologically active metabolite is discovered serendipitously, that is, no prodrug design per se was undertaken. An assay for activity of a metabolite of a compound of the present invention is known to one of skill in the art in light of the present disclosure.

[0095] 'Treating" or "treatment" of a disease, disorder, or syndrome, as used herein, includes (i) preventing the disease, disorder, or syndrome from occurring in a human, i.e. causing the clinical symptoms of the disease, disorder, or syndrome not to develop in an animal that may be exposed to or predisposed to the disease, disorder, or syndrome but does not yet experience or display symptoms of the disease, disorder, or syndrome; (ii) inhibiting the disease, disorder, or syndrome, i.e., arresting its development; and (iii) relieving the disease, disorder, or syndrome, i.e., causing regression of the disease, disorder, or syndrome. As is known in the art, adjustments for systemic versus localized delivery, age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by one of ordinary skill in the art. Embodiments

[0096] One embodiment (A) of a compound of Formula I is where W ¹ , W², W³, and W⁴ are -C(R¹)=; or one or two of W¹, W², W³, and W⁴ are independently -N= and the remaining are -C(R^l)=; where each R¹ is independently hydrogen, alkyl, haloalkyl, nitro, alkoxy, haloalkoxy, halo, hydroxy, cyano, amino, alkylamino, or dialkylamino; and all other groups are as defined in the Summary of the Invention. Specifically, W¹, W², W³, and W⁴ are -QR¹^ and each R¹ is independently hydrogen or alkyl; or one of W¹ and W⁴ is -N= and the other is -C(H)=. More specifically, W¹, W², W³, and W⁴ are -C(R')= where each R¹ is independently hydrogen or alkyl. Even more specifically, R¹ is hydrogen.

[0097] Another embodiment (B) of a Compound of Formula I is where R⁵⁰ is hydrogen, alkyl, alkenyl, halo, haloalkyl, haloalkenyl, hydroxy, alkoxy, alkenyloxy, haloalkoxy, nitro, amino, alkylamino, dialkylamino, -N(R⁵⁵)C(0)-Ci-C6-alkylene- N(R^55a)R^55b, alkylcarbonyl, alkenylcarbonyl, carboxy, alkoxycarbonyl, cyano, alkylthio, -S(0)₂NR⁵⁵R^55a, or alkylcarbonylamino; where R⁵⁵ and R^55b are indepedently hydrogen, alkyl, or alkenyl and R^55a is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy; and all other groups are as defined in the Summary of the Invention. Specifically, R⁵⁰ is hydrogen.

[0098] Another embodiment (C) of a Compound of Formula I is where R⁵¹ is hydrogen or alkyl; and all other groups are as defined in the Summary of the Invention. Specifically, R⁵¹ is alkyl, More specifically, R⁵¹ is methyl.

[0099] Another embodiment (D) of a Compound of Formula I is where R⁵² is hydrogen or halo; and all other groups are as defined in the Summary of the Invention. Specifically R⁵² is hydrogen or fluoro. More specifically, R⁵² is hydrogen.

[00100] Another embodiment (E) of a Compound of Formula I is where R⁵³ is hydrogen, alkyl, alkenyl, halo, haloalkyl, haloalkenyl, hydroxy, alkoxy, alkenyloxy, haloalkoxy, nitro, amino, alkylamino, dialkylamino, -N(R⁵⁵)C(0)-C|-C₆-alkylene-N(R^55a)R^55b, alkylcarbonyl, alkenylcarbonyl, carboxy, alkoxycarbonyl, cyano, alkylthio, -S(0)₂NR⁵⁵R^55a, or alkylcarbonylamino; where R⁵⁵ and R^55b are indepedently hydrogen, alkyl, or alkenyl and R^55a is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy; and all other groups are as defined in the Summary of the Invention. Specifically, R⁵³ is hydrogen, alkoxy, nitro, amino, or -N(R⁵⁵)C(0)-Ci-C₆-alkylene-N(R^55a)R^55b. More specifically, R⁵³ is hydrogen, methoxy, nitro, amino, or -NHC(0)CH₂N(CH3)2. Even more specifically, R⁵³ is hydrogen or methoxy.

[00101] Another embodiment (F) of a Compound of Formula I is where R⁵⁴ is hydrogen, alkyl, alkenyl, halo, haloalkyl, haloalkenyl, hydroxy, alkoxy, alkenyloxy, haloalkoxy, nitro, amino, alkylamino, dialkylamino, -N(R⁵⁵)C(0)-C₁-C₆-alkylene-N(R^55a)R^55b, alkylcarbonyl, alkenylcarbonyl, carboxy, alkoxycarbonyl, cyano, alkylthio, -S(0)₂NR⁵⁵R^55a, or alkylcarbonylamino; where R⁵⁵ and R^55b are indepedently hydrogen, alkyl, or alkenyl and R^55a is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy; and all other groups are as defined in the Summary of the Invention. Specifically, R⁵⁴ is hydrogen, alkyl, alkoxy, or halo. More specifically, R⁵⁴ is hydrogen, methyl, methoxy, bromo, or chloro. Even more specifically, R⁵⁴ is hydrogen, methoxy, or chloro.

[00102] Another embodiment (G) of a compound of Formula I is where R⁵⁰, R⁵², and R⁵³ are hydrogen and R⁵⁴ is halo or alkoxy; R⁵⁰, R⁵², and R⁵⁴ are hydrogen and R⁵³ is alkoxy; or R⁵⁰ and R⁵² are hydrogen and R⁵³ and R⁵⁴ together with the carbons to which they are attached form a 6-membered heteroaryl; and all other groups are as defined in the Summary of the Invention. More specifically, R⁵⁰, R⁵², and R⁵³ are hydrogen and R⁵⁴ is chloro or methoxy; R⁵⁰, R⁵², and R⁵⁴ are hydrogen and R⁵³ is methoxy; or R⁵⁰ and R⁵² are hydrogen and R⁵³ and R⁵⁴ together with the carbons to which they are attached form pyridinyl. Even more specifically, R⁵⁰, R⁵², and R⁵³ are hydrogen and R⁵⁴ is chloro or methoxy; or R⁵⁰, R⁵², and R⁵⁴ are hydrogen and R⁵³ is methoxy.

[00103] In a more specific embodiment (Gl) of embodiment G is a compound of Formula I where R⁵¹ is methyl.

[00104] Another embodiment (H) of a Compound of Formula I is where B is phenyl substituted with R^3a and optionally further substituted with one, two, or three R³; and all other groups are as defined in the Summary of the Invention. Specifically, B is phenyl substituted with R^3a. More specifically the Compound is of Formula 1(a):

1(a).

Even more specifically, B is phenyl substituted with R^3a as depicted in la and is not further substituted with R³.

[00105] Another embodiment (J) is directed to a compound of Formula I where B is heteroaryl optionally substituted with one, two, or three R³. Specifically, B is thien-3-yl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, oxazolyl, isoxazolyl, pyrrolyl, imidazolyl, pyrazolyl, or thiazolyl, each of which is optionally substituted with one or two R . More specifically, B is thien-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, oxazol-2-yl, oxazol-4- yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, imidazol-2-yl, pyrrol-2-yl, pyrrol-3-yl, imidazol-4-yl, imidazol-5-yl, pyrazol-3-yl, pyrazol-4-yl, or pyrazol-5-yl, each of which is optionally substituted with one or two R³. Even more specifically, B is thien-3- yl, pyridin-3-yl, pyridin-4-yl, isoxazol-4-yl, or pyrazol-4-yl, each of which is optionally substituted with one or two R³. Yet even more specifically, B is pyridin-3-yl, 2-hydroxy- pyridin-5-yl, isoxazol-4-yl, or pyrazol-4-yl, each of which is optionally substituted with one or two R³.

[00106] Another embodiment (K) provides a compound of Formula I or la where R^3a is cyano; hydroxyamino; carboxy; alkylsulfonyl, aminoalkyloxy; alkylaminoalkyloxy;

dialkylaminoalkyloxy; -N(R⁷)C(0)-C_rC₆-alkylene-N(R^7a)(R ^b); -C(0)NR⁸R^8a;

-NR⁹C(0)R^9a; -C^NiR'^-d-Ca-alkylene-NiR'^R¹⁰"; -NRⁿC(0)NR^{l la}R^{l lb} where R^{l la}; -C(0)R¹²; -NR¹³C(0)OR^13a; -C(0)N(R¹⁴)N(R^,4a)(R^l4b); -S(0)₂N(R¹⁵)-C,.C6-alkylene- _N(Ri5a_)Ri5b. .c(0)N(R¹⁶)-Ci.C₆-alkylene-C(0)OR^16a; heteroaryl optionally substituted with one or two aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl; -N(R¹⁷)- C(=N(R¹⁷ )(R^,7a))(NR^l7cR^17d); -N(R^l8)C(0)-C,-C₆-alkylene-N(R^18b)C(0)R^18a; -C(0)N(R¹⁹)- C,-C₆-alkylene-C(0)R^19a; -N(R²²)C(0)-C,.C₆-alkylene-N(R^22b)-N(R^22c)(R^22a); -Co-C₆- alkylene-N(R ³)-C₁.C₆-alkylene-N(R^23b)R^23a; or - R²⁴C(0)-C_1-C₆-alkylene-OR^24a; where each of the alkylene in R^3a is independently optionally further substituted with 1 , 2, 3, 4, or 5 groups selected from halo, hydroxy, amino, alkylamino, and dialkylamino; and all other groups are as defined in the Summary of the Invention.

[00107] Specifically, R^3a is -NHC(0)CH₂NH(CH₃), -NHC(0)CH₂NH(CH₂CH₃), -NHC(0)CH(CH₃)NH₂, -NHC(0)C(CH₃)₂NH₂, -NHC(0)CH₂N(CH₃)₂,

-NHC(0)CH₂N(CH₃)CH₂CH₂N(CH₃)₂, -NHC(0)CH(NH₂)CH₂CH₃,

-NHC(0)CH₂N(CH₃)CH₂CH₂N(CH₃)₂, -NHC(0)CH(CH₃)NH(CH₃), -NHC(0)CH₂NH₂, -NHC(0)H, -NHC(0)CH₂(azetidin-l-yl), -NHC(0)(pyrrolidin-2-yl),

-NHC(0)CH(NH₂)CH₂OH, -NHC(0)(azetidin-4-yl), -NHC(0)C(CH₃)₂NH(CH₃), -NH₂, -NHC(0)CH₂NH(CH₂CH₂CH₃), -NHC(0)CH₂CH₂NH₂, -NHOH, -NHC(0)(piperidin-3-yl), -NHC(0)CH₂(4-methyl- 1 ,4-diazepan- 1 -yl), - HC(0)CH(NH₂)(CH₂CH₃),

-NHC(0)CH₂NH(CH₂CH(OH)(CH₃)), -NHC(0)CH₂NHCH₂CH₂F,

-NHC(0)CH₂NH(OCH₂CH(CH₃)₂), -NHC(0)( 1 -aminocycloprop- 1 -y 1),

-NHC(0)CH₂NH(CH₂cyclopropyl), -NHC(0)CH₂(3-(dimethylamino)-azetidin- 1 -yl), -NHC(0)(piperidin-2-yl), -NHC(0)(mo holin-4-yl), -NHC(0)CH₂(pyrrolidin- 1 -yl), -NHC(0)CH(NH₂)CH₂CH₂CH₂CH₂N(CH3)2, -NHC(0)CH₂N(CH3)(CH₂CH3),

-NHC(0)CH₂(imidazol-5-yl), -NHC(0)( 1 -aminocyclopent-l-yl),

-NHC(0)CH₂NH(CH₂CH(CH₃)₂), -NHC(0)CH₂N(CH3)(CH₂CH₃), -NHC(0)(N-(imidazol- 4-ylmethyl)-azetidin-3-yl), -NHC(0)(N-ethyl-azetidin-3-yl),

-NHCH₂N(CH3)CH₂CH₂N(CH3)₂, -NHC(0)CH₂N(CH₃)(N-methyl-pyrrolidin-3-yl), - HC(0)CH₂N(CH₃)(CH₂CH₂N(CH₃)₂), -NHC(0)CH₂(3-hydroxy-pyrrolidin- 1 -yl), -NHC(0)( 1 -amino-cyclobut- 1 -yl), - HC(0)CH₂NH(CH₂)₃CH₃, -NHC(0)CH₂(3-piperidin- 1 -ylazetidin-lyl), -NHC(0)NH₂, -NHC(0)(l-hydroxycyclopropyl),

-NHC(0)CH₂NHN(CH₃)₂, -NHC(0)NH(CH₂)₂N(CH₃)₂, -NHC(0)CH₂OH,

-NHC(0)(pyridazin-4-yl), -NHC(0)(N-methyl-piperidin-4-yl), -NHC(0)CH₂NHCH(CH₃)₃, -NHC(0)CH₂(3-dimethylamino-pyrrolidin- 1 yl), -NHC(0)CH₂NH(CH₂)₂N(CH₃)₂.

-NHC(0)( 1 -cyclopropylmethyl-azetidin-3-yl), -NHC(0)CH₂NH(CH₃)₃,

-NHC(0)(imidazol-2-yl), -NHC(0)(imidazol-4-yl), -NHC(0)( 1 ,2-oxazol-5-yl),

-NHC(0)CH₂NHCH₂CF₃, -NHC(0)CH₂CH₂(piperidin- 1 -yl), -NHC(0)(3-oxo-cyclopent- 1 - yl), -NHC(0)(2-hydroxy-pyridin-6-yl), -NHC(0)CH₂NH(3-fluoro-4-hydroxyphenyl), -NHC(0)(CH₂)₃N(CH₃)₂, -NHC(0)( 1 -(furan-2-ylmethyl)-azetidin-3-yl),

-NHC(0)(pyrimidin-5-yl), -NHC(0)(pyrrol-2-yl), -NHC(0)CH₂N(CH3)CH(CH₃)₂, -NHC(0)CH₂N(CH₂CH₃)₂, -NHC(0)CH₂(3-methyl- 1 ,2-oxazol-5-yl),

-NHC(0)CH₂NHCH₂(3-hydroxyphenyl), -NHC(0)(N-methyl-pyrrol-2-yl), -NHC(0)(2- amino-tetrahydropyran-2-yl), -NHC(0)CH₂(4-methylamino-piperidin- 1 -yl),

-NHC(0)(piperidin- 1 -yl), -NHC(0)(N-methyl-pyrrolidin-2yl), -NHC(0)(thien-3yl), -NHC(0)(N-(cyclopropy lcarbonyl)azetidin-3-yl), -NHC(0)CH₂(4-methylpiperazin- 1 -yl), -NHC(0)(N-benzylazetidin-3-yl), -NHC(0)(2-chloro-pyridin-3-yl), -NHC(0)CH₂(pyridin- 4-yl), -NHC(0)CH₂N(CH₃)(CH₂CH=CH₂), -NHC(0)CH₂NH(benzyl), -NHC(0)CH₂OCH₃, -NHC(0)[ 1 -(C(0)CH₂CH₃)-azetidin-3-yl], -NHC(0)(pyridin-3-yl),

-NHC(0)CH₂NHCH₂CH₂OCH₃, -NHC(0)( 1 -[C(0)CH₃]piperidin-4-yl), -NHC(0)CH₂(2- methyl-pyrrolidin- l -yl), -NHC(0)(furan-3-yl), -NHC(0)CH₂N(CH₃)₂, -NHC(0)(2-chloro- pyridin-5-yl), -NHC(0)(2-chlorophenyl), -NHC(0)CH₂(pyridin-2-yl), -NHC(0)CH₂(3- dimethylamino-azetidin-l-yi), -NHC(0)CH₂(pyridin-3-yl), -NHC(0)CH₂(2-chlorophenyl), -NHC(0)CH₂N(CH₃)CH₂CH₂CH₂N(CH3)₂, -NHC(0)CH₂N(CH₂CH₃)CH₂CH₂OH, -NHC(0)CH₂(2-benzyl-pyrrolidin- 1 -yl), -NHC(0)(furan-2-yl, -NHC(0)(2-chloro-pyridin- 4-yl), -NHC(0)CH₂NHC(0)CH₃, -NHC(0)CH₂CH₂CH₃, -NHC(0)(4-chlorophenyl), -NHC(0)(4-methyl-phenyl), -NHC(0)CH₂NHC(0)0(CH₃)₃,

-NHC(0)(benzo[d][l ,3]dioxol-5-yl), -NHC(0)CH₂NHOCH₂(2-methoxyphenyl), - HC(0)(pyridin-4-yl), -NHC(0)CH₂[4-(3,4-dichlorophenyl)-piperazin- 1 -yl],

-NHC(0)CH₂CH₂(pyridin-3-yl), - HC(0)(tetrahydrofuran-3-yl), -NHC(0)CH₂NHCH₂(2- methylphenyl), -NHC(0)CH(CH₃)C¾CH₃, -NHC(0)CH₂(3-fluorophenyl),

-NHC(0)CH₂C(CH₃)₂phenyl, -NHC(0)(2-methy 1-cycloprop- 1 -yl), -NHC(0)(2-methyl- 4-methoxyphenyl), -NHC(0)(2-methylpyridin-3-yl), -NHC(0)(4-methoxyphenyl), -NHC(0)CH₂(4-ethylpiperazin-l-yl), -NHC(0)(thien-2-yl), -NHC(0)(3-fiuoro-2- methylphenyl), -NHC(0)(2-bromo-thien-3-yl), -NHC(0)(4-fluorophenyl), -NHC(0)CH₂(3- methylpiperidin-l-yl), -NHC(0)CH(CH₃)₂, -NHC(0)(CH₂)₃CH₃, -NHC(0)CH₂OCH₂CH₃, -NHC(0)CH₂NH(2-fluorophenyl), -NHC(0)(3-dimethylaminophenyl), -NHC(0)CH₂(4- methylpiperidin- 1-yl), -NHC(0)CH₂NH(2-«-propylphenyl), -NHC(0)phenyl,

-NHC(0)(pyrazin2-yl), -NHC(0)(3-fluoro-4-methoxyphenyl), -NHC(0)C(CH₃)₂CH₂CH₃, -NHC(0)CH₂0(4-fluorophenyl), -NHC(0)( 1 -methylcarbonyl-azetidin-3-yl),

- HC(0)CH₂NH(4-methylphenyl), -NHC(0)CH₂NH(phenyl), -NHC(0)CH₂(4-allyl- piperazin-l-yl), - HC(0)(2-methylphenyl), -NHC(0)CH₂CH₂OCH₃, -NHC(0)(3-methyl- furan-2-yl), -NHC(0)C(CH₃)₃, -NHC(0)CH₂NHObenzyl,

-NHC(0)CH₂NH(3-chlorophenyl), -NHC(0)cyclobutyl, -NHC(0)CH₂(3-methoxyphenyl), -NHC(0)( 1 -methylcycloprop- 1 -yl), -NHC(0)(3-fluropheny 1),

-NHC(0)(4-dimethylaminophenyl), -NHC(0)(3,4-dichlorophenyl),

-NHC(0)CH₂NHCH₂(2-methylthiophenyl), -NHC(0)CH₂(2-fluorophenyl),

-NHC(0)CH₂N(CH₂CH₃)CH(CH₃)₂, -NHC(0)(thiazol-4-yl), -NHC(0)CH₂N(CH₃)benzyl, -NHC(0)CH₂ HCH₂(thien-2-yl), -NHC(0)CH₂NHCH₂(pyridin-2-yl), -NHC(0)(3- methoxyphenyl), - HC(0)CH₂NHCH₂(3-chloro-4-methylphenyl),

-NHC(0)CH(CH₃)CH₂CH₂CH₃, -NHC(0)CH₂(4-chlorophenyl), -NHC(0)(3-fluoro-4- methylphenyl), -NHC(0)CH₂0(2-methylphenyl), -NHC(0)CH₂(cyclohexyl), -NHC(0)(2- phenyl-cycloprop- 1 -yl), -NHC(0)(3-chlorophenyl), -NHC(0)CH₂(2-methoxypheny 1), -NHC(0)CH₂CH₂(3-methoxyphenyl), -NHC(0)CH₂NH(2-nuoro-4-methyl-phenyl), -NHC(0)CH₂NHCH₂(3-fluoro-phenyl), -NHC(0)CH₂(4-methoxy-phenyl),

-NHC(0)benzyl, -NHC(0)(2,4-dichloropheny 1), -NHC(0)(3-oxo-cyclohex- 1 -yl),

-NHC(0)CH₂NH(3-fluorophenyl), -NHC(0)CH₂(3-chlorophenyl),

-NHC(0)CH₂NHCH₂CH(CH₃)phenyl, -NHC(0)CH₂NHCH₂(2,4-dimethylphenyl), -NHC(0)CH₂(2-methyl-piperidin-l-yl), -NHC(0)CH₂NH(2-methoxyphenyl),

-NHC(0)CH₂( 1 ,2,3,4-tetrahydroisoquinolin-2-yl), - HC(0)CH₂CH₂CH=CH₂,

-NHC(0)CH₂NH(2-methylphenyl), -NHC(0)CH₂(4-oxo-piperidin- 1-yl), -NHC(0)(2- nuorophenyl), -NHC(0)CH₂NHCH(CH₃)phenyl, -NHC(0)(2-fluoro-6-methoxyphenyl), -NHC(0)CH₂NH(2-isopropylphenyl), -NHC(0)CH₂CH₂(2-methoxyphenyl),

-NHC(0)CH₂CH₂CH(CH₃)₂, -NHC(0)CH₂(2-phenyl-morpholin-4-yl),

-NHC(0)CH₂CH₂(4-methoxyphenyl), -NHC(0)CH₂N(allyl)cyclopentyl,

-NHC(0)CH₂N(CH₃)CH₂CH₂OCH₃, -NHC(0)CH₂CH₂C(0)cyclopropyl,

-NHC(0)CH₂NH(3-½rf-butylphenyl), -NHC(0)CH₂N( i-propyl)(cyclopropylmethyl), -NHC(0)CH₂(2-oxo-cyclopentyl), -NHC(0)CH₂NH(4-chlorophenyl), -NHC(0)CH₂(4- piperidin- 1-ylpiperidin- 1 -yl), -NHC(0)CH₂(4-cyclopentylpiperazin- 1 -yl), -NHC(0)CH₂(2- methylphenyl), -NHC(0)CH₂NHCH₂(3-fluoro-6-methylphenyl), -NHC(0)CH₂C(CH₃)₃, -NHC(0)CH₂NH(2-chlorophenyl), -NHC(0)(3-nuoro-6-methylphenyl), -NHC(0)(4-fluoro-

3- methylphenyl), -NHC(0)(2,3-dichlorophenyl), -NHC(0)CH₂Ophenyl,

-NHC(0)CH₂NH(2,3-dimethylphenyl), -NHC(0)(2-fluoro-5-methylphenyl),

-NHC(0)CH₂NHOCH₂(4-methylphenyl), -NHC(0)CH₂(4-isopropylpiperazin- 1 -yl), -NHC(0)CH₂(4-fluorophenyl), -NHC(0)CH₂CH(CH₃)₂, -NHC(0)(2-methoxy-

4- methylphenyl), -NHC(0)CH₂(4-n-propylpiperidin- 1 -yl), -NHC(0)CH₂0(3- methylphenyl), -NHC(0)(tetrahydrofuran-2-yl), -NHC(0)CH₂(3-hydroxymethylpiperidin- 1-yl), -NHC(0)( l-½rt-butoxycarbonylpiperidin-2-yl), -NHC(0)CH₂N(CH₃)CH₂(pyridin-3- yl), -NHC(0)CH₂N(CH₂CH₃)phenyl, -NHC(0)CH₂OCH₂CH₂OCH₃,

■NHC(0)CH₂CH₂(cyclopentyl), -NHC(0)(2,5-dichlorophenyl), -NHC(0)CH₂(4- methy lcarbonylpiperazin- 1 -yl), -NHC(0)(5-fluoro-2-methoxyphenyl),

-NHC(0)CH₂N(CH₂CH₃)cyclohexy 1, -NHC(0)(5-methyl- 1 ,2-oxazol-3-yl), -NHC(0)(3- methy lpyridin-3-y 1), -NHC(0)(2-methoxypyridin-3-yl), -NHC(0)(3 ,5-dichlorophenyl), -NHC(0)CH₂(thiazolidin3-yl), -NHC(0)CH₂(4-[C(0)H]-piperazin- l-yl), -NHC(0)CH₂(2- pyridin-4-ylpiperidin- 1 -yl), -NHC(0)(2-methoxyphenyl),

-NHC(0)CH₂N(CH₃)CH₂CH(CH₃)₂, -NHC(0)CH₂(4-[C(0)H]-homopiperazin- 1 -yl), -NHC(0)( 1 -phenylcycloprop- 1 -yl), -NHC(0)CH₂(2,6-dimethylmorpholin-4-yl),

NHC(0)CH₂(2-phenylpyrrolidin- 1 -yl), -NHC(0)CH₂(morpholin-4-yl),

-C(0)NHCH(CH₃)CH₂N(CH₃)₂, -C(0)NHCH₂CH₂N(CH₃)₂, -C(0)NH(pyrrolidin-3-yl), -C(0)NHCH₂CH₂(pyrrolidin- 1 -y 1), -C(0)NHCH₂CH₂NH₂, -C(0)N(CH₃)CH₂CH₂N(CH₃)₂, -C(0)NHCH₂(piperidin-2-yl), -C(0)NH( 1 -methy lazetidin-3-y 1),

-C(0) HCH₂CH₂(piperidin- 1 -yl), -C(0)NHCH₂CH₂N(CH₂CH₃)₂, -C(0)NH( 1- methy lpiperidin-3-yl), -C(0)NH(piperidin-3-yl), -C(0)NHCH₂( 1 -methylpiperidin-3-yl), -C(0) HCH₂CH₂N(CH₂CH₂OH)₂, -C(0)NH(l-ethylpiperidin-3-yl), -C(0)NH₂, -C(0)(3- aminopyrrolidin- 1 -yl), -C(0)(3-methylaminopyrrolidin- 1 -yl), -C(0)OH,

-C(0)NHCH2CH₂(moφholin-4-y 1), -C(0)NHCH₂( 1 -ethylpyrrolidin-2-y 1), -C(0)(4-amino- 3-oxo-pyrazolidin- l-yl), -C(0)NHCH₃, -C(0)(3-aminocyclobut-l-yl),

-C(0)NHCH₂(pyridin-3-yl), -C(0)NHCH₂CH₂OH, -C(0)NH(3-oxo-pyrazolidin-4-yl), -NHCH₂CH₂(imidazol-4-yl), -C(0)(3-dimethylaminopyrrolidin- 1-yl),

-C(0)NHCH₂(pyridin-4-yl), -C(0)N(CH₃)( 1 -methyl-pyrrolidin-3-yl), -C(0)(3- diethy laminopyrrolidin- 1 -yl), -C(0)NH(pyrrol- 1-yl), -C(0)NHCH₂CH₂CH₂(pyrrolidin- 1 - yl), -C(0)N(CH₃)CH₂CH₂CN, -C(0)NHCH₂CH₂OCH₃, -C(0)N(CH₂CH₃)CH₂CH₂CN, -C(0)(3-aminopiperidin- l-yl), -C(0)NHCH₂CH₂CH₂N(CH₃)₂, -C(0)NH(mo holin-4-yl), -C(0)NHN(CH₃)₂, -C(0)NHCH₂CH₂CH₂(imidazol- 1-yl),

-C(0)NHCH₂CH₂CH₂N(CH₂CH₃)₂, -C(0)NHCH₂CH₂CN, -C(0) HCH₂CH2C(0)OCH_3j -C(0)NHCH₂CH₂SCH₃, -C(0)NHCH₂CH₂SCH₂CH₃, -C(0)N(CH₂CH₃)CH₂CH₂N(CH₃)₂, -C(0)NHCH₂CH₂CH₂(2-oxo-pyrroIidin- l-yl), -C(0) HCH₂CH₂(pyridin-4-yl),

-C(0)NHCH₂CH₂CH₂OCH₂CH₃, -C(0)NHCH₂CH₂CH₂(morpholin-4-yl),

-C(0)NHCH₂CH₂CH₂OCH₃, -C(0)N(CH₃)CH₂CH₂CH₂N(CH₃)₂,

-C(0)NHCH₂CH₂CH₂OCH₂CH₂CH₃, -C(0)NHCH₂CH₂C(0)OCH₂CH₃,

-C(0)NHCH₂CH₂CH₂OCH(CH₃)₂, -C(0)NHC(CH₃)₂CH₂(piperidin- 1-yl),

-C(0)N(CH₃)CH₂CH₂CH₃, -C(0)NH(piperidin-l-yl), -C(0)NHCH(CH₃)CH₂OCH₃, -C(0)NHC(CH₃)₂CH₂(morpholin-4-yl), -C(0)(2-dimethy laminomethy lpiperidin- 1 -yl), -C(0) H(CH₂)₃0(CH₂)₃CH₃, -C(0)NHCH(CH₃)(CH₂)₃N(CH₂CH₃)₂,

-C(0) HC(CH₃)₂C(0)(piperidin- 1 -yl), -C(0)(4-methy Ipiperazin- 1 -yl), -C(0)(2-piperidin- 1-ylmethyl-piperidin-l-yl), cyano, - HCH₃, -CH(CH₃)NHCH₂CH₂N(CH₃)₂, -C(0)CH₃₎ -S(0) NHCH₂CH₂N(CH₃)₂₎ -S(0)₂NH(CH₂)₃N(CH₃)₂, 5-(N,N-dimethylaminomethyl)- l,3,4-oxadiazol-2-yl, -NHCH₂CH₂N(CH₃)₂, -N(CH₃)₂, -OCH₂CH₂N(CH₃)₂,

-NHC[N(CH₃)₂][=N(CH₃)₂], -OCHF₂, -S(0)₂CH₃, -OCF₃, or -NHC(0)CH₂(4- dimethylaminopiperidin- 1 -yl).

[00108] In a more specific embodiment (L), the compound of Formula I or la is that where R^3a is hydroxyamino, -N(R⁷)C(0)-C₁-C₆-alkylene-N(R^7a)(R^7b), -CiOiNR^⁸³ ,

- iR^JCiOi-C.Ce-alkylene-NiR^ iR^iR^. -NR^CiO R¹³³, -N(R^l8)C(0)-d-C₆- alkylene-N(R¹⁸ )C(0)R^18a , -NR²⁴C(0)-Ci.C₆-alkylene-OR^24a, or -N(R²⁰)C(O)-C_rC₆- alkylene-C(O)R^20a; where each of the alkylene in R^3a is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, and amino; and all other groups are as defined in the Summary of the Invention. Specifically, R^3a is

-NHC(0)CH₂NH(CH₃), -NHC(0)CH(CH₃)NH₂, -NHC(0)C(CH₃)₂NH₂,

-NHC(0)CH₂N(CH₃)₂, -NHC(0)CH₂N(CH₃)CH₂CH₂N(CH₃)₂, -NHC(0)CH(NH₂)CH₂CH₃₎ -NHC(0)CH₂N(CH₃)CH₂CH₂N(CH₃)2, - HC(0)CH(CH₃)NH(CH₃), -NHC(0)H,

-NHC(0)CH₂(azetidin-l-yl), -NHC(0)(pyrrolidin-2-yl), -NHC(0)CH(NH₂)CH₂OH, -NHC(0)(azetidin-4-yl), -NHC(0)C(CH₃)₂NH(CH₃), -NH₂,

-NHC(0)CH₂NH(CH₂CH₂CH₃), -NHC(0)CH₂CH₂NH₂, -NHOH, or -NHC(0)(piperidin-3- yi)-

[00109] In a more specific embodiment (M) the compound is of Formula I or la and R^3a ■N(R⁷)C(0)-Ci-C₆-alkylene-N(R^7a)(R^7b); and R⁷ is hydrogen or alkyl and R^7a and R^7b are independently hydrogen, alkyl, aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl; and all other groups are as defined in the Summary of the Invention. More specifically, R³ is -NHC(0)CH₂NH(CH₃), -NHC(0)CH(CH₃)NH₂, -NHC(0)C(CH₃)₂NH₂,

-NHC(0)CH₂N(CH₃)₂₎ -NHC(0)CH₂N(CH₃)CH₂CH₂N(CH₃)₂, -NHC(0)CH(NH₂)CH₂CH₃, -NHC(0)CH₂N(CH₃)CH₂CH₂N(CH₃)₂, or - HC(0)CH(CH₃)NH(CH₃).

[00110] Embodiment (N) provides a compound of Formula I where each R³ is independently halo; cyano; alkyl; alkenyl; alkoxy; hydroxyamino; carboxy; alkylsulfonyl, aminoalkyloxy; alkylaminoalkyloxy; dialkylaminoalkyloxy; -N(R⁷)C(0)-Ci-C6-alkylene- N(R^7a)(R^7b); -C(0)NR⁸R^8a; -NR⁹C(0)R^9a; -C(O)N(R^l0)-C₁-C₆-alkylene-N(R^10a)R^10b;

-NRⁿC(0)NR^UaR^Ub where R^{1 ,a}; -C(0)R¹²; -NR¹³C(0)OR^13a; -C(0)N(R¹⁴)N(R^14a)(R^14b); -S(0)₂N(R¹⁵)-C,.C₆-alkylene-N(R^15a)R^l5b; -C(0)N(R^l6)-Ci-C₆-alkylene-C(0)OR^16a;

heteroaryl optionally substituted with one or two aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl; -N(R¹⁷)-C(=N(R^17b)(R^17a))(NR^l7cR^17d); -N(R¹⁸)C(0)-C,-C₆-alkylene- N(R^18b)C(0)R^18a; -C(0)N(R¹⁹)-C,-C₆-alkylene-C(0)R^19a; -N(R²²)C(0)-C,.C₆-alkylene- N(R^22b)-N(R^22c)(R^22a); -Co-C₆-alkylene-N(R²³)-C|.C₆-aIkylene-N(R^23b)R^23a; or -NR ⁴C(0)- Ci.C6-alkylene-OR²⁴ ; where each of the alkylene in R³ is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, amino, alkylamino, and dialkylamino; and all other groups are as defined in the Summary of the Invention.

[00111] Specifically, each R³ is independently methyl, bromo, chloro, fluoro,

-NHC(0)CH₂NH(CH₃), -NHC(0)CH₂NH(CH₂CH₃), -NHC(0)CH(CH₃)NH₂,

-NHC(0)C(CH₃)₂NH_2j -NHC(0)CH₂N(CH₃)₂₎ -NHC(0)CH₂N(CH₃)CH₂CH₂N(CH₃)₂, -NHC(0)CH(NH₂)CH₂CH₃, -NHC(0)CH₂N(CH₃)CH₂CH₂N(CH₃)₂,

-NHC(0)CH(CH₃)NH(CH₃), -NHC(0)CH₂NH₂, -NHC(0)H, -NHC(0)CH₂(azetidin-l-yl), -NHC(0)(pyrrolidin-2-yl), -NHC(O)CH(NH₂)CH₂0H, -NHC(0)(azetidin-4-yl),

-NHC(0)C(CH₃)₂NH(CH₃), -NH₂, -NHC(0)CH₂NH(CH₂CH₂CH₃), -NHC(0)CH₂CH₂NH₂, -NHOH, -NHC(0)(piperidin-3-yI), -NHC(0)CH₂(4-methyl- 1 ,4-diazepan- 1 -y 1),

-NHC(0)CH(NH₂)(CH₂CH₃), -NHC(0)CH₂NH(CH₂CH(OH)(CH₃», -NHC(0)CH₂NHCH₂CH₂F, -NHC(0)CH₂NH(OCH₂CH(CH₃)₂), -NHC(0)(1- aminocycloprop-l-yl), -NHC(0)CH₂NH(CH₂cyclopropyl), -NHC(0)CH₂(3- (dimethylamino)-azetidin- 1 -yl), -NHC(0)(piperidin-2-yl), -NHC(0)(morpholin-4-yl), -NHC(0)CH₂(pyrrolidin- 1-yl), -NHC(0)CH(NH₂)CH₂CH₂CH₂CH₂N(CH₃)₂,

-NHC(0)CH₂N(CH₃)(CH₂CH₃), -NHC(0)CH₂(imidazol-5-yl), -NHC(0)( 1- aminocyclopent-l-yl), -NHC(0)CH₂NH(CH2CH(CH₃)₂), -NHC(0)CH₂N(CH₃)(CH₂CH₃), -NHC(0)(N-(imidazol-4-ylmethyl)-azetidin-3-yl), - HC(0)(N-ethyl-azetidin-3-yI), -NHCH₂N(CH₃)CH₂CH₂N(CH₃)₂, -NHC(0)CH₂N(CH₃)(N-niethyl-pyrrolidin-3-yl), -NHC(0)CH₂N(CH₃)(CH2CH₂N(CH₃)2), -NHC(0)CH₂(3-hydroxy-pyrrolidin-l-yl), - HC(0)(l-amino-cyclobut-l-yl), -NHC(0)CH2NH(CH₂)₃CH3, -NHC(0)CH₂(3-piperidin- 1-ylazetidin-lyl), -NHC(0)NH₂, - HC(0)(l-hydroxycyclopropyl),

-NHC(0)CH₂ HN(CH₃)₂, -NHC(0)NH(CH₂)₂N(CH₃)₂, -NHC(0)CH₂OH,

-NHC(0)(pyridazin-4-yl), -NHC(0)(N-methyl-piperidin-4-yl), -NHC(0)CH₂NHCH(CH₃)₃, - HC(0)CH₂(3-dimethylamino-py-Tolidin-lyl), -NHC(0)CH₂NH(CH₂)₂N(CH₃)₂,

-NHC(0)( 1 -cyclopropylmethyl-azetidin-3-yl), -NHC(0)CH₂NH(CH₃)₃,

-NHC{0)(imidazol-2-y 1), -NHC(0)(imidazol-4-yl), -NHC(0)( 1 ,2-oxazol-5-y 1),

-NHC(0)CH₂NHCH₂CF₃, -NHC(0)CH₂CH₂(piperidin- 1 -yl), -NHC(0)(3-oxo-cyclopent- 1 - yl), -NHC(0)(2-hydroxy-pyridin-6-yl), -NHC(0)CH₂NH(3-fluoro-4-hydroxyphenyl), -NHC(0)(CH₂)₃N(CH₃)₂, -NHC(0)(l-(furan-2-ylmethyl)-azetidin-3-yl),

-NHC(0)(pyrimidin-5-yl), -NHC(0)(pyrrol-2-yl), -NHC(0)CH₂N(CH₃)CH(CH₃)2,

-NHC(0)CH₂N(CH₂CH₃)₂, -NHC(0)CH₂(3-methyl- 1 ,2-oxazol-5-yl),

-NHC(0)CH₂NHCH₂(3-hydroxyphenyl), -NHC(0)(N-methyl-pyiTol-2-yl), -NHC(0)(2- amino-tetrahydropyran-2-yl), -NHC(0)CH₂(4-methylamino-piperidin- 1-yl),

-NHC(0)(piperidin- 1 -yl), -NHC(0)(N-methyl-pyrrolidin-2y 1), -NHC(0)(thien-3yl), -NHC(0)(N-(cyclopropylcarbonyl)azetidin-3-y I), -NHC(0)CH₂(4-methylpiperazin- 1 -yl), -NHC(0)(N-benzylazetidin-3-yl), -NHC(0)(2-chloro-pyridin-3-yl), -NHC(0)CH₂(pyridin- 4-yl), -NHC(0)CH2N(CH₃)(CH₂CH=CH2), -NHC(0)CH2 H(benzyl), -NHC(0)CH₂OCH_3> -NHC(0)[l-(C(0)CH₂CH₃)-azetidin-3-yl], -NHC(0)(pyridin-3-yl),

-NHC(0)CH₂NHCH₂CH₂OCH₃, -NHC(0)(l-[C(0)CH₃]piperidin-4-yl), -NHC(0)CH₂(2- methyl-pyrrolidin-l-yl), -NHC(0)(furan-3-yl), -NHC(0)CH₂N(CH₃)₂, -NHC(0)(2-chloro- pyridin-5-yl), -NHC(0)(2-chlorophenyl), -NHC(0)CH₂(pyridin-2-yl), -NHC(0)CH₂(3- dimethylamino-azetidin-l-yl), - HC(0)CH₂(pyridin-3-yl), -NHC(0)CH₂(2-chlorophenyl), -NHC(0)CH₂N(CH₃)CH₂CH₂CH₂N(CH₃)₂, -NHC(0)CH2N(CH₂CH₃)CH₂CH₂OH, -NHC(0)CH₂(2-benzyl-pyrroIidin- 1-yl), -NHC(0)(furan-2-y 1, -NHC(0)(2-chloro-pyridin- 4-yl), -NHC(0)CH₂NHC(0)CH₃, -NHC(0)CH₂CH₂CH₃, -NHC(0)(4-chlorophenyl), -NHC(0)(4-methyl-phenyl), -NHC(0)CH₂NHC(0)0(CH₃)₃,

-NHC(0)(benzo[d][l,3]dioxol-5-yl), -NHC(0)CH₂NHOCH₂(2-methoxyphenyl),

-NHC(0)(pyridin-4-yl), -NHC(0)CH₂[4-(3,4-dichlorophenyl)-piperazin-l-yl],

-NHC(0)CH₂CH₂(pyridin-3-yl), -NHC(0)(tetrahydrofuran-3-yl), -NHC(0)CH₂NHCH₂(2- methylphenyl), -NHC(0)CH(CH₃)CH₂CH₃, -NHC(0)CH₂(3-fluorophenyl),

-NHC(0)CH₂C(CH₃)₂phenyl, -NHC(0)(2-methyl-cycloprop-l-yl), -NHC(0)(2-methyl- 4-methoxyphenyl), -NHC(0)(2-methylpyridin-3-yl), -NHC(0)(4-methoxyphenyl), -NHC(0)CH₂(4-ethylpiperazin- 1 -yl), -NHC(0)(thien-2-yl), -NHC(0)(3-fluoro-2- methylphenyl), -NHC(0)(2-bromo-thien-3-yl), -NHC(0)(4-fluorophenyl), -NHC(0)CH₂(3- methylpiperidin-l-yl), -NHC(0)CH(CH₃)₂, -NHC(0)(CH₂)₃CH₃, -NHC(0)CH₂OCH₂CH₃, -NHC(0)CH₂NH(2-fluorophenyl), -NHC(0)(3-dimethylaminophenyl), -NHC(0)CH₂(4- methylpiperidin- 1 -yl), -NHC(0)CH₂NH(2-«-propy Iphenyl), -NHC(0)phenyl,

-NHC(0)(pyrazin2-yl), -NHC(0)(3-fluoro-4-methoxyphenyl), -NHC(0)C(CH₃)₂CH₂CH₃, -NHC(0)CH₂0(4-fluorophenyl), -NHC(0)(l-methylcarbonyl-azetidin-3-yl),

-NHC(0)CH₂NH(4-methylphenyl), -NHC(0)CH₂NH(phenyl), -NHC(0)CH₂(4-allyl- piperazin-l-yl), -NHC(0)(2-methylphenyl), -NHC(0)CH₂CH₂OCH₃, -NHC(0)(3-methyl- furan-2-yl), -NHC(0)C(CH₃)₃, -NHC(0)CH₂NHObenzyl,

-NHC(0)CH₂NH(3-chlorophenyl), -NHC(0)cyclobutyl, -NHC(0)CH₂(3-methoxyphenyl), -NHC(0)(l-methylcycloprop- 1-yl), -NHC(0)(3-flurophenyl),

-NHC(0)(4-dimethylaminophenyl), -NHC(0)(3,4-dichlorophenyl),

-NHC(0)CH₂NHCH₂(2-methylthiophenyl), -NHC(0)CH₂(2-fluorophenyl),

-NHC(0)CH₂N(CH₂CH₃)CH(CH₃)₂, -NHC(0)(thiazol-4-yl), -NHC(0)CH₂N(CH₃)benzyl, -NHC(0)CH₂NHCH₂(thien-2-yl), -NHC(0)CH₂NHCH₂(pyridin-2-yl), -NHC(0)(3- methoxyphenyl), -NHC(0)CH₂NHCH₂(3-chloro-4-methylphenyl),

-NHC(0)CH(CH₃)CH₂CH₂CH₃, -NHC(0)CH₂(4-chlorophenyl), -NHC(0)(3-fluoro-4- methylphenyl), -NHC(0)CH₂0(2-methylphenyl), -NHC(0)CH₂(cyclohexyl), -NHC(0)(2- phenyl-cycloprop- 1 -yl), - HC(0)(3-chlorophenyl), -NHC(0)CH₂(2-methoxyphenyl), -NHC(0)CH₂CH₂(3-methoxyphenyl), -NHC(0)CH NH(2-fluoro-4-methyl-phenyl), -NHC(0)CH₂NHCH₂(3-fluoro-phenyl), -NHC(0)CH₂(4-methoxy-phenyl),

-NHC(0)benzyl, -NHC(0)(2,4-dichlorophenyl), -NHC(0)(3-oxo-cyclohex- 1 -yl),

-NHC(0)CH₂NH(3-fluorophenyl), - HC(0)CH₂(3-chlorophenyl),

-NHC(0)CH₂NHCH₂CH(CH₃)phenyl, -NHC(0)CH₂NHCH₂(2,4-dimethylphenyl), -NHC(0)CH₂(2-methyl-piperidin- 1 -yl), -NHC(0)CH₂NH(2-methoxyphenyl), -NHC(0)CH₂( 1 ,2,3,4-tetrahydroisoquinolin-2-yl), -NHC(0)CH₂CH₂CH=CH₂,

-NHC(0)CH₂NH(2-methylphenyl), -NHC(0)CH₂(4-oxo-piperidin-l-yl), -NHC(0)(2- fluorophenyl), -NHC(0)CH₂NHCH(CH₃)phenyl, -NHC(0)(2-fluoro-6-methoxyphenyl), - HC(0)CH₂NH(2-isopropylphenyl), -NHC(0)CH₂CH₂(2-methoxyphenyl),

- HC(0)CH₂CH₂CH(CH₃)₂, -NHC(0)CH₂(2-phenyl-mo holin-4-yl),

-NHC(0)CH₂CH₂(4-methoxyphenyl), -NHC(0)CH₂N(allyl)cyclopentyl,

-NHC(0)CH₂N(CH₃)CH₂CH₂OCH₃, -NHC(0)CH₂CH₂C(0)cyclopropyl,

-NHC(0)CH₂NH(3-tert-butylphenyl), -NHC(0)CH₂N(n-propyl)(cyclopropylmethyl), -NHC(0)CH₂(2-oxo-cyclopentyl), -NHC(0)CH₂NH(4-chlorophenyl), -NHC(0)CH₂(4- piperidin- 1 -ylpiperidin- 1 -y 1), -NHC(0)CH₂(4-cyclopenty Ipiperazin- 1 -y I), -NHC(0)CH₂(2- methylphenyl), - HC(0)CH₂NHCH₂(3-fluoro-6-methylphenyl), -NHC(0)CH₂C(CH₃)₃, -NHC(0)CH₂NH(2-chlorophenyl), -NHC(0)(3-fluoro-6-methylphenyl), -NHC(0)(4-fluoro-

3- methylphenyl), -NHC(0)(2,3-dichlorophenyl), -NHC(0)CH₂Ophenyl,

-NHC(0)CH₂NH(2,3-dimethylphenyl), -NHC(0)(2-fluoro-5-methylphenyl),

-NHC(0)CH₂ HOCH₂(4-methylphenyl), -NHC(0)CH₂(4-isopropylpiperazin- 1 -yl), -NHC(0)CH₂(4-fluorophenyl), -NHC(0)CH₂CH(CH₃)₂, -NHC(0)(2-methoxy-

4- methylphenyl), -NHC(0)CH₂(4-«-propylpiperidin- 1-yl), -NHC(0)CH₂0(3- methylphenyl), -NHC(0)(tetrahydrofuran-2-yl), -NHC(0)CH₂(3-hydroxymethylpiperidin- 1 -yl), -NHC(0)( 1 -tm-butoxycarbonylpiperidin-2-yl), -NHC(0)CH₂N(CH₃)CH₂(pyridin-3- yl), -NHC(0)CH₂N(CH₂CH₃)phenyl, -NHC(0)CH₂OCH₂CH₂OCH₃,

- HC(0)CH₂CH₂(cyclopentyl), -lSfHC(0)(2,5-dichlorophenyl), -NHC(0)CH₂(4- methylcarbonylpiperazin- 1 -yl), -NHC(0)(5-fluoro-2-methoxyphenyl),

-NHC(0)CH₂N(CH₂CH₃)cyclohexyl, -NHC(0)(5-methyl-l,2-oxazol-3-yl), -NHC(0)(3- methylpyridin-3-yl), -NHC(0)(2-methoxypyridin-3-yl), -NHC(0)(3,5-dichlorophenyl), -NHC(0)CH₂(thiazolidin3-yl), -NHC(0)CH₂(4-[C(0)H]-piperazin-l -yl), -NHC(0)CH₂(2- pyridin-4-y lpiperidin- 1 -y 1), -NHC(0)(2-methoxyphenyl),

-NHC(0)CH₂N(CH₃)CH₂CH(CH₃)₂, -NHC(0)CH₂(4-[C(0)H]-homopiperazin- 1 -yl), -NHC(0)( 1-phenylcycloprop- 1 -yl), -NHC(0)CH₂(2,6-dimethylmorpholin-4-yl),

^ΉC(0)CH₂(2-phenylpy-τoIidin-l-yl)_> -NHC(0)CH₂(rnoφholin-4-yl),

-C(0)NHCH(CH₃)CH₂N(CH₃)₂, -C(0)NHCH₂CH₂N(CH₃)₂, -C(0)NH(pyrrolidin-3-yl), -C(0) HCH₂CH₂(pyrrolidin-l-yl), -C(0)NHCH₂CH₂NH₂, -C(0)N(CH₃)CH₂CH₂N(CH₃)₂, -C(0)NHCH₂(piperidin-2-yl), -C(0)NH( l-methylazetidin-3-yl),

-C(0) HCH₂CH₂(piperidin-l-yl), -C(0)NHCH₂CH₂N(CH₂CH₃)₂, -C(0)NH(1- methylpiperidin-3-y 1), -C(0)NH(piperidin-3-yl), -C(0)NHCH₂( 1 -methy lpiperidin-3-y 1), -C(0)NHCH₂CH₂N(CH₂CH20H)_2> -C(0)NH(l-ethylpiperidin-3-yl), -C(0)NH₂, -C(0)(3- aminopyrrolidin- l-yl), -C(0)(3-methylaminopyrrolidin-l-yl), -C(0)OH,

-C(0)raCH₂CH₂(morpholin-4-y 1), -C(0)NHCH₂( 1 -ethy lpyrrolidin-2-y 1), -C(0)(4-amino- 3-oxo-pyrazolidin- 1 -y 1), -C(0)NHC¾, -C(0)(3-aminocyclobut- 1 -yl),

-C(0)NHCH₂(pyridin-3-yl), -C(0)NHCH₂CH₂OH, -C(0)NH(3-oxo-pyrazoIidin-4-yl), -NHCH₂CH₂(imidazol-4-yl), -C(0)(3-dimethylaminopyrrolidin- l-yl),

-C(0)NHCH₂(pyridin-4-y 1), -C(0)N(CH₃)( -methy l-pyrrolidin-3-y 1), -C(0)(3- diethy laminopyrrolidin- l-yl), -C(0)NH(pyrrol- l-yl), -C(0)NHCH₂CH₂CH₂(pyrrolidin- 1 - yl), -C(0)N(CH₃)CH₂CH₂CN, -C(0)NHCH₂CH₂OCH₃, -C(0)N(CH₂CH₃)CH₂CH₂CN, -C(0)(3-aminopiperidin- 1 -yl), -C(0)NHCH₂CH₂CH₂N(CH₃)2, -C(0)NH(mo holin-4-yl), -C(0)NHN(CH₃)₂, -C(0)NHCH₂CH₂CH2(imidazol- 1 -yl),

-C(0)NHCH₂CH₂CH2N(CH2CH3)2, -C(0)NHCH₂CH₂CN, -C(0)NHCH₂CH₂C(0)OCH₃, -C(0)NHCH₂CH₂SCH₃, -C(0)NHCH2CH₂SCH₂CH3, -C(0)N(CH₂CH₃)CH₂CH₂N(CH₃)2, -C(0) HCH₂CH₂CH₂(2-oxo-pyrrolidin- 1 -yl), -C(0)NHCH₂CH₂(pyridin-4-yl),

-C(0)NHCH₂CH₂CH₂OCH₂CH₃, -C(0)NHCH₂CH₂CH₂(morpholin-4-yl),

-C(0)NHCH₂CH₂CH₂OCH₃, -C(0)N(CH₃)CH₂CH₂CH₂N(CH₃)₂,

-C(0)NHCH₂CH₂CH₂OCH2CH₂CH₃, -C(0)NHCH₂CH₂C(0)OCH₂CH₃,

-C(0)NHCH₂CH₂CH₂OCH(CH3)₂, -C(0)NHC(CH₃)₂CH₂(piperidin- l-yl),

-C(0)N(CH₃)CH₂CH₂CH₃, -C(0)NH(piperidin- 1 -yl), -C(0)NHCH(CH₃)CH₂OCH₃, -C(0)NHC(CH3)2CH₂(mo holίn-4-yl), -C(0)(2-dimethylaminomethylpiperidin-l-yl), -C(0)NH(CH₂)₃0(CH₂)₃CH3, -C(0)NHCH(CH₃)(CH₂)₃N(CH₂CH₃)₂,

-C(0)NHC(CH₃)₂C(0)(piperidin- 1 -yl), -C(0)(4-methylpiperazin- 1 -yl), -C(0)(2-piperidin- 1-ylmethyl-piperidin- l-yl), cyano, -NHCH₃, -CH(CH₃)NHCH2CH₂N(CH₃)₂, -C(0)CH₃, -S(0)2NHCH₂CH₂N(CH3)₂, -S(0)₂NH(CH₂)₃N(CH₃)₂, 5-(NN-dimethylaminomethyl)- l,3,4-oxadiazol-2-yl, -NHCH₂CH₂N(CH₃)₂, -N(CH₃)₂, -OCH₂CH₂N(CH₃)₂,

-NHC[N(CH₃)₂][=N(CH₃)₂], -OCHF₂, -CF₃, -S(0)₂CH₃, -OCF₃, -NHC(0)CH₂(4- dimethylaminopiperidin-l-yl), or methoxy.

[00112] In a more specific embodiment (P), the Compound of Formula I is that where each R³ is independently halo, alky], hydroxyamino, -N(R⁷)C(0)-C| -C6-alkylene- N(R^7a)(R^7b), -C(0)NR⁸R^8a , -NR⁹C(0)R^9a, -QOJNiR'Vd-Ce-alkylene- N(R^10a)R^10b-NR"C(O)NR^{l la}R^{l lb}, -N(R²²)C(0)-C,.C₆-alkylene-N(R^2Zb)-N(R^22c)(R^22a), -NR¹³C(0)OR^l3a, -N(R¹⁸)C(0)-C,-C₆-alkylene-N(R^{l 8b})C(0)R^,8a , -NR²⁴C(0)-C,.C₆- alkylene-OR^{2 a}, or -N(R²⁰)C(O)-C,-C6-alkylene-C(O)R^20a; where each of the alkylene in R³ is independently optionally further substituted with 1 , 2, 3, 4, or 5 groups selected from halo, hydroxy, and amino; and all other groups are as defined in the Summary of the Invention. Specifically, each R³ is independently methyl, chloro, -NHC(0)CH₂NH(CH₃), -NHC(0)CH(CH₃)NH₂, -NHC(0)C(CH₃)₂NH₂, -NHC(0)CH₂N(CH₃)₂,

-NHC(0)CH₂N(CH₃)CH₂CH₂N(CH₃)₂, -NHC(0)CH(NH₂)CH₂CH₃,

- HC(0)CH₂N(CH₃)CH₂CH₂N(CH₃)₂, -NHC(0)CH(CH₃) H(CH₃), -NHC(0)H, -NHC(0)CH₂(azetidin-l -yl), - HC(0)(pyrrolidin-2-yl), -NHC(0)CH(NH₂)CH₂OH, -NHC(0)(azetidin-4-yl), -NHC(0)C(CH₃)₂NH(CH₃), -NH₂,

-NHC(0)CH₂NH(CH₂CH₂CH₃), -NHC(0)CH₂CH₂NH₂, -NHOH, or -NHC(0)(piperidin-3- yi).

[00113] In a more specific embodiment (Q), the Compound of Formula I is that where R³ is alkyl or -N(R⁷)C(0)-C,-C₆-alkylene-N(R^7a)(R^7b); and R⁷ is hydrogen or alkyl and R^7a and R^7b are independently hydrogen, alkyl, aminoalkyl, alkylaminoalkyl, or

dialkylaminoalkyl; and all other groups are as defined in the Summary of the Invention. More specifically, each R³ is independently methyl, -NHC(0)CH₂NH(CH₃),

-NHC(0)CH(CH₃)NH₂, -NHC(0)C(CH₃)₂NH₂, -NHC(0)CH₂N(CH₃)₂,

-NHC(0)CH₂N(CH₃)CH₂CH₂N(CH₃)₂, -NHC(0)CH(NH₂)CH₂CH₃,

-NHC(0)CH₂N(CH₃)CH₂CH₂N(CH₃)₂, or -NHC(0)CH(CH₃)NH(CH₃).

[00114] In another specific embodiment (R), the Compound of Formula I is that where B is phenyl, R³ is not present or R³ is halo, alkyl, or alkoxy; R^3a is -C(0)NR⁸R^8a,

-NR⁹C(0)R^9a, -N(R⁷)C(0)-C|-C₆-alkylene-N(R^7a)(R^7b), or -C(O)N(R¹⁰)-C,-C₅-alkylene- N(R^IOa)R^10b where each of the alkylene in R³ is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, and amino; and all other groups are as defined in the Summary of the Invention.

[00115] In a more specific embodiment (Rl) of embodiment R, the compound is that where R⁵⁰, R⁵², and R⁵³ are hydrogen and R⁵⁴ is halo or alkoxy; R⁵⁰, R⁵², and R⁵⁴ are hydrogen and R⁵³ is alkoxy; or R⁵⁰ and R⁵² are hydrogen and R⁵³ and R⁵⁴ together with the carbons to which they are attached form a 6-membered heteroaryl; and all other groups are as defined in the Summary of the Invention. Specifically, R⁵⁰, R⁵², and R⁵³ are hydrogen and R⁵⁴ is halo or alkoxy; or R⁵⁰, R⁵², and R⁵⁴ are hydrogen and R⁵³ is alkoxy.

[00116] In a more specific embodiment of (R2) of embodiment R, the compound is that where R⁵¹ is methyl. [00117] In a more specific embodiment (S), the compound of Formula la:

1(a)

is that where R³ is not present or R³ is alkyl and R³ is -N(R⁷)C(0)-Ci-C6-alkylene- N(R^7a)(R^7b), -C(0)NR⁸R^8a , -NR⁹C(0)R^9a, or -C(O)N(R¹⁰)-C,-C₆-alkylene-N(R^10a)R^10b; where each of the alkylene in R^3a is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, and amino; and all other groups are as defined in the Summary of the Invention. Specifically, R³ is not present or is methyl. More specifically, R³ is not present.

[00118] In a more specific embodiment (S 1 ) of embodiment S is that where R⁷ is hydrogen or alkyl and R^7a, and R^7b are independently hydrogen, alkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl; R^s is hydrogen or alkyl and R^8a is heterocycloalkyl or heterocycloalkylalkyl; R⁹ is hydrogen or alkyl and R^9a is hydrogen, heterocycloalkyl, or heterocycloalkylalkyl; and R¹⁰, R^10a, and R^10b are independently hydrogen, alkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl.

[00119] In a more specific embodiment (S2) of embodiment S is that where R⁵⁰, R⁵², and R⁵³ are hydrogen and R⁵⁴ is halo or alkoxy; or R⁵⁰, R⁵², and R⁵⁴ are hydrogen and R⁵³ is alkoxy; or R⁵⁰ and R⁵² are hydrogen and R⁵³ and R⁵⁴ together with the carbons to which they are attached form a 6-membered heteroaryl. Specifically, R⁵⁰, R⁵², and R⁵³ are hydrogen and R⁵⁴ is halo or alkoxy; or R⁵⁰, R⁵², and R⁵⁴ are hydrogen and R⁵³ is alkoxy.

[00120] In a more specific embodiment of (S3) of embodiment S, the compound is that where R⁵¹ is methyl.

[00121] In another specific embodiment (T), the Compound of Formula I is that where B is heteroaryl, one R³ is halo, alkyl, or alkoxy and a second R³ is -C(0)NR⁸R^8a, -NR⁹C(0)R ^a, -N(R⁷)C(0)-C_rC₆-alkylene-N(R^7a)(R^7b), or -C(O)N(R¹⁰)-Ci-C₆-alkyIene- N(R^10a)R^10b where each of the alkylene in R³ is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, and amino; and all other groups are as defined in the Summary of the Invention. [00122] In another specific embodiment (Tl) of embodiment T, the compound is that where R⁷ is hydrogen or alkyl and R ^a, and R^7b are independently hydrogen, alkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyi, or dialkylaminoalkyl; R⁸ is hydrogen or alkyl and R^8a is heterocycloalkyl or heterocycloalkylalkyl; R⁹ is hydrogen or alkyl and R^9a is hydrogen, heterocycloalkyl, or heterocycloalkylalkyl; R¹⁰, R^10a, and R^l0b are independently hydrogen, alkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyi, or dialkylaminoalkyl.

[00123] In another specific embodiment U, the compound of Formula I is that where B is

is independently halo, alkyl, alkoxy, aminoalkyloxy, alkylaminoalkyloxy,

dialkylaminoalkyloxy, alkylamino, dialkylamino, -C(0)NR⁸R^8a, -NR⁹C(0)R^9a, -N(R⁷)C(0)- C,-C₆-alkylene-N(R^7a)(R ^b), or -C(O)N(R^l0)-Ci-C₆-alkylene-N(R^10a)R^10b; and all other groups are as defined in the Summary of the Invention.

[00124] In a more specific embodiment (Ul) of embodiment U, the compound of Formula I is that where R⁵⁰, R⁵², and R⁵³ are hydrogen and R⁵⁴ is halo or alkoxy; R⁵⁰, R⁵², and R⁵⁴ are hydrogen and R⁵³ is alkoxy; or R⁵⁰ and R⁵² are hydrogen and R⁵³ and R⁵⁴ together with the carbons to which they are attached form a 6-membered heteroaryl; and all other groups are as defined in the Summary of the Invention. Specifically, R⁵⁰, R⁵², and R⁵³ are hydrogen and R⁵⁴ is halo or alkoxy; or R⁵⁰, R⁵², and R⁵⁴ are hydrogen and R⁵³ is alkoxy.

[00125] In a more specific embodiment (U2) of embodiment Ul, the compound of Formula I is that where R⁵¹ is methyl.

[00126] In another specific embodiment (U3) of embodiment U, the Compound of Formula I is that where R⁷ is hydrogen or alkyl and R^7a, and R^7b are independently hydrogen, alkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyi, or dialkylaminoalkyl; R⁸ is hydrogen or alkyl and R⁸³ is heterocycloalkyl or heterocycloalkylalkyl; R⁹ is hydrogen or alkyl and R^9a is hydrogen, heterocycloalkyl, or heterocycloalkylalkyl; R¹⁰, R^IOa, and R^10b are independently hydrogen, alkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyi, or

dialkylaminoalkyl

In another embodiment of the Invention (V) the Compound of Formula I is that whereW¹, W², W³, and W⁴ are -C(H)=; or W² and W³ are -C(H)= and one of W¹ and W⁴ is -N= and the other is -C(H)=;

R⁵⁰ is hydrogen; R⁵¹ is hydrogen or alkyl;

R⁵² is hydrogen;

R⁵³ is hydrogen, alkoxy, nitro, amino, or -N(R⁵⁵)C(0)-Ci-C₆-alkylene-N(R^55a)R^55b; and R⁵⁴ is hydrogen, alkyl, alkoxy, or halo; or R⁵³ and R⁵⁴ together with the carbons to which they are attached form a 6-membered heteroaryl;

B is phenyl substituted with R^3a and optionally further substituted with one R³; or

B is heteroaryl optionally substituted with one or two R³;

R^3a is cyano; hydroxyamino; carboxy; alkylsulfonyl, aminoalkyloxy; alkylaminoalkyloxy; dialkylaminoalkyloxy; -N(R⁷)C(0)-C,-C₆-alkylene-N(R^7a)(R^7b); -C(0)NR⁸R^8a;

-NR⁹C(0)R^9a; -C(O)N(R¹⁰)-C,-C₆-alkylene-N(R^,0a)R^10b; -NRⁿC(0)NR^{l la}R^{l lb} where R^{1 ,a}; -C(0)R¹²; -NR¹³C(0)OR^13a; -C(0)N(R¹⁴)N(R^14a)(R^14b); -S(0)₂N(R¹⁵)-Ci.C₆- alkylene-N(R^15a)R^,5b; -C(0)N(R¹⁶)-Ci.C₆-alkylene-C(0)OR^16a; heteroaryl optionally substituted with one or two aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl;

-N(R^,7)-C(=N(R^17b)(R^,7a))(NR^17cR^17d); -N(R¹⁸)C(0)-C,-C₆-alkylene-N(R^,8b)C(0)R^18a; -C(0)N(R¹⁹)-Ci-C₆-alkylene-C(0)R^19a; -NiR^CiC -C -alkylene-NtR²²")- N(R^22c)(R^22a); -Co-C₆-alkylene-N(R²³)-C,.C₆-alkylene-N(R^23b)R^23a; or -NR²⁴C(0)- Ci.C₆-alkylene-OR^24a; where each of the alkylene in R^3a is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, and amino; each R³ (when R³ is present) is independently halo; cyano; alkyl; alkenyl; alkoxy;

hydroxyamino; carboxy; alkylsulfonyl, aminoalkyloxy; alkylaminoalkyloxy;

dialkylaminoalkyloxy; -N(R⁷)C(0)-Ci-C₆-alkylene-N(R^7a)(R^7b); -C(0)NR⁸R^8a;

-NR⁹C(0)R^9a; -C(O)N(R¹⁰)-C|-C₆-alkylene-N(R^l0a)R^10b; -NR^{l l}C(0)NR^{l la}R^{l lb} where R^{l la}; -C(0)R¹²; -NR^, C(0)OR^{l 3a}; -C(0)N(R¹⁴)N(R^14a)(R^14b); -S(0)2 (R¹⁵)-Ci.C6- alkylene-N(R^l3a)R^15b; -C(0)N(R^l6)-C,.C6-alkylene-C(0)OR^,6a; heteroaryl optionally substituted with one or two aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl;

-N(R¹⁷)-C(=N(R^17b)(R^l7a))(NR^l7cR^17d); -N(R^l8)C(0)-Ci-C₆-alkylene-N(R^18b)C(0)R^18a; -C(0)N(R¹⁹)-C_rC₆-alkylene-C(0)R^19a; -N(R²²)C(0)-C,.C₆-alkylene-N(R^{2 b})- N(R^22c)(R^{2 a}); -Co-C₆-alkylene-N(R²³)-C_1-C₆-alkylene-N(R²³ )R^23a; or -NR²⁴C(0)- Ci-C₆-alkylene-OR^24a; where each of the alkylene in R³ is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, and amino; provided that when R⁵⁰ and R⁵² are hydrogen, R⁵¹ is hydrogen or methyl, R⁵³ is hydrogen or methoxy, and R⁵⁴ is hydrogen or methoxy, then B is not 2,3-dihydro-l,4- benzodioxinyl, thien-2-yl, or thien-2-yl substituted with one R³ where R³ is halo. [00127] Another embodiment (W) of the invention is a Compound of Formula I where R⁵⁰, R⁵³, and R⁵⁴ are independently hydrogen, alkyl, alkenyl, halo, haloalkyl, haloalkenyl, hydroxy, alkoxy, alkenyloxy, haloalkoxy, nitro, amino, alkylamino, dialkylamino, -N(R⁵⁵)C(0)-Ci-C₆-alkylene-N(R^55a)R^55b, alkylcarbonyl, alkenylcarbonyl, carboxy, alkoxycarbonyl, cyano, alkylthio, -S(0)₂NR⁵⁵R^55a, or alkylcarbonylamino and where R⁵⁵ and R^55b are indepedently hydrogen, alkyl, or alkenyl and R^55a is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy; or R⁵³ and R⁵⁴ together with the carbons to which they are attached form a 5- or 6-membered heteroaryl or 5- or 6-membered heterocycloalkyl.

[00128] Another embodiment (X) of the invention is a Compound of Formula I where R⁵³ and R⁵⁴ together with the carbons to which they are attached form a 5- or 6-membered heteroaryl or 5- or 6-membered heterocycloalkyl.

Compounds of Formula II

[00129] In another embodiment, the compound of Formula I or la is a compound of Formula Π:

II

or a pharmaceutically acceptable salt thereof, wherein:

R⁵⁰ is hydrogen;

R⁵¹is methyl;

R is hydrogen;

R⁵³ is hydrogen or alkoxy; and

R⁵⁴ is hydrogen, alkyl, alkoxy, or halo; or R⁵³ and R⁵⁴ together with the carbons to which they are attached form a 6-membered heteroaryl; and

R³ is halo or methyl; and

R^3a is -N(R⁷)C(0)-C|-C⁶-alkylene-N(R^7a)(R^7b) where R⁷ is hydrogen and R^7a and R^7b are independently hydrogen, alkyl, aminoalkyl, alkylaminoalkyl, or

dialkylaminoalkyl. [00130] In one embodiment of the compound of Formula II, R⁵¹ is methyl; and R⁵⁰, R⁵², and R⁵³ are hydrogen and R⁵⁴ is halo or alkoxy or R⁵⁰, R⁵², and R⁵⁴ are hydrogen and R⁵³ is alkoxy; or a single stereoisomer or mixture of stereoisomers thereof.

[00131] In another embodiment, R^3a is -NHC(0)CH₂NH(CH₃), -NHC(0)CH(CH₃)NH₂, -

NHC(0)C(CH₃)₂NH₂₎ -NHC(0)-CH1N(CH₃)₂, - HC(0)CH₂N(CH₃)CH₂CH₂N(CH₃)₂, -

NHC(0)CH(NH₂)CH₂CH₃₍ -NHC(0)CH₂N(CH₃)CH₂CH₂N(CH₃)₂, or -

NHC(0)CH(CH₃)NH(CH₃).

[00132] In another embodiment, the compound of Formula Π is:

[00133] In another embodiment, the compound of Formula la is:

or a pharmaceutically acceptable salt thereof.

[00134] Another specific embodiment of the invention is a pharmaceutical composition comprising a compound of Formula I, Formula la, or Formula II or a compound according the above Embodiments A-X and a pharmaceutically acceptable carrier, excipient, or diluent.

[00135] Another specific embodiment of the invention is a method of inhibiting PI3K in a cell, comprising contacting a cell in which inhibition of PI3K is desired with a compound of Formula I, la, or II or a compound according to Embodiments A-X. Specifically, the Compound is of Formula II.

[00136] Another specific embodiment of the invention is a method of treating a disease, disorder, or syndrome mediated by PI3K which method comprises administering to a patient a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, la, or Π or a compound according to embodiments A-X. Specifically, the Compound is of Formula I or la. More specifically, the Compound is of Formula II.

[00137] More specifically, the disease is cancer. Even more specifically, the cancer is breast cancer, colon cancer, rectal cancer, endometrial cancer, gastric carcinoma, glioblastoma, hepatocellular carcinoma, small cell lung cancer, non-small cell lung cancer, melanoma, ovarian cancer, cervical cancer, pancreatic cancer, prostate carcinoma, acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), or thyroid carcinoma. Even more specifically, the cancer is ovarian cancer, cervical cancer, breast cancer, colon cancer, rectal cancer, or glioblastoma.

[00138] Another aspect of the Invention is directed to employing the compounds of the invention in a method of screening for candidate agents that bind to, for example PI3K. In that method, the protein is bound to a support, and a compound of the invention is added to the assay. Alternatively, the compound of the invention is bound to the support and the protein is added. Classes of candidate agents among which novel binding agents may be sought include specific antibodies, non-natural binding agents identified in screens of chemical libraries, peptide analogs, etc. Of particular interest are screening assays for candidate agents that have a low toxicity for human cells. A wide variety of assays may be used for this purpose, including labeled in vitro protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, functional assays (phosphorylation assays, etc.) and the like.

[00139] The determination of the binding of the candidate agent to, for example, PI3K may be done in a number of ways. In one example, the candidate agent (the compound of the invention) is labeled, for example, with a fluorescent or radioactive moiety and binding determined directly. For example, this may be done by attaching all or a portion of the PI3K protein to a solid support, adding a labeled agent (for example a compound of the invention in which at least one atom has been replaced by a detectable isotope), washing off excess reagent, and determining whether the amount of the label is that present on the solid support. Various blocking and washing steps may be utilized as is known in the art.

[00140] The term "labeled" as used herein is meant to include both direct and indirect labeling with a compound that provides a detectable signal, for example, radioisotope, fluorescent tag, enzyme, antibodies, particles such as magnetic particles, chemiluminescent tag, or specific binding molecules, and the like. Specific binding molecules include pairs, such as biotin and streptavidin, digoxin and antidigoxin, and the like. For the specific binding members, the complementary member would normally be labeled with a molecule which provides for detection, in accordance with known procedures, as outlined above. The label can directly or indirectly provide a detectable signal.

[00141] In some embodiments, only one of the components is labeled. For example, PI3K protein may be labeled at tyrosine positions using ^l25I, or with fluorophores.

Alternatively, more than one component may be labeled with different labels; using ^l25I for the proteins, for example, and a fluorophor for the candidate agents.

[00142] The compounds of the invention may also be used as competitors to screen for additional drug candidates. The terms "candidate bioactive agent" or "drag candidate" or grammatical equivalents as used herein describe any molecule, e.g., protein, oligopeptide, small organic molecule, polysaccharide, polynucleotide, etc., to be tested for bioactivity. They may be capable of directly or indirectly altering the cellular proliferation phenotype or the expression of a cellular proliferation sequence, including both nucleic acid sequences and protein sequences. In other cases, alteration of cellular proliferation protein binding and/or activity is screened. In the case where protein binding or activity is screened, some embodiments exclude molecules already known to bind to that particular protein.

Exemplary embodiments of assays described herein include candidate agents, which do not bind the target protein in its endogenous native state, termed herein as "exogenous" agents. In one example, exogenous agents further exclude antibodies to PI3K.

[00143] Candidate agents can encompass numerous chemical classes, though typically they are organic molecules having a molecular weight of more than about 100 and less than about 2,500 daltons. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding and lipophilic binding, and typically include at least an amine, carbonyl, hydroxyl, ether, or carboxyl group, for example at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocycloalkyl structures and/or aromatic or heteroaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs, or combinations thereof.

[00144] Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification to produce structural analogs.

[00145] In one example, the binding of the candidate agent is determined through the use of competitive binding assays. In this example, the competitor is a binding moiety known to bind to IGF1R, such as an antibody, peptide, binding partner, ligand, etc. Under certain circumstances, there may be competitive binding as between the candidate agent and the binding moiety, with the binding moiety displacing the candidate agent.

[00146] In some embodiments, the candidate agent is labeled. Either the candidate agent, or the competitor, or both, is added first to PI3K protein for a time sufficient to allow binding, if present. Incubations may be performed at any temperature that facilitates optimal activity, typically between 4°C and 40°C.

[00147] Incubation periods are selected for optimum activity, but may also be optimized to facilitate rapid high throughput screening. Typically between 0.1 and 1 hour will be sufficient. Excess reagent is generally removed or washed away. The second component is then added, and the presence or absence of the labeled component is followed, to indicate binding.

[00148] In one example, the competitor is added first, followed by the candidate agent. Displacement of the competitor is an indication the candidate agent is binding to PI3K and thus is capable of binding to, and potentially modulating, the activity of the PI3K. In this embodiment, either component can be labeled. Thus, for example, if the competitor is labeled, the presence of label in the wash solution indicates displacement by the agent. Alternatively, if the candidate agent is labeled, the presence of the label on the support indicates displacement.

[00149] In an alternative embodiment, the candidate agent is added first, with incubation and washing, followed by the competitor. The absence of binding by the competitor may indicate the candidate agent is bound to PI3K with a higher affinity. Thus, if the candidate agent is labeled, the presence of the label on the support, coupled with a lack of competitor binding, may indicate the candidate agent is capable of binding to PI3K.

[00150] It may be of value to identify the binding site of PI3K. This can be done in a variety of ways. In one embodiment, once PI3K is identified as binding to the candidate agent, the PI3K is fragmented or modified and the assays repeated to identify the necessary components for binding. [00151] Modulation is tested by screening for candidate agents capable of modulating the activity of PI3K comprising the steps of combining a candidate agent with PI3K, as above, and determining an alteration in the biological activity of the PI3K. Thus, in this embodiment, the candidate agent should both bind to (although this may not be necessary), and alter its biological or biochemical activity as defined herein. The methods include both in vitro screening methods and in vivo screening of cells for alterations in cell viability, morphology, and the like.

[00152] Alternatively, differential screening may be used to identify drug candidates that bind to native PI3K, but cannot bind to modified PI3K.

[00153] Positive controls and negative controls can be used in the assays. For example, all control and test samples are performed in at least triplicate to obtain statistically significant results. Incubation of samples is for a time sufficient for the binding of the agent to the protein. Following incubation, samples are washed free of non-specifically bound material and the amount of bound, generally labeled agent determined. For example, where a radiolabel is employed, the samples can be counted in a scintillation counter to determine the amount of bound compound.

[00154] A variety of other reagents can be included in the screening assays. These include reagents like salts, neutral proteins, e.g., albumin, detergents, etc which may be used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Also reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may be used. The mixture of components can be added in any order that provides for the requisite binding.

[00155] One of ordinary skill in the art would understand that certain crystallized, protein-ligand complexes, in particular PI3 -ligand complexes, and their corresponding x- ray structure coordinates can be used to reveal new structural information useful for understanding the biological activity of kinases as described herein. As well, the key structural features of the aforementioned proteins, particularly, the shape of the ligand binding site, are useful in methods for designing or identifying selective modulators of kinases and in solving the structures of other proteins with similar features. Such protein- ligand complexes, having compounds of the invention as their ligand component, are an aspect of the invention.

[00156] Another aspect of the invention is directed to suitable x-ray quality crystals, and one of ordinary skill in the art would appreciate that they can be used as part of a method of identifying a candidate agent capable of binding to and modulating the activity of kinases. Such methods may be characterized by the following aspects: a) introducing into a suitable computer program, information defining a ligand binding domain of a kinase in a , conformation (e.g. as defined by x-ray structure coordinates obtained from suitable x-ray quality crystals as described above) wherein the computer program creates a model of the three dimensional structures of the ligand binding domain, b) introducing a model of the three dimensional structure of a candidate agent in the computer program, c) superimposing the model of the candidate agent on the model of the ligand binding domain, and d) assessing whether the candidate agent model fits spatially into the ligand binding domain. Aspects a-d are not necessarily carried out in the aforementioned order. Such methods may further entail: performing rational drug design with the model of the three-dimensional structure, and selecting a potential candidate agent in conjunction with computer modeling.

[00157] Additionally, one skilled in the art would appreciate that such methods may further entail: employing a candidate agent, so-determined to fit spatially into the ligand binding domain, in a biological activity assay for kinase modulation, and determining whether said candidate agent modulates kinase activity in the assay. Such methods may also include administering the candidate agent, determined to modulate kinase activity, to a mammal suffering from a condition treatable by kinase modulation, such as those described above.

[00158] Also, one skilled in the art would appreciate that compounds of the invention can be used in a method of evaluating the ability of a test agent to associate with a molecule or molecular complex comprising a ligand binding domain of a kinase. Such a methqd may be characterized by the following aspects: a) creating a computer model of a kinase hinding pocket using structure coordinates obtained from suitable x-ray quality crystals of the kinase, b) employing computational algorithms to perform a fitting operation between the test agent and the computer model of the binding pocket, and c) analyzing the results of the fitting operation to quantify the association between the test agent and the computer model of the binding pocket.

Representative Compounds

[00159] Representative compounds of Formula I and/or II are depicted below. The examples are merely illustrative and do not limit the scope of the invention in any way. Compounds of the invention are named according to systematic application of the nomenclature rules agreed upon by the International Union of Pure and Applied Chemistry (IUPAC), International Union of Biochemistry and Molecular Biology (IUBMB), and the Chemical Abstracts Service (CAS). Names in Table 1 were generated using ACD/Labs naming software 8.00 release, product version 8.08 with the exception of Compound 374 which was named using ChemDraw v. 9.0.1.

quinoxalin-

l(2/)-

1 -

Cpd. No. Structure Name

4-{[3-({ [4-

127 H ^HV"0 (acetylamino)phenyl]sulfonyl }amino)quinoxali n-2-yl]amino } -2-hydroxybenzoic acid

N-[3-(naphthalen-l-ylamino)quinoxalin-2-yl]-

128

4-nitrobenzetiesulfonamide

4-[(3-{[(4-

129 bromophenyl)sulfonyl]amino}quinoxalin-2- yl)amino] benzoic acid

JV-{4-[({3-[(3-

130 hydroxyphenyl)amino]quinoxalin-2- yl}amino)sulfonyl]phenyl }acetamide

3-[(3-{[(4-

131 bromophenyl)sulfonyl]amino } quinoxalin-2- yl)amino]benzoic acid

4-bromo-W-(3-{ [3-

132 (butyloxy)phenyI]amino } quinoxalin-2- yl)benzenesulfonamide

4-bromo-A/-(3-{[3-

133 (trifluoromethyl)phenyl]amino}quinoxalin-2- yl)benzenesulfonamide

}-

Cpd. No. Structure Name

Λ- { 3-[(2-fluorophenyl)amino]quinoxalin-2-yl } -

180

o=s=o 3-nitrobenzenesulfonamide o

/V-[2-(butyloxy)-2-hydroxyethyl]-4-({3-

181 [(phenylsulfonyl)amino]quinoxalin-2- y 1 ) amino)benzamide

3-nitro-A'-(3- {[4-

182 (phenylamino)phenyl]amino } quinoxalin-2- y benzenesulfonamide

4-bromo-/V-{3-[(4-

183 fluorophenyI)amino]quinoxalin-2- yl Jbenzenesulfonamide

4-methyl-/V-[3-({2-

184 [(trifluoromethyl)thio]phenyl}amino)quinoxali n-2-yl]benzenesulfonamide

Cpd. No. Structure Name

261 Q iV-{3-[(3-fluorophenyl)amino]quinoxalin-2- yl}benzenesulfonamide

F

N-Q- [ [4-(morpholin-4-

262 ylsulfonyl)phenyl]amino}quinoxalin-2- yl)benzenesulfonamide

^H S Q H ethyl 2-{[3-({[4-

263 (acetylamino)phenyl]sulfonyl }amino)quinoxali

n-2-y 1] amino } -4,5,6,7-tetrahydro- 1 - benzothiophene-3-carboxylate

ethyl 2-[(3-{[(4-

264 chlorophenyl)sulfonyl]amino}quinoxalin-2- yl)amino]-5-ethylthiophene-3-carboxylate W-diethyl-4-[(3-{[(4-

265 methylphenyl)sulfonyl]amino }quinoxalin-2- yl)amino]benzenesulfonamide

ethy! 2-{ [3-({ [4-

266 (acetylamino)phenyl]sulfonyl } amino)quinoxali

fi V-NH H 0 ° n-2-yl]amino}-5-ethylthiophene-3-carboxylate

ethyl 2-[(3-{ [(4- chlorophenyl)sulfonyl]amino } quinoxalin-2-

267

yl)amino]-4,5,6,7-tetrahydro- 1- benzothiophene-3-carboxylate

[(3-

methylglycinamide

General Administration

[00160] In one aspect, the invention provides pharmaceutical compositions comprising an inhibitor of PI3K according to the invention and a pharmaceutically acceptable carrier, excipient, or diluent. In certain other specific embodiments, administration may specifically be by the oral route. Administration of the compounds of the invention, or their pharmaceutically acceptable salts, in pure form or in an appropriate pharmaceutical composition, can be carried out via any of the accepted modes of administration or agents for serving similar utilities. Thus, administration can be, for example, orally, nasally, parenterally (intravenous, intramuscular, or subcutaneous), topically, transdermally, intravaginally, intravesically, intracistemally, or rectally, in the form of solid, semi-solid, lyophilized powder, or liquid dosage forms, such as for example, tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, or aerosols, or the like, specifically in unit dosage forms suitable for simple administration of precise dosages.

[00161] The compositions will include a conventional pharmaceutical carrier or excipient and a compound of the invention as the/an active agent, and, in addition, may include carriers and adjuvants, etc.

[00162] Adjuvants include preserving, wetting, suspending, sweetening, flavoring, perfuming, emulsifying, and dispensing agents. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.

[00163] If desired, a pharmaceutical composition of the invention may also contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, antioxidants, and the like, such as, for example, citric acid, sorbitan monolaurate, triethanolamine oleate, butylalted hydroxytoluene, etc.

[00164] The choice of formulation depends on various factors such as the mode of drug administration (e.g., for oral administration, formulations in the form of tablets, pills or capsules) and the bioavailability of the drug substance. Recently, pharmaceutical formulations have been developed especially for drugs that show poor bioavailability based upon the principle that bioavailability can be increased by increasing the surface area i.e., decreasing particle size. For example, U.S. Pat. No. 4, 107,288 describes a pharmaceutical formulation having particles in the size range from 10 to 1 ,000 nm in which the active material is supported on a crosslinked matrix of macromolecules. U.S. Pat. No. 5,145,684 describes the production of a pharmaceutical formulation in which the drug substance is pulverized to nanoparticles (average particle size of 400 nm) in the presence of a surface modifier and then dispersed in a liquid medium to give a pharmaceutical formulation that exhibits remarkably high bioavailability.

[00165] Compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.

Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.

[00166] One specific route of administration is oral, using a convenient daily dosage regimen that can be adjusted according to the degree of severity of the disease-state to be treated.

[00167] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders, as for example, cellulose derivatives, starch, alignates, gelatin, polyvinylpyrrolidone, sucrose, and gum acacia, (c) humectants; as for example, glycerol, (d) disintegrating agents, as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, croscarmellose sodium, complex silicates, and sodium carbonate, (e) solution retarders, as for example paraffin, (f) absorption accelerators, as for example, quaternary ammonium compounds, (g) wetting agents, as for example, cetyl alcohol, and glycerol monostearate, magnesium stearate and the like (h) adsorbents, as for example, kaolin and bentonite, and (i) lubricants, as for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents. [00168] Solid dosage forms as described above can be prepared with coatings and shells, such as enteric coatings and others well known in the art. They may contain pacifying agents, and can also be of such composition that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Examples of embedded compositions that can be used are polymeric substances and waxes. The active compounds can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.

[00169] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. Such dosage forms are prepared, for example, by dissolving, dispersing, etc., a compound(s) of the invention, or a

pharmaceutically acceptable salt or solvate thereof, and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol and the like; solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3- butyleneglycol, dimethylformamide; oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols and fatty acid esters of sorbitan; or mixtures of these substances, and the like, to thereby form a solution or suspension.

[00170] Suspensions, in addition to the active compounds, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.

[00171] Compositions for rectal administrations are, for example, suppositories that can be prepared by mixing the compounds of the present invention with for example suitable non-irritating excipients or carriers such as cocoa butter, polyethyleneglycol or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore, melt while in a suitable body cavity and release the active component therein.

[00172] Dosage forms for topical administration of a compound of this invention include ointments, powders, sprays, and inhalants. The active component is admixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants as may be required. Ophthalmic formulations, eye ointments, powders, and solutions are also contemplated as being within the scope of this invention.

[00173] Compressed gases may be used to disperse a compound of this invention in aerosol form. Inert gases suitable for this purpose are nitrogen, carbon dioxide, etc. [00174] Generally, depending on the intended mode of administration, the

pharmaceutically acceptable compositions will contain about 1% to about 99% by weight of a compound(s) of the invention, or a pharmaceutically acceptable salt or solvate thereof, and 99% to 1 % by weight of a suitable pharmaceutical excipient. In one example, the composition will be between about 5% and about 75% by weight of a compound(s) of the invention, or a pharmaceutically acceptable salt or solvate thereof, with the rest being suitable pharmaceutical excipients.

[00175] Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, 18th Ed., (Mack Publishing Company, Easton, Pa., 1 90). The composition to be administered will, in any event, contain a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt or solvate thereof, for treatment of a disease-state in accordance with the teachings of this invention.

[00176] The compounds of the invention, or their pharmaceutically acceptable salts, are administered in a therapeutically effective amount which will vary depending upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of the compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular disease-states, and the host undergoing therapy. The compounds of the present invention can be administered to a patient at dosage levels in the range of about 0.1 to about 1,000 mg per day. For a normal human adult having a body weight of about 70 kilograms, a dosage in the range of about 0.01 to about 100 mg per kilogram of body weight per day is an example. The specific dosage used, however, can vary. For example, the dosage can depend on a number of factors including the requirements of the patient, the severity of the condition being treated, and the pharmacological activity of the compound being used. The determination of optimum dosages for a particular patient is well known to one of ordinary skill in the art.

[00177] Representative pharmaceutical formulations containing a compound of Formula I are described below in the Pharmaceutical Composition Examples.

Utility

[00178] Certain compounds of this invention have been tested using the assay described in Biological Example 1 and have been determined to be PI3K inhibitors. As such compounds of Formula I, Iaor II are useful for treating diseases, particularly cancer in which PDKactivity contributes to the pathology and/or symptomatology of the disease. For example, cancer in which PI3K activity contributes to its pathology and/or symptomatology include breast cancer, colorectal cancer, endometrial cancer, gastric carcinoma,

glioblastoma, hepatocellular carcinoma, small cell lung cancer, non-small cell lung cancer, melanoma, ovarian cancer, pancreatic cancer, prostate carcinoma, and thyroid carcinoma, and the like.

[00179] Suitable in vitro assays for measuring PI3K activity and the inhibition thereof by compounds are known. Typically, the assay will measure PI3K-induced ATP consumption. For further details of an in vitro assay for measuring PI3K activity see Biological Examples, Example 1 infra. Cellular activity can be determined using assays as described in

Biological Examples 2, 3, and 4 infra. Suitable in vivo models of cancer are known to those of ordinary skill in the art. For further details of in vivo assays see Biological Examples 5-10, n/ra.Following the examples disclosed herein, as well as that disclosed in the art, a person of ordinary skill in the art can determine the inhibitory activity of a compound of this invention.

Preparations of the Intermediates and Compounds

[00180] Compounds of this invention can be made by the synthetic procedures described below. The starting materials and reagents used in preparing these compounds are either available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wis.), or Bachem (Torrance, Calif.), or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplemental (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), March's Advanced Organic Chemistry, (John Wiley and Sons, 4^th Edition) and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989). These schemes are merely illustrative of some methods by which the compounds of this invention can be synthesized, and various modifications to these schemes can be made and will be suggested to one skilled in the art having referred to this disclosure. The starting materials and the intermediates of the reaction may be isolated and purified if desired using conventional techniques, including but not limited to filtration, distillation, crystallization,

chromatography and the like. Such materials may be characterized using conventional means, including physical constants and spectral data. [00181] Unless specified to the contrary, the reactions described herein take place at atmospheric pressure and over a temperature range from about -78 °C to about 150°C, more specifically from about 0°C. to about 125 °C and most specifically at about room (or ambient) temperature, e.g., about 20 °C. Unless otherwise stated (as in the case of an hydrogenation), all reactions are performed under an atmosphere of nitrogen.

[00182] Prodrugs can be prepared by techniques known to one skilled in the art. These techniques generally modify appropriate functional groups in a given compound. These modified functional groups regenerate original functional groups by routine manipulation or in vivo. Amides and esters of the compounds of the present invention may be prepared according to conventional methods. A thorough discussion of prodrugs is provided in T. Higuchi and V. Stella, "Pro-drugs as Novel Delivery Systems," Vol 14 of the A.C.S.

Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference for all purposes.

[00183] The compounds of the invention, or their pharmaceutically acceptable salts, may have asymmetric carbon atoms or quaternized nitrogen atoms in their structure. Compounds of Formula I that may be prepared through the syntheses described herein may exist as single stereoisomers, racemates, and as mixtures of enantiomers and diastereomers. The compounds may also exist as geometric isomers. All such single stereoisomers, racemates and mixtures thereof, and geometric isomers are intended to be within the scope of this invention. Some of the compounds of the invention may exist as tautomers. For example, where a ketone or aldehyde is present, the molecule may exist in the enol form; where an amide is present, the molecule may exist as the imidic acid; and where an enamine is present, the molecule may exist as an imine. All such tautomers are within the scope of the invention.

[00184] In particular, in this application B can be 2-hydroxy-pyridinyl, also described as its structure:

14.

Both 2-hydroxy-pyridinyl and the above structure 14 include, and are equivalent to, pyridin- 2(lH)-one and its structure 15:

Regardless of which structure or which terminology is used, each tautomer is included within the scope of the Invention.

[00185] The present invention also includes N-oxide derivatives and protected derivatives of compounds of Formula I. For example, when compounds of Formula I contain an oxidizable nitrogen atom, the nitrogen atom can be converted to an N-oxide by methods well known in the art. When compounds of Formula I contain groups such as hydroxy, carboxy, thiol or any group containing a nitrogen atom(s), these groups can be protected with a suitable "protecting group" or "protective group". A comprehensive list of suitable protective groups can be found in T.W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, Inc. 1991, the disclosure of which is incorporated herein by reference in its entirety. The protected derivatives of compounds of Formula I can be prepared by methods well known in the art.

[00186] Methods for the preparation and/or separation and isolation of single stereoisomers from racemic mixtures or non-racemic mixtures of stereoisomers are well known in the art. For example, optically active (R)- and (S)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. Enantiomers (R- and S-isomers) may be resolved by methods known to one of ordinary skill in the art, for example by: formation of diastereoisomeric salts or complexes which may be separated, for example, by crystallization; via formation of diastereoisomeric derivatives which may be separated, for example, by crystallization, selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantiomers; or gas-liquid or liquid

chromatography in a chiral environment, for example on a chiral support, such as silica with a bound chiral ligand or in the presence of a chiral solvent. It will be appreciated that where a desired enantiomer is converted into another chemical entity by one of the separation procedures described above, a further step may be required to liberate the desired enantiomeric form. Alternatively, specific enantiomer may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents or by converting on enantiomer to the other by asymmetric transformation. For a mixture of enantiomers, enriched in a particular enantiomer, the major component enantiomer may be further enriched (with concomitant loss in yield) by recrystallization.

[00187] In addition, the compounds of the present invention can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the present invention.

[00188] In Compounds of Formula I

the hydrogen on the -NHS(0)₂- group is highly acidic. Thus, intermediates leading to Compounds of Formula I, as well as Compounds of Formula I themselves, can be recovered as uncharged or zwitterionic molecules, or cationic salts such a sodium or potassium, depending on the substitutions on the B ring and on reaction conditions. In the examples that follow, unless otherwise specified, the final form of the compound was assumed to be the uncharged molecule in the absence of analytical techniques that would have determined otherwise.

[00189] Compounds of Formula I can be prepared using methods known to one of ordinary skill in the art. Specifically, fusion of appropriate reagents at 180 °C in the presence of a base such as K₂C0₃ and metallic copper is known to provide intermediates of formula 1 (see S. H. Dandegaonker and C. K. Mesta, /. Med. Chem. 1965, 8, 884).

[00190] Alternatively, the intermediate of formula 3 can be prepared according to the scheme below where each LG¹ is a leaving group (specifically, halo, more specifically, chloro) and all other groups are as defined in the Detailed Description of the Invention.

1 S 1 cheme 1

[00191] In scheme 1, an intermediate of formula 3 can be prepared by briefly heating commercially available 2,3-dichloroquinoxaline and an intermediate of formula 2 (which are commercially available or can be prepared by one of ordinary skill in the art), a base such as K₂C0₃, in a solvent, such as DMF or DMSO. Upon completion (about 2 hours), the reaction mixture is then poured into water and followed by 2 N HCI. The product is then extracted into a solvent such as ethyl acetate and washed with water and brine. The organic layers are combined and dried over a drying agent such as sodium sulfate, filtered, and concentrated under vacuum.

[00192] The intermediate of formula 3 is then treated with an intermediate of formula 4 in a solvent such as DMF or p-xylene at reflux temperature. Upon completion of the reaction (about 16 hours or less), the reaction is allowed to cool, extracted into DCM, washed with 2 N HCI and brine, dried over a drying agent such as sodium sulfate or magnesium sulfate, filtered, and concentrated to give a compound of Formula I.

[00193] Alternatively, other methods to prepare quinoxaline derivatives are known to one skilled in the art and include, but are not limited to S. V. Litvinenko, V. I. Savich, D. D. Bobrovnik, Chem. Heterocycl. Compd. (Engl. Transl), 1994, 30, 340 and W. C. Lumma, R. D. Hartman, /. Med. Chem. 1981, 24, 93.

[00194] The following compounds were prepared in a manner similar to that described above.

Example 1: N-(3-{ [2,5-bis(methoxy)phenyl]amino }quinoxalin-2-yl)-3- nitrobenzenesulfonamide.

Example 2: N-(3-{[2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4- chlorobenzenesulfonamide.

Example 3: N-(3-chloroquinoxalin-2-yl)-3-nitrobenzenesulfonamide.

Example 4: 4-chloro-N-(3-chloroquinoxalin-2-yl)benzenesulfonamide.

Example 5: 4-chIoro-N-(3-(2,5-dimethoxy-phenylamino)quinoxalin-2- yObenzenesulfonamide. Ή NMR (400 MHz, DMSO-rf₆) δ 9.18 (s, 1H), 8.78 (s, 1H), 8.40- 8.60 (m, 3H), 7.98 (t, 2H), 7.62 (d, I H), 7.41 (m, 2H), 6.98 (d, IH), 6.59 (d, IH), 3.78 (s, 3H), 3.76 (s, 3H); MS (EI) m/z for C^H^NsOeS: 482.1 (MH⁺).

Example 6: N-(3-(2,5-dimethoxyphenylamino)quinoxalin-2-yl)-3- nitrobenzenesulfonamide. Ή NMR (400 MHz, CDC1₃) δ 12.68 ( br s, IH ), 9.18 (s, IH), 8.55 (s, IH), 8.08 (d, 2H), 7.98 (d, IH), 7.78 (d, 2H), 7.62 (dd, IH), 7.40 (m, 2H), 7.00 (d, IH), 6.60 (dd, IH), 3.78 (s, 6H) ; MS (EI) m/z for C₂2H₁₉CW₄0₄S: 471.1 (Μ1Γ).

Example 7: N-(3-(N-(3-(2-chloro-5-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)-4- methylphenyl)-2-(dimethyIamino)acetamide. Ή NMR (400 MHz, DMSO-ii₆) δ 12.0 (br s, 1 H), 10.6 (s, 1 H), 10.0 (br s, 1 H), 9.52 (s, 1 H), 8.91 (d, 1 H), 8.25 (d, 1 H), 7.69 (dd, IH), 7.47 (m, 1 H), 7.39 (d, 1 H), 7.16 (m, 3 H), 6.01 (dd, 1 H); MS (EI) m/z for C₂₆H₂₇CW₆0₄S: 555 (MH⁺).

[00195] Compounds of Formula I where B is phenyl substituted with R^3a where R^3a is alkylamino or dialkylamino or B is heteroaryl substituted with R³ where R³ is amino, alkylamino, or dialkylamino, and all other groups are as defined in the Summary of the Invention can be prepared according to Scheme 2.

Scheme 2

5 1(c)

LG is a leaving group such as chloro. 5 is reacted with NHR^aR^b or HO-C|-C₆-alkylene- NHR^aR where R^a and R are independently hydrogen or alkyl. The reaction is carried out in the presence of a base, such as KHCO3, in a solvent such as DMF.

[00196] Compounds of Formula I where B is phenyl substituted with R^3a where R^3a is aminoalkyloxy, alkylaminoalkyloxy, or dialkylaminoalkyloxy or B is heteroaryl substituted with R³ where R³ is aminoalkyloxy, alkylaminoalkyloxy, or dialkylaminoalkyloxy, and all other groups are as defined in the Summary of the Invention can be prepared according to Scheme 3. Scheme

1(c)

The reaction is carried out in the presence of a base such as NaH in a solvent such as DMF.

[00197] Compounds of Formula I where B is phenyl substituted with R^3a or B is heteroaryl substituted with R³ where R^3a and R³ are

i. -N(R⁷)C(0)-C_rC₆-alkylene-N(R^7a)(R^7b) where R⁷, R^7a, and R^7b are as defined in the Summary of the Invention;

ii. -NR⁹C(0)R^9a where R⁹ is as defined in the Summary of the Invention;

iii. -NR¹ 'C(0)NR' ^laR* ^lb where R^{l la}, R^{1 la}, and R^{1 lb} are as defined in the Summary of the Invention;

iv. -NR^l3C(0)OR^13a where R¹³ and R^13a are as defined in the Summary of the

Invention;

v. -N(R^I8)C(0)-C,-C₆-alkylene-N(R^18b)C(0)R^18a where R¹⁸, R^l8a, and R^l8b are as defined in the Summary of the Invention;

vi. -N(R²⁰)C(O)-Ci-C₆-alkylene-C(O)R^20a where R²⁰ and R^20a as defined in the

Summary of the Invention;

vii. -NR²¹S(0)₂R-Ci.C₆-alkylene-N(R^21b)R^2la where R²¹, R^21a, and R^21b are as defined in the Summary of the Invention;

viii. -N(R²²)C(0)-Co-C₆-alkylene-N(R^22b)-N(R ^2c)(R^22a), where R²², R^22a and R^22b are as defined in the Summary of the Invention;

ix. -NR^CiOJ-d.Ce-alkylene-OR²⁴³ where R²⁴ and R^24a are as defined in the

Summary of the Invention;

and where the alkylene in R³ and R^3a are independently optionally substituted as described in the Summary of the Invention can be prepared according to Scheme 4 by reacting with an intermediate of formula 9(a), 9(b), 9(c), 9(d), 9(e), 9(f), or 9(g):

9(a) HOC(0)-C i -C₆-alky lene-N(R^7a)(R^7b) where R^a is R^7a or a N-protecting

group, such as Boc or Fmoc;

9(b) HOC(0)R^9a; 9(c) HOC(0)NR^{l la}R^{, lb};

9(d) HOC(0)OR^13a;

9(e) HOC(0)-C,-C₅-alkylene-N(R^l8b)C(0)R^18a;

9(f) HOC(O)-C,-C₆-alkylene-C(O)R^20a;

9(g) LG-S(0)₂R-C|.C₆-alkylene-N(R^21b)R^a where R^a is R^2la or a N-protecting group, such as Boc or Fmoc.

Scheme 4

8 1(e)

R¹⁰⁰ in Scheme 4 is -C(0)R^9a, -C(0)NR^{l la}R^{l lb}, -C(0)OR^13a, -C(0)-C,-C₆-alkylene- N(R^18b)C(0)R^18a, -C(O)-C,-C₆-alkylene-C(O)R^20a, or -S(0)₂R-C,.C₆-alkylene-N(R^21b)R^a. The reaction is carried out under standard amide coupling conditions known to one of ordinary skill in the art. In particular, the reaction is carried out in the presence of a coupling agent such as HATU, a base such as DIEA, and in a solvent such as DMF. Where applicable, the N-protecting group is then removed using procedures known to one of ordinary skill in the art, such as treating with acid where PG is Boc.

[00198] Proceeding as described for Scheme 4, compounds of the invention where B is phenyl substituted with R^3a or B is heteroaryl substituted with R³ where R^3a and R³ are a) -C(0)NR⁸R^8a;

b) -C(O)N(R¹⁰)-Ci-C₆-alkylene-N(R^10a)R^l0b;

c) -C(0)R¹² where R¹² is an N-substituted heterocycloalkyl;

d) -C(0)N(R¹⁴)N(R^14a)(R^{1 b});

e) -C(0)N(R¹⁶)-C,.C₆-alkylene-C(0)OR^,6a; or

f) -C(0)N(R¹⁹)-C,-C₆-alkylene-C(0)R^19a; or

can be prepared by exchanging the starting materials as necessary. In particular, the intermediate of formula 1 1 :

11

is used instead of 8.

[00199] Compounds of Formula I where B is phenyl substituted with R^3a or B is heteroaryl substituted with R³ where R^3a and R³ are -NHC(0)CH₂NR^7aR^7b where R^7a and

_R7b are as defined in the Summary of the Invention can be prepared according to Scheme 5. Scheme 5

12 l(f)

LG is a leaving group such as bromo or chloro. 12 is reacted with NH(R^7b)R^7a in the presence of a base, such as DIEA, in a solvent such as ACN.

[00200] Compounds of Formula I can be prepared according to Scheme 6.

Scheme 6

1(h)

LG in Scheme 6 is a leaving group such as chloro. The reaction can be carried out by irradiating in a solvent such as DMA. Alternatively, the reaction can be carried out in the presence of acetic acid in a solvent such as DMA and by heating. Example 8

-(3,5-dimethoxyphenylamino)

[00201] 6-chloropyridine-3-sulfonaraide. 6-chloropyridine-3-sulfonyl chloride (4.1 g, 19.3 mmol) was stirred in ammonium hydroxide (30 mL) at room temperature for 2 hr. The reaction mixture was diluted with EtOAc ( 150 mL) and any insoluble material filtered. The filtrate was transferred to a separatory funnel and the phases were separated. The aqueous phase was further extracted with EtOAc (1 x 15 mL). The combined EtOAc extractions were washed with H₂0 (1 x 50 mL) and saturated NaCl (1 x 50 mL), dried over Na₂S0₄, and concentrated in vacuo to give 6-chloropyridine-3-sulfonamide (2.58 g, 69%). MS (EI) m/z for C₅H₅Cl₂N₂0₂S: 190.9 (MH^").

[00202] 6-chloro-/V-(3-chloroquinoxalin-2-yl)pyridine-3-sulfonamide.

2,3-dichloroquinoxaline (1.09 g, 5.48 mmol), 6-chloropyridine-3-sulfonamide (1.05 g, 5.45 mmol), K₂C0₃ (753 mg, 5.45 mmol) and dry DMSO (30 mL) were combined and heated to 150 °C with vigorous stirring for 3-4 hr. The reaction mixture was allowed to cool to room temperature, then poured into 1% AcOH in ice water (300 mL) with vigorous stirring. The resulting solids were filtered, washed with H₂0 and dried under high vacuum to give 6- chloro-N-(3-chloroquinoxalin-2-yl)pyridine-3-sulfonamide (1.87g, 96%). MS (EI) m/z for C,₃H8C1₂N₄0₂S: 354.99 (MH⁺).

[00203] 6-chIoro-A^f-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yI)pyridine-3- sulfonamide. 6 -Chloro-N-(3-chloroquinoxalin-2-yl)pyridine-3-sulfonamide (775 mg, 2.2 mmol), 3,5-dimethoxyaniline (355 mg, 2.3 mmol) and toluene (12 mL) were combined and heated to 125 °C with stirring overnight. The reaction was allowed to cool to room temperature and diluted with Et₂0 with vigorous stirring. The resulting solids were filtered, washed with Et₂0 and dried to give 6-chloro-N-(3-(3,5-dimethoxy- phenylamino)quinoxalin-2-yl)pyridine-3-sulfonamide (920 mg, 89%). Ή NMR (400 MHz, DMSO- ) δ 12.20 (br s, IH), 9.12 (d, IH), 9.01 (br s, IH), 8.53 (dd, IH), 7.91 (br d, IH), 7.77 (d, IH), 7.60 (dd, IH), 7.40 (m, 4H), 6.26 (m, IH), 3.78 (s, 6H). MS (EI) m/z for C₂iHi₈ClN₅0₄S: 472.0 (MH⁺).

Example 9

V-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)-6-(2-(dimethylamino)- -3-sulfbnamide

[00204] 6-chloro-N-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)-pyridine-3- sulfonamide (100 mg, 0.21 mmol), prepared using procedures similar to those used in Example 8, KHC0₃ (40 mg, 0.40 mmol), N'^'-dimethylethane-l^-diamine (225 L, 2.0 mmol) and dry DMF (1.0 mL) were combined and heated to 130 °C with stirring overnight. The reaction mixture was concentrated in vacuo and purified by preparative HPLC to give N-(3-(3,5-dimethoxy-phenylamino)-quinoxalin-2-yl)-6-(2-

(dimethylamino)ethylamino)pyridine-3-sulfonamide (21.0 mg, 19%). 1H NMR (400 MHz, DMSO-i/e) δ 8.76 (br s, IH), 8.63 (d, IH), 8.07 (dd, IH), 7.40 (m, IH), 7.34 (m, IH), 7.28 (d, 2H), 7.14 (m, 4H), 6.47 (d, IH), 6.12 (m, IH), 3.75 (s, 6H), 3.35 (m, 2H), 3.14 (m, 2H), 2.74 (s, 6H). MS (EI) m/z for C25H29N₇O4S: 524.1 (MH*).

[00205] Example 10: iV-(3-(3,5-dimethoxyphenylamino)quinoxaIin-2-yl)-6- (dimethylamino)pyridine-3-sulfonamide was prepared using procedures similar to those used in Example 9. Ή NMR (400 MHz, DMSO-ii₆) δ 12.00 (br s, IH), 8.92 (br s, IH), 8.74 (d, IH), 8.10 (dd, IH), 7.38 (br s, IH), 7.54 (m, IH), 7.33 (m, 4H), 6.70 (d, IH), 6.22 (s, IH), 3.77 (s, 6H), 3.08 (s, 6H). MS (EI) m/z for C₂3H₂4N60₄S: 481.1 (MH⁺). Example 11

A^-(3 3,5-dimethoxyphenylamino)quinoxalin-2-yl)-6-(2 diraethylamino)- -3-sulfonanude

[00206] N-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)pyridine-3-sulfonamide (100 mg, 0.21 mmol), prepared using procedures similar to those described above in Example 1 , 2-(dimethylamino)ethanol (50 μΐ., 0.50 mmol) and dry DMF were combined and 60% NaH in oil (80 mg, 2.0 mmol) was added. The mixture was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo and purified by preparative HPLC to give N-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)-6-(2- (dimethylamino)ethoxy)pyridine-3-sulfonamide (23 mg, 21%). Ή NMR (400 MHz, DMSO-rf₆) δ 8.78 (d, IH), 8.73 (s, IH), 8.38 (dd, IH), 7.40 (dd, IH), 7.31 (m, 3H), 7.14 (m, 2H), 6.85 (d, IH), 6.12 (m, IH), 4.56 (m, 2H), 3.76 (s, 6H), 3.43 (m, 2H), 2.77 (s, 6H). MS (EI) m/z for CaHaNeOsS: 525.1 (MH*).

Example 12

/V-(3-(3,5-dimethoxyphenylamino)quinoxaIin-2-yl)-6-oxo-l,6-dihydropyridine- -sulfonamide

[00207] N-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)pyridine-3-sulfonamide (220 mg, 0.47 mmol), prepared using procedures similar to those described above in Example 8, DMSO (5 mL), and 3Ν NaOH (5 mL) are combined and heated to 100 °C overnight with stirring. Upon cooling to room temperature, the reaction mixture was diluted with H₂0 and the pH was adjusted to 7.0 with IN HCl. The resulting solid was filtered, washed with H₂0, and air-dried. The solid was then sonicated in EtOAc, filtered, washed with EtOAc, and dried under high vacuum to give N-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)-6-oxo- l,6-dihydropyridine-3-sulfonamide ( 190 mg, 90%). Ή NMR (400 MHz, DMSO-</₆) δ 12.23 (br s, IH), 12.10 (br s, IH), 8.97 (s, IH), 8.23 (s, IH), 7.95 (m, 2H), 7.59 (m, IH), 7.37 (m, 4H), 6.43 (d, IH), 6.25 (s, IH), 3.77 (s, 6H). MS (EI) m/z for C₂iHi₉N₅0₅S: 454.0 (MH⁺).

[00208] Example 13: A^r-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)-6- oxo-l,6-dihydropyridine-3-sulfonamide. The title compound was prepared according to the above Example 12. Ή NMR (400 MHz, DMSO-<¾) δ 12.22 (br s, IH), 12.10 (br s, IH), 9.16 (s, I H), 8.60 (s, IH), 8.14 (d, IH), 7.94 (m, IH), 7.85 (dd, IH), 7.62 (m, IH), 7.40 (m, 3H) 6.69 (dd, IH), 6.43 (d, IH), 3.81 (s, 3H). MS (EI) m/z for C₂oH|₅ClN₅0₄S: 456.0 (ΜΗ^').

Example 14

3-amino-i ^( -(3,5-dimethoxyphenylamino)quinoxalin-2<-yI)benzenesuIfonamide.

[00209] N-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)-3- nitrobenzenesulfonamide. A flask was charged with N-(3-chloroquinoxalin-2-yl)-3- nitrobenzenesulfonamide (5 g, 13.7 mmol), prepared using procedures similar to those in Example 1, 3,5-dimethoxyaniline (4.2 g, 27.4 mmol), and 80 mL of xylene. The reaction mixture was stirred under an N₂ atmosphere at 150 °C for 3 hours, after which time, solvent was removed on a rotary evaporator, and 10 mL of Dichloromethane and 50 mL of methanol were added. The slurry was heated to reflux and Filtered while hot, resulting in 4.6 g (69.7 %) of N-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)-3- nitrobenzenesulfonamide MS (EI) m/z for C₂₂H₁₉N₅0₆S: 482.2 (ΜΗ*). Example 15

3-aimno- -(3,5-dimethoxyphenyIamino)quino^

[00210] A flask was charged with N-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)-3- nitro-benzenesulfonamide (3.4g, 7.06 mmol), prepared using procedures similar to those in Example 14, tin chloride solvate (6.4 g, 28.2 mmol), and 30 mL of DMA. A few drops of water were added and the reaction mixture was stirred at 80 °C for 3 hours, after which time, solvent was removed on a rotary evaporator, and 50 mL of water and 10 mL of Methanol were added. The slurry was filtered, and the filtrate was washed with MeOH, water, and diethyl ether (20 mL of each), resulting in 3.25 g 3-amino-N-(3-(3,5-dimethoxy- phenylamino)quinoxalin-2-yl)benzenesulfonamide. Ή NMR (400 MHz, DMSO) δ 12.2 (br s, IH), 8.85 (s, IH), 7.90 (br s, IH), 7.50-7.60 (m, IH), 7.3-7.4 (m, 4H), 7.2 (m, 3H), 6.74 (m, IH), 6.24 (m, IH), 5.56 (br s, 2H), 3.76 (s, 6H). MS (EI) m/z for C₂₂H₂i ₅0₄S: 452.0

(MH⁺).

[00211] The following compounds were made using procedures similar to those used in Example 15.

Example 16: Proceeding as above, 3-amino-N-(3-(2,5-dimethoxy- phenylamino)quinoxalin-2-yl)benzenesulfonamide was prepared. Ή NMR (400 MHz, DMSO) δ 12.4 (br s, IH), 9.20 (s, IH), 8.56 (d, IH), 7.95 (d, IH), 7.62 (m, IH), 7.38 (m, 2H), 7.24 (q, 2H), 7.14 (d, IH), 6.98 (d, IH), 6.8 (m, IH), 6.60 (m, IH), 5.6 (br s, 2H), 3.78 (d, 6H). MS (EI) m/z for C₂₂H₂iN₅0₄S: 452.3 (MH⁺).

Example 17: Proceeding as above, 3-amino-^-(3-(2-chloro-5-hydroxy- phenylamino)quinoxalin-2-yl)benzenesulfonamide was prepared. MS (EI) m/z for C₂oH,₆ClN₅03S 1.0 x C₂H,0₂F₃: 442.2, 444.2 (MH⁺). Example 18: Proceeding as above, 3-amino-N-(3-(6-methoxyquinolin-8- ylamino)quinoxalin-2-yl)benzenesulfonamide was prepared. MS (EI) m/z for

Q4H20N6O3S: 473.0 (MH⁺).

Example 19: 3-aimno- V-(3-(3-fluoro-5-methoxy-phenylamino)quinoxalin-2- yl)benzenesulfonamide. MS (EI) m/z for C₂|Hi8FN₅0₃S: 439.99 (MH⁺).

Example 20: 3-amino-iV-(3-(2-chloro-5-methoxy-phenylamino)quinoxaIin-2- yDbenzenesulfonamide. MS (EI) m/z for C₂iH₁₈CIN₅0₃S: 457.02 (MH⁺).

Example 21 : 3-amino-jY-(3-(5-methoxy-2-methyl-phenylamino)quinoxalin-2- yl)benzenesulfonamide. MS (EI) m z for C₂₂H₂iN₅0₃S: 436.32 (MH⁺).

Example 22a and Example 22b

3-amino-iV-(3-(3-methoxy-5-nitro-phenylamino)quinoxalin-2-yl)benzenesu]fonamide and 3-amino- V-(3-(3-amino-5-methoxy-phenylamino)quinoxalin-2-

[00212] To a mixture of N-(3-{ [3-(methyloxy)-5-nitrophenyl]amino }quinoxalin-2-yl)-3- nitrobenzenesulfonamide (400 mg), THF (2 mL) and EtOH (2 mL) was added formic acid (938 uL), potassium formate (203 mg). After the mixture was flushed with N₂, 10 wt Pd/C (50 mg) was added. The resulting mixture was heated at 60 °C with stirring. LC/MS analysis indicated that the reaction mixture contained the complete reduced di-amino compound as the major product and the partially reduced mono-amino compound as a minor product. A portion of the crude mixture was purified by HPLC to give the two products. Product A: 3-amino-N-(3-(3-methoxy-5-nitro-phenylamino)quinoxaIin-2- yl)benzenesulfonamide. Ή NMR (400 MHz, DMSO) δ 12.2 (br s, IH), 9.51 (s, IH), 8.77 (s, IH), 8.21 (s, IH), 7.92 (s, IH), 7.48 (m, IH), 7.43-7.38 (m, 3H), 7.24-7.16 (m, 3H), 6.75 (d, lH), 5.57 (br s, 2H), 3.90 (s, 3H). MS (EI) for C₂iHi₈N₆0₅S: 467.00 (MH+). Product B: 3-amino-N-(3-(3-amino-5-methoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide. Ή NMR (400 MHz, DMSO) δ 12.0 (br. s, IH), 8.53 (s, IH), 7.84 (s, IH), 7.56 (d, IH), 7.37-7.30 (m, 2H), 7.21-7.17 (m, 3H), 6.87 (s, IH), 6.81 (s, IH), 6.74 (br s, 2H), 5.91 (s, IH), 5.56 (br s, 3H), 3.69 (s, 3H). MS (EI) for C₂₁H₂₀N₆O₃S: 437.2 (MH+). Example 23a and Example 23b

A -(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-3-(hydroxyainino)- benzenesulfonamide and 3-amino-N-(3-{[3,5-(dimethoxy)phenyl]amino}quinoxalin-2 yl)benzenesulfonamide

[00213] To a solution N-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)- 3-nitrobenzenesulfonamide ( 1.3g) in 20 mL of THF and 10 mL of MeOH was added 10% wt Pd/C (100 mg). The mixture was stirred under a H₂ balloon overnight. A portion of the reaction mixture was taken out and filtered, then purified by HPLC to afford two products. Product A: N-(3-{ [3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-3- (hydroxyamino)benzenesulfonamide. MS (EI) for C₂₂H₂iN₅0₅S: 468.1 (MH⁺). Product B: 3-amino-N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yI)benzenesulfonamide. Ή NMR (400 MHz, DMSO) 5 12.2 (br s, IH), 8.85 (s, I H), 7.90 (br s, IH), 7.50-7.60 (m, IH), 7.3- 7.4 (m, 4H), 7.2 (m, 3H), 6.74 (m, IH), 6.24 (m, IH), 5.56 (br s, 2H), 3.76 (s, 6H). MS (EI) for C₂₂H₂iN₅0₄S: 452.0 (MH⁺).

Example 24

(S)-2-amino-N-(3-(-V-(3-(3,5-diraethoxyphenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)propanamide hydrochloride.

[00214] (S)-tert-butyl l-(3-(N-(3-(3,5-dimethoxyphenylamino)quinoxalin-2- yl)sulfamoyl)phenylamino)-l-oxopropan-2-ylcarbamate. 3-amino-N-(3-(3,5-dimethoxy- phenylamino)quinoxalin-2-yl)benzenesulfonamide (1.1 mmol, 500 mg), prepared using procedures similar to those described above in Example 15, (L)-Boc-Ala-OH (1.5 mmol, 284 mg), dichloromethane (15 mL), DMF (10 mL), DEA (2 mmol, 330 μί), and HATU (2 mmol, 760 mg) stirred at room temperature over night. The crude mixture was column purified using 1/1 ethyl acetate hexanes on silica to gave 160 mg.

[00215] (S)-2-amino-N-(3-(N-(3-(3,5-dimethoxyphenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)propanamide hydrochloride. 4 N HC1 is dioxane ( 10 mL) was added to a solution of (S)-r<?rr-butyl l-(3-(N-(3-(3,5-dimethoxyphenylamino)quinoxalin- 2-yl)sulfamoyl)phenylamino)-l-oxopropan-2-ylcarbamate ( 160 mg) and DCM (15 mL). The mixture was stirred at room temperature for 3 hours. The solvent decanted and ether added to the solid, ether decanted to gave 80 mg product as HC1 salt. Ή NMR (400 MHz, CD₃OD) δ 8.50-8.49 (t, IH), 7.89-7.87 (m, IH), 7.74-7.72 (m, IH), 7.61-7.5 (m, 3H), 7.40- 7.36 (m, 2H), 7.21-7.20 (d, 2H), 6.23-6.21 (t, IH), 4.09-4.03 (q, IH), 3.78 (s, 6H), 1.60-1.58 (d, 3H); MS (EI) m/z for C₂₅H₂₆N₆0₅S-HC1: 523.1 (MH⁺). [00216] The following compounds were prepared as the free amine and/or HC1 salt using procedures similar to those in Example 24. Where the deprotection step is not necessary, Step B in the above scheme was not preformed.

Example25: N-(2-chloro-5-(N-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(methylamino)acetamide. The title compound was prepared according to the Examples above. Ή NMR (400 MHz, DMSO-i/₆) δ 10.50 (s, IH), 9.14 (s, IH), 9.03 (m, 2H), 8.63 (d, IH), 8.44 (d, IH), 7.98 (m, IH), 7.91 (dd, IH), 7.80 (d, IH), 7.67 (m, IH), 7.44 (m, 3H), 6.71 (dd, IH), 4.06 (m, 2H), 3.83 (s, 3H), 2.64 (t, 3H). MS (EI) m/z for C24H22CI2N6O4S: 561.0 (MH⁺).

Example 26: (S)-2-amino-A^-(3-(N-(3-(2-chloro-S-methoxy-phenyIamino)quinoxalin-2- yl)sulfamoyl)phenyl)propanamide hydrochloride. Ή NMR (400 MHz, CD3OD) 5 8.72- 8.71 (d, IH), 8.48-8.46 (t, IH), 7.86-7.84 (m, IH), 7.80-7.78 (m, IH), 7.63-7.59 (m, 2H),

7.58- 7.55 (t, IH), 7.41-7.38 (m, 2H), 7.24-7.22 (d, IH), 6.60-6.58 (dd, IH), 4.10-4.04 (q, IH), 3.83 (s, 3H), 1.61- 1.60 (d, 3H); MS (EI) m/z for C₂4H₂₃C1N₆0₄S HC1: 527.2 (MH*). Example 27 : (S)-2-amino-A^r-(3-(N-(3-(2-chloro-5-methox pheny lamino)quinoxalin-2- y Dsulfamoyl) phenyl )bu tana mide hydrochloride. Ή NMR (400 MHz, CD₃OD) δ 8.74- 8.73 (d, IH), 8.80-8.47 (t, IH), 7.87-7.85 (m, IH), 7.80-7.78 (m, IH), 7.67-7.61 (m, 2H),

7.59- 7.55 (t, IH), 7.42-7.39 (m, 2H), 7.26-7.24 (d, I H), 6.62-6.59 (dd, IH), 3.96-3.93 (t, IH), 3.84 (s, 3H), 2.02- 1.94 (m, 2H, 1.09-1.06 (t, 3H); MS (EI) m/z for

C₂₅H₂₅C1N60₄S-HC1: 541.3 (MH⁺).

Example 28: (5)-N-(3-( V-(3-(2-chloro-5-methoxyphenylamino)quinoxaIin-2- yI)sulfamoyI)phenyl)pyrrolidine-2-carboxamide hydrochloride. Ή NMR (400 MHz, CD3OD) 5 8.78-8.77 (d, IH), 8.47-8.46 (t, IH), 7.87-7.85 (m, IH), 7.80-7.75 (m, IH), 7.69-7.65 (m, 2H), 7.59-7.55 (t, IH), 7.45-7.41 (m, 2H), 7.31-7.28 (d, IH), 6.65-6.63 (dd, IH), 4.42-4.38 (m, IH), 3.86 (s, 3H), 3.48-3.42 (m, 2H), 2.55-2.49 (m, IH), 2.18-2.08 (m, 3H); MS (EI) m/z for C₂₆H₂5C1N₆0₄S-HC1: 553.3 (MH⁺).

Exmaple 29: (S)-N-(3-(.V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yI)sulfamoyl)phenyl)pyrrolidine-2-carboxamide hydrochloride. Ή NMR (400 MHz, CD₃OD) 5 10.62 (br s, IH), 8.50-8.49 (t, IH), 7.90-7.87 (m, I H), 7.76-7.73 (m, IH), 7.63- 7.58 (m, 3H), 7.43-7.35 (m, 2H), 7.14 (s, 2H), 6.27-6.26 (t, IH), 4.43-4.38 (m, IH), 3.78 (s, 6H), 3.48-3.41 (m, IH), 3.40-3.36 (m, 1 H(, 2.54-2.48 (m, IH), 2.19-2.05 (m, 3H); MS (EI) m/z for C₂7H28N₆05S-HC1: 549.3 (MH⁺).

Example 30: (R)-2-amino- V-(3-(^V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)suIfamoyl)phenyl)-3-hydroxypropanamide hydrochloride. Ή NMR (400 MHz, CD3OD) 5 8.49-8.48 (t, IH), 7.89-7.87 (m, IH), 7.75-7.72 (m, IH), 7.65-7.62 (m, 2H), 7.62-7.55 (t, IH), 7.44-7.38 (m, 2H), 7.23-7.22 (d, 2H), 6.27-6.26 (t, IH), 4.07-4.05 (m, IH), 3.99-3.93 (m, 2H), 3.80 (s, 6H); MS (EI) m/z for C₂₅H₂6N₆0₆S-HC1: 539.1 (Mi?). Example 31: N-(3-(N-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)piperidine-3-carboxamide hydrochloride. Ή NMR (400 MHz, CD₃OD) δ 8.79-8.78 (d, IH), 8.45 (m, IH), 7.83-7.81 (d, IH), 7.76-7.74 (m, IH), 7.636 (m, 2H), 7.54-7.50 (t, IH), 7.41 (m, 2H), 7.30-7.28 (d, IH), 6.65-6.62 (dd, IH), 3.86 (s, 3H), 3.40-3.32 (m, 2H), 3.20-3.13 (m, 3H), 2.93 (m, IH), 2.15-2.1 1 (m, IH), 1.98-1.93 (m, 2H), 1.83 (m, IH); MS (EI) m/z for C₂₇H₂₇C1N₆0₄S HC1: 567.3 (MH*).

Example32: (S)-2-amino-N-(3-(jV-(3-(3,5-dimethoxyphenylamino)quinoxaIin-2- yl)sulfamoyl)phenyl)butanamide hydrochloride. MS (EI) m/z for C^H^NeOsS-HCl: 537.1 (MH*).

Example 33: (R)-N-(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)pyrrolidine-2-carboxamide hydrochloride. MS (EI) m/z for C₂₇H₂₈N₆0₅S-HC1: 549.1 (MlT).

Example 34: ( f)-N-(3-(/V-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2- yI)sulfamoyl)phenyl)pyrrolidine-2-carboxamide hydrochloride. MS (EI) m/z for C26H25C1N60₄S HC1: 553 (MH*).

Example 35: (R)-2-amino-iV-(3-(iV-(3-(3,5-dimethoxyphenylamino)quinoxalin-2- yI)sulfamoyl)phenyl)propanamide. Ή NMR (400 MHz, DMSO-</₆) δ 10.2 (br s, 1 H), 8.82 (s, 1 H), 8.27 (m, 1 H), 7.75 (m, 2 H), 7.33 (m, 5 H), 7.13 (m, 2 H), 6.14 (t, 1 H), 3.77 (s, 6 H), 1.39 (d, 3 H); MS (EI) m/z for C₂₅H₂₆N₆0₅S: 523 (MH⁺).

Example 36 :.V-(3-(iV-(3-(2-chIoro-5-methoxy-phenyIamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(methylamino)acetamide. Ή NMR (400 MHz, DMSO-</₆) δ 10.6 (s, 1 H), 9.48 (s, 1 H), 8.95 (br s, 1 H), 8.75 (br s, 1 H), 8.19 (br s, 1 H), 7.77 (dd, 1 H), 7.69 (dd, 1 H), 7.41 (m, 4 H), 7.17 (m, 2 H), 6.60 (dd, 1 H), 3.91 (s, 2 H), 3.82 (s, 6 H), 2.62 (s, 3 H); MS (EI) m/z for C₂₄H₂₃C1N₆0₄S: 527 (MH⁺).

Example 37: (R)-2-amino-N-(3-(.V-(3-(2 hloro-5-methoxy-phenylammo)quinoxalin-2- yl)suIfamoyl)phenyl)propanamide. Ή NMR (400 MHz, DMSO-i/₆) δ 10.5 (s, 1 H), 9.47 (s, 1 H), 8.95 (d, 1 H), 8.22 (d, 2 H), 8.14 (br s, 2 H), 7.76 (m, 2 H), 7.40 (m, 4 H), 7.17 (m, 2 H), 6.60 (m, 1 H), 3.97 (q, 1 H), 3.96 (s, 3 H), 1.45 (d, 3 H); MS (EI) m/z for

C₂₄H₂3CIN₆0₄S: 527 (MH⁺).

Example 38: 2-aimno-N-(3-( V-(3-(2-chloro-5-methoxy-phenylamino)quinoxaIin-2- yl)sulfamoyl)phenyl)-2-methylpropanamide. Ή NMR (400 MHz, DMSO-cfe) δ 10.1 (s, 1 H), 9.46 (s, 1 H), 8.95 (d, 1 H), 8.50 (br s, 1 H), 8.27 (m, 1 H), 7.81 (m, 2 H), 7.47 (m, 1 H), 7.37 (m, 3 H), 7.17 (m, 2 H), 6.61 (dd, 1 H), 3.83 (s, 3 H), 1.60 (s, 6 H); MS (EI) m/z for C₂₅H2₅C1N₆0₄S: 541 (MH⁺).

Example 39: 2-amino-A^"-(3-(^-(3-(3,5-dimethoxy^henylainino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-methylpropanamide. Ή NMR (400 MHz, DMSO-i.₆) δ 10.33 (s, 1 H), 8.89 (s, 1 H), 8.32 (br s, 4 H), 7.92 (m, 3 H), 7.59 (m, 2 H), 7.37 (m, 4 H), 6.24 (s, 1 H), 3.76 (s, 6 H), 1.61 (s, 6 H); MS (EI) m/z for C₂₆H₂₈N₆0₅S: 537 (MH⁺).

Example 40: ^-(3^A^r-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-4- methylphenyl)-2-(dimethylamino)acetamide. Ή NMR (400 MHz, DMSO-</₆) δ 10.58 (s, 1 H), 9.80 (br s, 1 H), 8.85 (s, 1 H), 8.25 (s, 1 H), 7.67 (dd, 1 H), 7.30 (m, 7 H), 6.16 (m, 1 H), 4.02 (br s, 2 H), 3.77 (s, 6 H), 2.81 (s, 6 H), 2.54 (s, 3 H); MS (EI) m/z for

C₂₇H₃₀N₆O₅S: 551 (MH⁺).

Example 41: iV-(3-(N-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-((2-(dimethylamino)ethyl)(methyl)amino)acetamide. Ή NMR

(400 MHz, DMSO-4 δ 10.0 (s, 1 H), 9.48 (s, 1 H), 8.96 (d, 1 H), 8.16 (m, 1 H), 7.76 (m, 2 H), 7.39 (m, 4 H), 7.17 (m, 2 H), 6.61 (dd, 1 H), 3.82 (s, 3 H), 3.40 (br s, 2 H), 2.94 (br s, 2 H), 2.71 (br t, 2 H), 2.60 (s, 6 H), 2.33 (s, 3 H); MS (EI) m/z for C₂₈H₃₂CW₇0₄S: 598 (MH⁺).

Example 42: 2-amino-A^-(3 N-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)acetamide. Ή NMR (400 MHz, DMSO-</₆) δ 10.5 (s, 1 H), 9.48 (s, 1 H), 8.94 (s, 1 H), 8.15 (s, 1 H), 8.06 (br s, 3 H), 7.74 (m, 2 H), 7.39 (m, 4 H), 7.18 (m, 2 H), 6.61 (dd, I H), 3.83 (s, 3 H), 3.77 (s, 2 H); MS (EI) m z for C₂₃H_2]C1N₆0₄S: 513 (MH*). Example 43: N-(3-(N-(3-(2-acetyl-5-methoxy-phenylamino)quinoxalin-2- l)sulfamo l)phenvl)-2-( dimethyl a minojacetamide. Ή NMR (400 MHz, DMSO-i/₆) δ 12.4 (s, 1 H), 10.5 (s, 1 H), 9.27 (s, 1 H), 8.25 (s, 1 H), 8.01 (d, 1 H), 7.82 (d, 1 H), 7.71 (d, 1 H), 7.42 (m, 3 H), 7.21 (m, 2 H), 6.63 (dd, 1 H),3.91 (m, 5 H), 2.75 (s, 6 H), 2.61 (s, 3 H); MS (EI) m/z for C₂₇H₂₈N₆0₅S: 549 (MH⁺).

Example 44: ^V-(3-(iV-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)formamide. Ή NMR (400 MHz, DMSO-rf₆) δ 12.6 (s, 1 H), 10.5 (s, 1 H), 9.16 (s, 1 H), 8.53 (br s, 1 H), 8.35 (m, 2 H), 8.02 (s, 1 H), 7.56 (m, 7 H), 6.70 (dd, 1 H), 3.83 (s, 3 H); MS (EI) m/z for C₂₂H,₈C1N50₄S: 484 (MH⁺).

Example 45: 2-amino-A^*-(5-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)-2-methylphenyl)acetamide. Ή NMR (400 MHz, DMSO-i/₆) δ 12.4 (s, 1 H), 10.1 (br s, 1 H), 8.82 (s, 1 H), 8.20 (m, 3 H), 7.82 (m, 1 H), 7.30 (m, 6 H), 6.20 (s, 1 H), 3.85 (s, 2 H), 3.77 (s, 6 H), 2.26 (s, 3 H); MS (EI) m/z for C₂₅H26 ₆0₅S: 523 (MH*).

Example 46: jV-(3-( V-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-methyl-2-(methylamino)propanamide. Ή NMR (400 MHz, DMSO- ) δ 10.09 (s, 1 H), 9.46 (s, 1 H), 8.95 (m, 3 H), 8.28 (s, 1 H), 7.81 (m, 2 H), 7.41 (m, 4 H), 7.17 (m, 2 H), 6.60 (dd, 1 H), 3.82 (s, 3 H), 2.53 (s, 3 H), 1.60 (s, 6 H); MS (EI) m/z for C26H27CIN6O40: 555 (MH*).

Example 47: (5)-iV-(3-(N-(3-(2-chloro-5-methoxy-phenylamino)quinoxaIin-2- yl)sulfamoyl)phenyl)-2-(methylamino)propanamide. Ή NMR (400 MHz, DMSO-i/₆) δ 10.61 (s, 1 H), 9.47 (s, 1 H), 8.95 (s, 1 H), 8.82 (br s, 2 H), 8.27 (m, 1 H), 7.74 (m, 2 H), 7.42 (m, 4 H), 7.17 (m, 2 H), 6.60 (dd, 1 H), 3.90 (m, 1 H), 3.82 (s, 3 H), 2.59 (s, 3 H), 1.49 (d, 3 H); MS (EI) m z for C₂₅H₂₅C1N₆0₄S: 541 (MH⁺).

Example 48: 3-amino-A^"-(5-(N-(3-(2-chloro-5-methoxyphenyIamino)quinoxaIin-2- yl)suIfamoyl)-2-methylphenyl)propanamide. Ή NMR (400 MHz, DMSO-cfe) 5 12.25 (s, 1 H), 9.77 (s, 1 H), 8.82 (s, 1 H), 7.84 (m, 5 H), 7.50 (d, 1 H), 7.37 (m, 5 H), 6.22 (m, 1 H), 3.74 (s, 6 H), 3.08 (m, 2 H), 2.77 (m, 2 H), 2.27 (s, 3 H); MS (EI) m/z for C₂₆H₂8N₆0₅S: 537 (MH⁺).

Example 49: l-aimno--V-(3-(N-(3-(2-chloro-5-methoxy-phenylaiiiino)quinoxalin-2- yl)sulfamoyl)phenyl)cyclopropanecarboxamide. Ή NMR (400 MHz, DMSO-i ₆) δ 9.54 (br s, 1 H), 9.42 (s, 1 H), 8.91 (s, 1 H), 8.21 (s, 1 H), 8.20 (br s, 2 H), 7.81 (m, 2 H), 7.48 (m, 4 H), 7.22 (m, 2 H), 6.61 (dd, 1 H), 3.82 (s, 3 H), 1.63 (m, 2 H), 1.26 (m, 2 H); MS (EI) m z for C₂5H₂₃C1N₆0₄S: 539 (MH⁺).

Example 50: (S)-2-amino-N-(3-( V-(3-(2-chloro-5-methoxy-phenylaimno)quinoxalin-2- yl)sulfamoyl)phenyl)-6-(dimethylamino)hexanamide. Ή NMR (400 MHz, DMSO-c¾) δ 9.47 (br s, 1 H), 8.95 (d, 1 H), 8.26 (m, 1 H), 7.73 (m, 2 H), 7.30 (m, 4 H), 7.26 (m, 4 H), 7.16 (m, 2 H), 6.59 (dd, I H), 3.82 (s, 3 H), 3.34 (m, 1 H), 2.20 (m, 2 H), 2.09 (s, 6 H), 1.50 (m, 6 H); MS (EI) m/z for C29H₃₄C ₇0₄S: 610 (MH^1").

Example 51 : l-aii-mo--V-(3-(N-(3-(2-chloro-5-methoxy-phenyIamino)quinoxalin-2- yl)sulfamoyl)phenyI)cyclopentanecarboxamide. Ή NMR (400 MHz, DMSO-cfe) δ 10.12 (br s, 1 H), 9.46 (s, I H), 8.95 (d, 1 H), 8.26 (m, 1 H), 8.16 (m, 3 H), 7.84 (m, 2 H), 7.35 (m, 6 H), 6.60 (dd, 1 H), 3.82 (s, 3 H), 2.34 (m, 2 H), 1.91 (m, 6 H); MS (EI) m z for

C₂₇H₂₇C1N₆0₄S: 567 (MH⁺).

Example 52: iV-(5-(iV-(3-(2-chloro-5-methoxyphenylamino)quinoxalin-2-yI)sulfamoyI)- 2-methylphenyl)-2 dimethylamino)acetamide. ¹ H NMR (400 MHz, DMSO-cfe) δ 12.0 (br s, 1 H), 9.98 (s, 1 H), 9.43 (s, I H), 8.91 (m, 1 H), 8.08 (s, 1 H), 7.84 (dd, 1 H), 7.32 (m, 6 H), 6.61 (dd, 1 H), 4.07 (s, 2 H), 3.82 (s, 3 H), 2.82 (s, 6 H), 2.21 (s, 3 H); MS (EI) m/z for C₂₆H₂₇C1N₆0₄S: 555 (MlF).

Example 53: l-araino-.V-(3-(iV-(3-(3,5-dirnethoxy-phenylainino)quinoxaliii-2- yI)suIfamoyl)phenyl)cyclobutanecarboxamide. Ή NMR (400 MHz, DMSO-i/₆) δ 10.34 (br s, 1 H), 8.81 (s, 1 H), 8.49 (br s, 3 H), 8.34 (s, 1 H), 7.83 (m, 2 H), 7.43 (m, 3 H), 7.31 (m, 2 H), 7.16 (m, 2 H), 6.16 (s, 1 H), 3.77 (s, 6 H), 2.83 (m, 2 H), 2.25 (m, 3 H), 2.05 (m, 1 H); MS (EI) m/z for C₂₇H₂₈N₆0₅S: 549 (MH⁺).

Example 54: V-(3-(3,5-diraethoxyphenylamino)quinoxalin-2-yl)-3-(3-(2- (dimethylamino)ethyl)ureido)benzenesulfonamide. Ή NMR (400 MHz, DMSO-</₆) δ 8.91 (br s, 1 H), 8.81 (s, 1 H), 8.08 (s, 1 H), 7.60 (s, 1 H), 7.38 (m, 9 H), 6.28 (m, 1 H), 6.15 (s, 1 H), 3.78 (s, 6 H), 3.40 (m, 2 H), 3.08 (m, 2 H), 2.74 (s, 6 H); MS (EI) m/z for C₂₇H₃iN₇0₅S: 566 (MH⁺).

Example 55: l-amino-iV-(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yI)sulfamoyl)phenyl)cyclopentanecarboxamide. Ή NMR (400 MHz, DMSO-fife) δ 12.40 (br s, 1 H), 10.58 (s, 1 H), 8.46 (m, 4 H), 7.80 (m, 3 H), 7.59 (m, 2 H), 7.34 (m, 4 H), 6.25 (m, I H), 3.76 (s, 6 H), 2.35 (m, 2 H), 1.90 (m, 8 H); MS (EI) m/z for

C₂₈H₃oN₆0₅S: 563 (MH⁺).

Example 56: l-amino-iV-(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)cyclopropanecarboxamide. *H NMR (400 MHz, DMSO-fifc) δ 9.54 (br s, 1 H), 8.84 (s, 1 H), 8.29 (s, 1 H), 7.75 (m, 2 H), 7.39 (m, 6 H), 7.17 (m, 2 H), 6.16 (m, I H), 3.78 (s, 6 H), 1.52 (m, 2 H), 1.17 (m, 2 H); MS (EI) m/z for C₂₆H₂₆N₆0₅S: 535 (MH⁺). Example 57: 2-(dimethylamino)ethyl 3-(/V-(3-(3,5-dimethoxy-phenylamino)quinoxalin- 2-yl)sulfamoyl)phenylcarbamate. Ή NMR (400 MHz, DMSO-rf₆) δ 9.78 (br s, 1 H), 8.79 (s, 1 H), 8.19 (s, 1 H), 7.66 (d, 1 H), 7.31 (m, 9 H), 6.14 (m, 1 H), 4.17 (t, 2 H), 3.78 (s, 6 H), 2.54 (t, 2 H), 2.21 (s, 6 H): MS (EI) m/z for C₂₇H₃oN₆0₆S: 567 (MlF).

Example 58 : 4-amino-N-(3-(N-(3-(3,5-dimethoxy-phen Iamino)quinoxalin-2- yl)sulfamoyl)phenyl)tetrahydro-2H-pyran-4-carboxamide. Ή NMR (400 MHz,

DMSO-4 δ 12.2 (br s, 1 H), 10.6 (s, 1 H), 8.74 (m, 5 H), 7.93 (m, 2 H), 7.47 (m, 6 H), 6.24 (m, 1 H), 3.77 (m, 10 H), 2.45 (m, 2 H), 1.81 (m, 2 H); MS (EI) m/z for C2₈H3oN₆0₆S: 579 (MH⁺).

Example 59: V-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)-iV3-(2- dimethvlamino)eth} I (benzene- 1,3-disiiIfonamide. Ή NMR (400 MHz, DMSO-ii₆) δ 9.35 (m, 2 H), 8.92 (m, 1 H), 8.64 (s, 1 H), 8.30 (m, 1 H), 8.1 1 (s, 1 H), 7.86 (m, 1 H), 7.68 (m, 1 H), 7.49 (s, 1 H), 7.42 (m, 2 H), 7.21 (m, 2 H), 6.61 (m, 1 H), 3.82 (s, 3 H), 3.05 (m, 4 H), 2.74 (s, 6 H); MS (EI) m/z for C₂5H₂₇C1N₆0₅S₂: 591 (MH⁺).

Example 60: A^r-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)-iV3-(3- (dimethylamino)propyl)benzene-l,3-disulfonamide. Ή NMR (400 MHz, DMSO-rf₆) δ 9.38 (m, 2 H), 8.90 (m, 1 H), 8.60 (s, 1 H), 8.32 (m, 1 H), 8.12 (s, 1 H), 7.88 (m, 1 H), 7.72 (m, 1 H), 7.59 (s, 1 H), 7.40 (m, 2 H), 7.20 (m, 2 H), 6.67 (m, 1 H), 3.82 (s, 3 H), 2.97 (m, 2 H), 2.78 (m, 2 H), 2.71 (s, 6 H), 1.70 (m, 2 H); MS (EI) m/z for C₂₆H₂₉C1N₆0₅S₂: 605 (MFF).

Example 61 : iV-(3-(^V-(3-(2-chloro-5-methoxy-pheny lamino)quinoxalin-2-yl)sulfamoyl)- 4-methy!phenyl)-2-(methylamino)acetamide. MS (EI) m/z for C₂₅H₂₅ C1N₆0₄S: 541.0 (MH⁺).

Example 62: (5)-2-aimno-^-(3-(^-(3 2-chloro-5-methoxy^henylaniino)quinoxalin-2- yl)sulfamoyl)-4-methylphenyl)propanamide. MS (EI) m/z for C₂₅H₂₅ C1N₆0₄S: 541.2 (MH⁺).

Example 63: (R)-2-amino -(3-(N-(3-(2-cWoro-5-methoxy-phenylammo)quinoxalin-2- yI)sulfamoyl)-4-methylphenyl)propanamide. MS (EI) m/z for C^H^ C1N₆0₄S: 541.0 (MH*).

Example 64: (5)-N-(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(methylamino)propanamide. MS (EI) m/z for C₂₆H₂8 N60₅S: 537.1 (MH^1").

Example 65: (R)-Λ^r-(3-(N-(3-(2-chloro-5-metho y hen Iammo)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(methylamino)propanamide. MS (EI) m/z for C₂₅H₂₅ C1N₆0₄S: 541.1(MH⁺).

Example 66: (R)-N-(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(methylamino)propanamide. MS (EI) m/z for

537.3 (MH⁺).

Example 67: N-(3-(N-(3-(3^-dimethoxy-phenylamino)quinoxalin-2- yl)suIfamoyl)phenyI)piperidine-2-carboxamide. MS (EI) m/z for

563.1 (MH*).

Example 68: iV-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(2-(dimethylamino)ethylamino)acetamide. MS (EI) m z for C₂₈H₃₃N₇O₅S: 580.1 (MH⁺). Example 69: V-(3-( V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(4-(methylamino)piperidin-l-yl)acetamide. MS (EI) m/z for C₃₀H₃₅N₇O₆S: 606.1 (MH⁺).

Example 70: iV-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(4-(dimethyIamino)piperidin-l-yl)acetamide. MS (EI) m z for C₃|H₃₇ N₇0₅S: 620.1 (MH⁺).

Example 71: N-(3-(iV-(3-(3,5-dimethoxyphenylamino)quinoxalin-2- y l)sulfamoyl)phen l)-2-(dimethylamino)acetamide. ¹ H MR (400 MHz, DMSO) δ 12.4

(br s, IH), 10.9 (s, IH), 9.8 (s, IH), 8.9 (s, IH), 8.3 (br s, I H), 7.9 (d, 2H), 7.8 (d, IH), 7.6

(t, 2H), 7.4 (q, 2H), 7.3 (s, IH), 6.25 (s, IH), 4.15 (s, 2H), 3.8 (s, 6H), 2.9 (s, 6H). MS (EI) m/z for C₂₆H₂₈N₆0₅S 2.0 x C₂H,0₂F₃: 537.1 (MH⁴).

Example 72: N-(3-(iiV-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(ethylamino)acetamide. 1H NMR (400 MHz, DMSO) δ 10.8 (s,

IH), 9.20 (s, IH), 8.84 (br s, 2H), 8.64 (br s, IH), 8.30 (s, IH), 7.9-8.0 (br s, IH), 7.80 (t,

2H), 7.55-7.68 (m, 2H), 7.4 (d, 3H), 6.70 (m, IH), 3.97 (br s, 2H), 3.83 (s, 3H), 3.04 (br s,

2H), 1.3 (t, 3H). MS (EI) m/z for C₂₅H₂₅C1N₆0₄S 2.0 x C₂H,0₂F₃: 541.3, 543.2 (MH*).

Example 73: 2-(azetidin-l-yl)- V-(3-(N-(3-(2-chloro-5- methoxyphenylamino)quinoxaIin-2-yl)sulfamoyl)phenyl)acetamide. Ή NMR (400 MHz, DMSO) δ 10.8 (s, IH), 10.2 (s, IH), 9.2 (s, IH), 8.7 (s, IH), 8.3 (s, IH), 7.9-8.0 (br s, IH), 7.80 (d, IH), 7.72 (d, IH), 7.65 (br s, IH), 7.56 (t, IH), 7.40 (d, 3H), 6.70 (m, IH), 4.28 (s, 2H), 4.15 (m, 4H), 3.82 (s, 3H), 2.32 (br s, IH). MS (EI) m/z for C₂₆H₂₅C1N₆0₄S 2.0 x C₂Hi0₂F₃: 553.3, 555.2 (MH⁺).

Example 74: -V-(3-(N-(3-(2-bromo-5-methoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(methylamino)acetamide. The title compound was prepared according to the Examples above. Ή NMR (400 MHz, DMSO) δ 10.6 (s, IH), 9.5 (s, IH), 8.95 (d, IH), 8.18 (t, IH), 7.78 (m, IH), 7.70 (m, IH), 7.54 (d, IH), 7.46 (m, IH), 7.38 (t, IH), 7.32 (d, IH), 7.12-7.22 (m, 2H), 6.56 (m, IH), 3.90 (s, 2H), 3.82 (s, 3H), 2.62 (s, 3H). MS (EI) m z for C₂₄H₂₃BrN₆0₄S: 572.77, 570.90 (MH⁺).

Example 75: 2-(dimethylamino)-N-(3-(^V-(3-(6-methoxy-quinolin-8- ylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide. The title compound was prepared according to the Examples above. Ή NMR (400 MHz, DMSO) δ 10.9 (s, IH), 10.6 (s, I H), 9.13 (s, IH), 8.80 (d, IH), 8.26-8.30 (m, 2H), 7.85 (d, IH), 7.70 (d, IH), 7.60 (q, IH), 7.54 (m, IH), 7.44 (t, 2H), 7.20 (t, 2H), 6.80 (d, IH), 4.00 (s, 2H), 3.94 (s, 3H), 2.78 (s, 6H). MS (EI) m z for C₂₈H₂₇N₇0₄S: 558.3 (MH⁺). Example 76: -V-(3 N-(3-(2-bromo-5-methoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(dimethylamino)acetamide. Ή NMR (400 MHz, DMSO) δ 10.6 (s, IH), 9.4 (s, IH), 8.9 (s, IH), 8.25 (s, IH), 7.78 (d, IH), 7.70 (d, IH), 7.54 (d, IH), 7.48 (d, IH), 7.40 (t, 2H), 6.56 (d, IH), 4.02 (s, 2H), 3.82 (s, 3H), 2.80 (s, 6H). MS (EI) m/z for C₂₅H₂₅BrN₆0₄S: 586.79, 584.91 (MH*).

Example 77: N-(3-(N-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(2-fluoroethylamino)acetamide. Ή NMR (400 MHz, DMSO) δ 10.6 (s, IH), 9.4 (s, IH), 8.9 (d, IH), 8.20 (s, IH), 7.78 (d, IH), 7.70 (d, IH), 7.48 (m, IH), 7.36-7.44 (m, 3H), 7.20 (q, 3H), 6.6 (m, IH), 4.78 (t, IH), 4.66 (t, IH), 3.94 (s, 2H), 3.82 (s, 3H), 3.4 (t, IH), 3.3 (t, IH). MS (EI) m/z for Czs^ClIW^S: 559.2, 561.2 (MlT).

Example 78: jV-(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)formamide. Ή NMR (400 MHz, DMSO) δ 12.4 (br s, IH), 10.5 (s, IH), 8.90 (s, IH), 8.3 (s, IH), 7.9 (br s, IH), 7.85 (d, IH), 7.75 (d, IH), 7.5-7.6 (m, 2H), 7.3-7.4 (m, 4H), 6.2 (s, IH), 3.8 (s, 3H). MS (EI) m/z for C2₃H₂₁N₅O₅S: 480.1 (MKT). Example 79: N-(3-(iV-(3-(2-chloro-5-methoxy-phenylamino)quinoxaliii-2- yl)sulfamoyl)phenyl)-2-(3-(dimethylamino)azetidin-l-yl)acetamide. Ή NMR (400 MHz, DMSO) δ 10.2 (br s, IH), 9.5 (s, IH), 8.95 (d, IH), 8.2 (s, IH), 7.75 (d, IH), 7.65 (d, I H), 7.45 (d, IH), 7.40 (d, IH), 7.30-7.35 (t, IH), 7.1-7.2 (q, 2H), 6.60 (m, IH), 3.82 (s, 3H). MS (EI) m/z for C₂₈H3oClN₇0₄S: 480.1 (MH⁺).

Example 80: N-(3-(Af-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(pyrrolidin-l-yl)acetamide. MS (EI) m/z for 8H30N6O5S: 563.18 (MH*).

Example 81: jV-(3-(yV-(3-(2-chloro-5-methoxyphenylamino)quinoxalin-2- yI)sulfamoyl)phenyl)-2-(ethyl(methyl)amino)acetamide. ¹ H NMR (400 MHz, DMSO) δ 12.0 (s, IH), 10.6 (s, IH), 9.65 (s, IH), 9.5 (s, IH), 8.95 (s, IH), 8.25 (s, IH), 7.8 (d, IH), 7.70 (d, IH), 7.45-7.50 (d, IH), 7.3-7.4 (m, 3H), 7.2 (t, 2H), 6.60 (d, IH), 4.02 (br s, 2H), 3.82 (s, 3H), 3.14 (br s, 2H), 2.80 (s, 3H) 1.2 (t, 3H). MS (EI) m/z for C₂₆H₂₇C1N₆0₄S: 555.2, 557.3 (MlF).

Example 82: N-(3-(A^r-(3-(2-chloro-5-methoxy-phenyIamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(3-(piperidin-l-yl)azetidin-l-yl)acetamide. MS (EI) m/z for C₃iH₃₄ClN₇0₄S 2.0 x C₂Hi0₂F₃: 636.3, 638.3 (MtT).

Example 83: N-(3-(N-(3-(3-fluoro-5-methoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyI)-2-(methyIamino)acetamide. MS (EI) m/z for C₂ H₂₃FN₆0₄S: 51 1.04 (MH*). Example 84: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyi)-l-methylpiperidine-4-carboxamide. MS (EI) m/z for

C₂₉H₃₂N₆0₅S 1.0 x C₂H40₂: 577.2 (MH⁺).

Example 85: A^*-(3-( V-(3-(3-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)- 2-(methyIamino)acetamide. Ή NMR (400 MHz, DMSO) δ 10.6 (s, IH), 8.82 (s, IH), 8.22 (t, IH), 7.86 (t, IH), 7.76 (m, IH), 7.66 (m, IH), 7.46 (m, IH), 7.41 (m, IH), 7.38 (t, IH), 7.28 (m IH), 7.24 (t, I H), 7.12 (m, 2H), 6.56 (d, IH), 3.88 (s, 2H), 3.80 (s, 3H), 2.60 (s, 3H). MS (EI) m/z for C₂4H₂4N₆0₄S: 492.99 (MH⁺).

Example 86: iV-(3-(iV-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(2,2,2-trifluoroethylamino)acetamide. Ή NMR (400 MHz, DMSO) δ 10.4 (s, IH), 9.2 (s, IH), 8.65 (s, IH), 8.4 (s, IH), 8.00 (m, IH), 7.80 (d, I H), 7.75 (d, IH), 7.65 (q, IH), 7.55 (t, IH), 7.40-7.5 (m, 3H), 6.7 (m, IH), 3.82 (s, 3H), 3.62 (br s, 2H), 3.55 (br d, 2H). MS (EI) m/z for C₂₅H₂₂C1F₃N₆0₄S 1.0 x C₂H,0₂F₃: 595.0, 597.0 (MH⁺).

Example 87: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yI)sulfamoyl)phenyl)-3-(piperidin-l-yl)propanamide. MS (EI) m z for C3oH₃₄N605S: 591.2 (MH⁺).

Example 88: iV-(3-(iV-(3-(3,5-dimethoxy-phenylainino)quinoxalin-2- yl)sulfamoyl)phenyl)-4-(dimethylamino)butanamide. MS (EI) m/z for C₂sH₃₂N₆05S 1.0 x C₂H₄O₂: 565.2 (MH⁺).

Example 89: 2-(dimethylamino)-N-(3-(N-(3-(3-fluoro-5-methoxy- phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide. Ή NMR (400 MHz, DMSO) δ 10.9 (s, IH), 9.8 (br s, IH), 9.1 (s, IH), 8.34 (s, IH), 7.90 (d, IH), 7.76 (d, IH), 7.52-7.68 (m, 4H), 7.40 (m, 2H), 6.54 (m, IH), 4.16 (s, 2H), 3.82 (s, 3H), 2.86 (s, 6H). MS (EI) m/z for C₂₅H₂₅FN₆0₄S: 525.05 (MH⁺).

Example 90: /V-(3-(/V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(piperidin-l-yl)acetamide. MS (EI) m/z for C₂₉H₃₂N₆0₅S:

577.37 (MKT).

Example 91: 2-(dimethylamino)-N-(3-(/V-(3-(3-methoxy-phenylamino)quinoxalin-2- yl)suIfamoyl)phenyl)acetamide. Ή NMR (400 MHz, DMSO) δ 10.5 (s, IH), 8.8 (s, IH), 8.25 (s, IH), 7.83 (t, IH), 7.76 (d, IH), 7.64 (d, IH), 7.3-7.48 (m, 4H), 7.22 (t, IH), 7.12 (t, 2H), 6.56 (m, IH), 3.96 (s, 2H), 3.78 (s, 3H), 2.76 (s, 6H). MS (EI) m/z for C₂₅H₂₆N₆0₄S: 507.1 (MH⁺). Example 92: N-(3-(N-(3-(2-chloro-5-hydroxy-phenyIamino)quinoxaIin-2- yl)suIfamoyl)phenyl)-2-(dimethylamino)acetamide. Ή NMR (400 MHz, DMSO) δ 10.8 (s, IH), 9.9 (s, IH), 9.8 (s, IH), 9.1 (s, IH), 8.55 (s, IH), 8.34 (s, IH), 7.9-8.0 (br s, IH), 7.82 (d, IH), 7.76 (d, IH), 7.52-7.66 (m, 2H), 7.42 (t, IH), 7.26 (d, IH), 6.50 (m, IH), 4.16 (s, 2H), 2.86 (s, 6H). MS (EI) m/z for C₂4H₂3C1N₆0₄S: 527.1, 529.0 (MH⁺).

Example 93: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxaIin-2- yl)sulfamoyl)phenyl)-2-morpholinoacetamide. MS (EI) m z for C28H3oN₆0₆S: 579.1 (MH⁺).

Example 94: ^V-(3-(N-(3-(3,5-dimethoxy-phenyIamino)quinoxalin-2- yl)sulfamoyl)phenyl)acetamide. MS (EI) m/z for uH^NsOsS: 494.0 (MH⁺).

Example 97: 2-amino-N-(3 A^r-(3-(2 hIoro-5-methoxy-phenylarriino)quinoxalin-2- yl)sulfamoyl)-4-methylphenyl)-2-methylpropanamide. MS (EI) m z for

C₂₆H₂₇C1N₆0₄S: 556.12 (MH¹).

Example 98: N-(3-(N-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2- yI)sulfamoyl)phenyl)-2-(dimethylamino)acetamide. MS (EI) m/z for C₂₅H2₅C1 ₆0₄S: 542.05 (MH⁺).

Example 99 : 2-amino-N-(3-(iV-(3-(3,5-dimethoxy-phen lamino)quinoxalin-2- yl)sulfamoyl)phenyl)acetamide. MS (EI) m/z for C₂₄H₂₄N₆0₅S: 509.59 (MH⁺).

Example 100

3-(-V-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)benzoic acid

[00217] To a solution of N-(3-{ [2-chloro-5-(methoxy)-phenyl]amino}quinoxalin-2-yl)-3- cyanobenzenesulfonamide (6.02 g, 12.95 mmol), prepared using procedures similar to those in Example 1 15 or Example 423, in methanol (20 mL) and 1 ,4-dioxane (20 mL) was added 6.0 N aqueous sodium hydroxide (40 mL) at room temperature. The solution was stirred at 90 °C for 3.5 h. The reaction was cooled to room temperature and neutralized slowly by adding 2.0 N hydrochloric acid until the pH of the solution became in the 2-3 range at 0° C. The solution was diluted with ethyl acetate (300 mL). The organic layer was washed with saturated aqueous sodium chloride (50 mL) and dried over magnesium sulfate. Filtration and concentration at reduced pressure afforded 3-{ [(3-{ [2-chloro-5-(methoxy)- phenyl]amino }quinoxalin-2-yl)amino]sulfonyl}benzoic acid (5.921 g, 94%). MS (EI) m/z for C22H17 C1N₄0₅S: 485.0 (MH⁺).

[00218] The following compounds were preapred using procedures ismilar to those used in Example 100.

Example 101: Proceeding as above, 3-(N-(3-(3,5-dimethoxyphenylamino)quinoxalin-2- yl)sulfamoyI)benzoic acid was prepared. MS (EI) m/z for C₂₃H₂₀ N₄0₆S: 481.0 (MH⁺). Example 102: 3-(N-(3-(2-chloro-5-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)- N-(2-methyl-l-(piperidin-l-yl)propan-2-yl)benzamide. MS (EI) m/z for C₃iH₃₅CIN₆0₄S: 623.06 (MH÷).

Example 103: 3-(N-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)- AH2-methyl-l-oxo-l-(piperidin-l-yl)propan-2-yl)benzamide. MS (EI) m/z for

C₃iH₃₃ClN₆05S: 637.65 (MKT).

Example 104

3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-A^r-[2-

(dimethylamino)ethyl]benzamide

[00219] To a solution of 3-{ [(3-{ [2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2- yl)amino]sulfonyl } benzoic acid (0.20 g, 0.42 mmol), prepared using procedures similar to Example 100, in dimethylformamide (4 mL) were added 2-(7-aza- lH-benzotriazole-l-yl)- 1, 1,3,3-tetramethyluronium hexafluorophosphate ( HATU, 0.32 g, 0.83 mmol) and

N-ethyldiisopropylamine (DIEA, 0.13 g, 1.04 mmol) at room temperature. The reaction was stirred for 15 min before N, N-dimethylethane-l,2-diamine (73 mg, 0.83 mmol) was added. The reaction mixture was allowed to stir overnight. The reaction was diluted with ethyl acetate (200 mL) and washed with water (50 mL), saturated aqueous sodium bicarbonate (40 mL), 1.0 N aqueous hydrochloric acid (30 mL), and saturated aqueous sodium chloride (25 mL). The organic layer was dried over magnesium sulfate, filtered and concentrated at reduced pressure to afford 3-{ [(3-{ [2-chloro-5- (methoxy)phenyl]amino }quinoxalin-2-yl)amino]sulfonyl }-N-[2- (dimethylamino)ethyl]benzamide (0.20 g, 87%) as yellow solid. MS (EI) m/z for C₂₆H₂₇ C1N₆0₄S: 555.1 (MET).

[00220] The following compounds were prepared using procedures similar to those in Example 104.

Example 105: 5-( V-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)- N-(2-(dimethylamino)ethyl)-2-methoxybenzamide. Ή NMR (400 MHz, DMSO-i/₆) δ 9.45 (s, IH), 8.95 (d, IH), 8.57 (d, IH), 8.28 (t, IH), 8.14 (dd, IH), 7.46 (dd, IH), 7.39 (m, 2H), 7.17 (m, 4H), 6.60 (dd, IH), 3.89 (s, 3H), 3.82 (s, 3H), 3.38 (m, 2H), 2.43 (m, 2H), 2.21 (s, 6H). MS (EI) m/z for C₂₇H₂₉C1N₆0₅S: 585.3 (MH⁺).

Example 106: 5-(A^-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)- ^-(2-(dimethylamino)ethyl)-2-fluorobenzamide. Ή NMR (400 MHz, DMSO-ii₆) δ 9.40 (br s, IH), 9.16 (s, IH), 8.73 (m, IH), 8.67 (d, IH), 8.36 (dd, IH), 8.26 (m, IH), 7.94 (br s, IH), 7.66 (m, IH), 7.59 (t, IH), 7.43 (m, 3H), 6.71 (dd, IH), 3.83 (s, 3H), 3.62 (m, 2H), 3.27 (m, 2H), 2.85 (d, 6H). MS (EI) m z for C₂₆H₂₆C1FN₆0₄S: 573.1 (MH⁺).

Example 107: 3-(N-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yI)sulfamoyI)-iV-(2- (dimethylamino)ethyl)benzamide. MS (EI) m z for C₂₇H₃₀ N₆0₅S: 551.1 (MH⁺).

Example 108: 3-(N-(3-(2-chloro-5-methoxy-phenylamino)quinoxaIin-2-yl)sulfamoyl)- iV-(2-(dimeth laniino)eth D- V-methylbenzamide. MS (EI) m/z for C₂₇H₂₉ C1N₆0₄S: 569.1 (MH⁺).

Example 109: 3-( -(3-(3,5-dimethoxyphenylainino)quinoxalin-2-yl)sulfamoyl)-N-(2- (dimethylamino)ethyl)-vV-methylbenzamide. MS (EI) m/z for C₂8H₃₂N₆0₅S: 565.1 (MET).

Example 110: 3-(N-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)benzamide. MS (EI) m/z for C₂₂H,8C1N₅0₄S: 484.0 (NOT).

Example 111: 3-(-V-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2- l)sulf amoyl)-

^-(2-morpholinoethyl)benzamide. MS (EI) m/z for C₂₈H₂₉ C1N₆0₅S: 597.0 (MH⁺).

Example 112: 3-(N-(3-(2-chloro-5-methoxy -phen lamino)quinoxalin-2- l)sulf amoyl)-

N-methylbenzamide. MS (EI) m/z for C₂₃H₂oClN₅0₄S: 498.0 (ΜΗΓ).

Example 113: 3-(/V-(3-(2-cUoro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-

Ar-morpholinobenzamide. MS (EI) m/z for C^H^ C1N₆0₅S: 569.0 (MH⁺). Example 114

iV-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-{5- dimeth lamino meth l -l 3 4-oxadiazol-2- l}benzenesulfonamide

[00221] To a solution of 3-{ [(3-{ [2-chloro-5-(methoxy)phenyl]amino}quinoxalin- 2-yl)amino]sulfonyl } benzoic acid (0.25 g, 0.52 mmol), prepared as described above in Example 100, in dimethylformamide (2.6 mL) were added 2-(7-aza-lH-benzotriazole-l-yl)- 1,1,3,3-tetramethyluronium hexafluorophosphate (HATU, 0.25 g, 0.67 mmol) and N- ethyldiisopropylamine (DIEA, 0.1 1 g, 0.88 mmol) at room temperature. The reaction was stirred for 15 min before 2-(dimethylamino)acetohydrazide (78 mg, 0.67 mmol) was added. The reaction mixture was allowed to stir overnight. The reaction was diluted with ethyl acetate (200 mL) and washed with water (30 mL), saturated aqueous sodium bicarbonate (30 mL), 1.0 N aqueous hydrochloric acid (20 mL), and saturated aqueous sodium chloride (25 mL). The organic layer was dried over magnesium sulfate, filtered and concentrated at reduced pressure to afford 180 mg of a coupled intermediate which was then heated in phosphorus oxychloride (5 mL) at 100 0C for 4h. The reaction was cooled to room temperature and treated with ice water (50 mL) and extracted with dichloromethane (3 X 50 mL). The organic layer was dried over magnesium sulfate, filtered and concentrated at reduced pressure to afford a crude product which was subjected to reverse phase HPLC to afford N-(3- { [2-chloro-5-(methoxy)-pheny l]amino } quinoxalin-2-y l)-3- { 5- [(dimethylamino)methyl]-l,3,4-oxadiazol-2-yl}-benzenesulfonamide (16 mg, 5 ) as yellow solid. MS (EI) m/z for C26H₂₄C1N₇0₄S: 566.0 (MH⁺). Example 115

A^-(3-(3-methox -5-nitro^henylamino)-quinoxaIin-2-yl)-3-nitrobenzenesulfonamide

[00222] iV-(3-chloroquinoxalin-2-yl)-3-nitrobenzenesulfonamide.

2,3-Dichloroquinoxaline (26.1 g, 131.1 mmol), m-Nitrobenzene sulfonamide (26.5 g, 131.1 mmol) and potassium carbonate (18.1 g, 131.1) were dissolved in anhydrous DMSO (500 mL). The reaction was heated to 150 °C for 2 h. The reaction mixture was poured into water (400 mL), followed by addition of 2M HC1 (60 mL). The product was extracted with EtOAc (3 x 500 mL). The organic layers were combined and washed water (2 x 500 mL) and brine (2 x 500 mL). The product was then dried with sodium sulfate to give N-(3- chloroquinoxalin-2-yl)-3-nitrobenzenesulfonamide. MS (EI) m z for C₁₄H₉CIN₄O₄S:

364.94, 366.97 (MH*)

[00223] iV-(3-(3-methoxy-5-nitrophenylamino)quinoxalin-2-yl)-3-nitro- benzenesulfonamide. N-(3-chloroquinoxalin-2-yl)-3-nitrobenzenesulfonamide (700 mg, 1.92 mmol), 3-methoxy-5-nitroaniline (645 mg, 3.84 mmol) and p-xylene (7 mL) were combined and heated to 140°C, then stirred for 16 hours at 130 °C. The reaction was allowed to cool, placed in a sep. funnel, diluted with DCM, and washed with 2M HC1 and brine and concentrated in vacuo. The resulting solid was washed with Et₂0 to give N-(3-(3- methoxy-5-nitro-phenylamino)quinoxalin-2-yl)-3-nitrobenzenesulfonamide (400 mg, 42%). MS (EI) m/z for C₂₁H,₆N₆0₇S: 496.94 (ΜΗΓ).

[00224] The following compounds were prepared using procedures similar to those in Example 115.

Example 116: jV-(3-(2-chloro-5-methoxyphenylamino)quinoxalin-2-yl)-3- cyanobenzenesulfonamide. MS (EI) m/z for C₂₂H|₆C1N₅0₃S: 465.9 (ΜΗ*).

Example 117: 3-cyano-N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yDbenzenesulfonamide. MS (EI) m/z for C₂₃Hi₉N₅0₄S: 462.3 (MH⁺).

Example 118: N-(3-(2^-dimethoxy-phenylamino)quinoxalin-2-yI)-3- fluorobenzenesulfonam.de. MS (EI) m/z for C₂₂H₁₉FN₄0₄S: 456.0 (MH⁺).

Example 119: 3-bromo-.V-(3-(3,5-dimethoxy-plienylamino)quinoxalin-2- yDbenzenesulfonamide. MS (EI) m/z for C₂₂Hi₉ BrN₄0₄S: 516.9 (MH⁺). Example 120: 3-bromo- V-(3-(2,5-dimethoxy-phenylamino)quinoxalin-2- yDbenzenesulfonamide. MS (EI) m z for C₂₂H,₉ BrN₄0₄S: 516.9 (MH⁺).

Example 121: N-(3-(3-methoxyphenylamino)quinoxalin-2-yl)benzenesulfonamide. MS

(EI) m/z for C₂,Hi₈ N₄0₃S: 407.0 (MH⁺).

Example 122: N-(3-(4-fluoro-3-methoxyphenylamino)quinoxalin-2- yl)benzenesulfonamide. MS (EI) m/z for C21H17FN4O3S: 425.0 (MIT).

Example 123: N-(3-(2,5-dimethoxy-phenylamino)quinoxalin-2-yl)-4- methoxybenzenesulfonamide. MS (EI) m/z for C23H₂₂N₄0₅S: 467.0 (MH⁺).

Example 124: N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-4- methoxybenzenesulfonamide. MS (EI) m/z for C₂3H22N₄0₅S: 467.0 (MH⁺).

Example 125: N-(3-(4-chloro-3-methoxy-phenylamino)quinoxalin-2- yl)benzenesulfonamide. MS (EI) m z for C₂iHi₇ClN₄0₃S: 440.9 (MH⁺).

Example 126: N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)thiophene-2- sulfonamide. MS (EI) m z for C₂oHi₈N₄0₄S₂: 443.0 (MH⁺).

Example 127: N-(3-(6-methoxyquinolin-8-ylamino)quinoxalin-2-yl)-3- nitrobenzenesulfonamide. MS (EI) m/z for C₂₄Hi₈N₆0₅S: 502.95 (MH⁺).

Example 128: 3-nitro-N-(3-(pyridin-4-ylamino)quinoxalin-2-yl)benzenesulfonamide.

MS (EI) m/z for C,₉H,₄N₆0₄S: 423.2 (MH⁺).

Example 129: N-(3-(2-cUoropyridin-4-ylamino)quinoxalin-2-yl)-3- nitrobenzenesulfonamide. MS (EI) m/z for Ci₉H,₃ClN₆0₄S: 456.93, 458.90 (MH⁺). Example 130: V-(3-(4,6-dimethoxypyrimidin-2-ylamino)quinoxalin-2-yl)-3- nitrobenzenesulfonamide. MS (EI) m/z for C₂oHi₇N₇0₆S: 484.03 (MIT).

Example 131: N-(3>(4-hydroxy-6-methoxypyrimidin-2-ylamino)quinoxalin-2-yl)-3- nitrobenzenesulfonamide. MS (EI) m/z for Ci₉Hi₅N₇0₆S: 469.97 (MH⁺).

Example 132: V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-2- fluorobenzenesulfonamide. MS (EI) m z for C₂₂H₁₉FN₄0₄S: 455.3 (MH⁺).

Example 133: N-(3-(2-bromo-5-methoxy-phenylamino)quinoxalin-2-yl)-3- nitrobenzenesulfonamide. MS (EI) m/z for C₂iH|₆BrN₅0₅S: 531.82, 532.84 (MH*). Example 134: -V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-4- methylbenzenesulfonamide. MS (EI) m/z for C₂3H₂2N₄0₄S: 451.0 (MIT).

Example 136: N-(3-(2,5-dimethoxy-phenylamino)quinoxalin-2-yl)-4- methylbenzenesulfonamide. MS (EI) m/z for C₂₃H₂₂N 0₄S: 451.0 (MH⁺).

Example 137: A^-(3-(3-fluoro-5-methoxy-phenylamino)quinoxalin-2-yl)-3- nitrobenzenesulfonamide. MS (EI) m/z for C2iHi6F ₅0₅S: 470.0 (Mlf^"). Example 138: 4-bromo-vV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yI)benzenesulfonamide. MS (EI) m/z for C₂₂H₁₉BrN₄0₄S: 516.9, 514.9 (MET).

Example 139: iV-(3-(3-methoxyphenylamino)quinoxalin-2-yl)-3-nitro- benzenesulfonamide. MS (EI) m/z for C₂₁H_]7N₅0₅S: 451.93 (MH⁺).

Example 140: N-(3-(2-chloro-5-hydroxy-phenyIamino)quinoxalin-2-yl)-3- nitrobenzenesulfonainide. MS (EI) m z for C₂oH|₄ClN₅0₅S: 472.15, 474.13 (MET).

Example 141 : 3-acetyl-N-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2- y benzenesulfonamide. MS (EI) m/z for C₂₃Hi₉ClN₄0₄S: 483.08 (MH⁺).

Example 142: iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide. MS (EI) m/z for C₂2H₂oN₄0₄S: 437.49 (ΜΗ*).

Example 143: jV-(3-(5-methoxy-2-methyl-phenylamino)quinoxalin-2- y benzenesulfonamide. MS (EI) m/z for C₂₂H2oN₄0₃S: 421.46 (MH⁺).

Example 144: N-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2- yl)benzenesulfonamide. MS (EI) m/z for C₂iHi₇ClN₄0₃S: 440.59 (MtT).

Example 145: V-(3-(2,5-dimethoxy-phenylamino)quinoxalm-2-yl)benzenesulfonamide.

MS (EI) m/z for C₂₂H₂₀N₄O₄S: 437.53 (MH⁺).

Example 146: 4-chloro-jV-(3-(3^-dimethoxy-phenylamino)quinoxalin-2- yl)benzenesulfonamide. MS (EI) m/z for C₂₂Hi₉ClN₄0₄S: 470.54 (MH⁺).

Example 147: N-(3-(5-methoxy-2-methyl-phenylamino)quinoxalin-2-yl)-3- nitrobenzenesulfonamide. MS (EI) m/z for C₂₂Hi₉N₅0₅S: 466.32 (MH⁺).

Example 148: N-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)-3- nitrobenzenesulfonamide. MS (EI) m/z for C₂|Hi₆ClN₅0₅S: 485.86 (MH⁺).

Example 149: yV-(3-(4-chloro-2,5-dimethoxy-phenylamino)quinoxalin-2- yl)benzenesulfonamide. MS (EI) m/z for C₂₂H,₉C1N₄0₄S: 470.99 (MH⁺).

Example 150

N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-(2H-tetrazol-5- yl)benzenesulfonamide

[00225] To a stirred solution of 3-cyano-N-(3-(3,5-dimethoxyphenylamino)quinoxalin- 2-yl)benzenesulfonamide (0.20 g, 0.44 mmol), prepared using procedures similar to those described in Example 1 15, in dimethylformamide ( 1.2 mL) at 50 °C were added sodium azide (0.1 1 g, 1.76 mmol) and ammonium chloride (94 mg, 1.76 mmol). The crude mixture was heated at 1 0 °C overnight. The reaction was cooled to room temperature treated with ice water (20 mL) followed by concentrated hydrochloric acid ( 10 mL). The solid obtained was filtered under reduced pressure and washed with hexane (20 mL), diethyl ether (20 mL), and ethyl acetate (5 mL) to afford N-(3-{ [3,5-bis(methoxy)phenyl]amino}quinoxalin-

2- yl)-3-(2H-tetrazol-5-yl)benzenesulfonamide (55 mg, 25%) as light yellow solid. MS (EI) m/z for C₂₃H₂oN₈0₄S: 505.0 (MET).

Example 151

A'-(3-(2,6-dichloropyridin-4-ylamino)quinoxalin-2-yl)-3-nitrobenzenesulfonamide.

[00226] A mixture of N-(3-chloroquinoxalin-2-yl)-3-nitrobenzenesulfonamide ( 1 g), 2,6- dichloropyridin-4-amine (760 mg) and p-xylene ( 10 mL) was heated at 135 °C with stirring overnight. Upon cooling to room temperature, the mixture was dissolved in

dichloromethane, washed with 2 N HCI (2 x) and brine, concentrated in vacuo to give a crude product of N-{3-[(2,6-dichloropyridin-4-yl)amino]quinoxaIin-2-yl }-3- nitrobenzenesulfonamide. A small portion of this crude product was purified by HPLC to give N-{ 3-[(2,6-dichIoropyridin-4-yl)amino]quinoxalin-2-yl }-3-nitro-benzenesulfonamide. Ή NMR (400 MHz, DMSO) δ 9.71 (s, 1H), 8.90 (s, 1H), 8.50 (d, 2H), 8.8.41 (d, 1H), 8.30 (s, 2H), 7.88-7.78 (m, 27.65 (d, 1H), 7.47-7.37 (m, 2H); MS (EI) m/z for C19H12CI2N6O4S: 491.1, 493.1 (MH⁺).

Example 152

jV-(3-(2-chloro-6-methoxypyridin-4-ylamino)quinoxalin-2-yl)-3- nitrobenzenesulfonamide

[00227] To a crude product of N-{3-[(2,6-dichloropyridin-4-yl)amino]quinoxalin-2-yl }-

3- nitrobenzenesulfonamide ( 1.24 g) prepared using procedures similar to those for Example 151 , was added anhydrous DMSO ( 10 mL), followed by sodium methoxide (273 mg). The resulting mixture was heated at 100 °C for 3 days. The mixture was diluted with EtOAc and water, and the pH was adjusted to about 4 by adding acetic acid. The product was extracted with EtOAc (3 x). The combined extracts were washed with brine to give the crude product. A portion of the crude product was purified by prep HPLC to give N-(3-{ [2- chloro-6-(methyloxy)pyridin-4-yl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonarnide. 1H NMR (400 MHz, DMSO) δ 9.44 (s, 1H), 8.90 (s, 1H), 8.50 (d, 1H), 8.42 (d, IH), 7.88-7.84 (m, 2H), 7.77 (s, IH), 7.74 (s, IH), 7.64 (d, IH), 7.45-7.38 (m, 2H), 3.82 (s, 3H); MS (EI) m/z for C₂oH₁₅ClN₆05S: 496.94 (MH*).

Example 153

2-(dimethylamino)-vV-(3-(N-(3-(3-(2-(dimethylarnino)acetamido)-5-rnethoxy- phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide

I

[00228] 3-amino-/V-(3-(3-amino-5-methoxyphenylamino)quinoxalin- 2-yl)benzenesulfonamide. N-(3-(3-Methoxy-5-nitrophenylamino)quinoxalin-2-yl)-3- nitrobenzenesulfonamide (400 mg, 0.81 mmol), prepared as described above in Example 1 15, was dissolved in 1: 1 THF:EtOH (4 mL), to which was added formic acid (938 μΐ, 2.42 mmol) and potassium formate (203 mg, 2.42 mmol). The system was flushed with nitrogen, and then 10% wt Pd/C (50 mg) was added. The reaction was then heated to 60°C. Once the reaction was determined complete by LC-MS, it was allowed to cool, and DMF was added for solubility. The solution was then filtered through a nylon frit to remove the catalyst. The filtrate was diluted water and the pH adjusted to 7 and extracted with DCM (2x) and EtOAc (2x). All organic layers were combined and evaporated to dryness to give 3-amino-N-(3-(3- amino-5-methoxyphenylamino)quinoxalin-2-yl)benzenesulfonamide (330 mg, 93%). MS (EI) m/z for C₂iH₂₀N₆O₃S: 437.06 (MH*)

[00229] 2-(dimethyIamino)--V-(3-(A?-(3^3 2 dimethylaiirino)-acetaraido)-5- methoxyphenyIamino)quinoxalin-2-yl)-sulfamoyI)phenyl)acetamide. 3-Amino-N-(3-(3- amino-5-methoxyphenylamino)quinoxalin-2-yl)benzenesulfonamide (330 mg, 0.76 mmol), DMF (4 mL), N,N,-Dimethylglycine (312 mg, 3.02 mmol), HATU (1.15 g, 3.02 mmol), and 1.29(mL) (7.56 mmol) DIEA ( 1.29 mL, 7,56 mmol) were combined and heated to 90°C, followed by heating at 50°C for over 16 hours. The reaction was allowed to cool, placed into a sep. funnel diluted with water and aqueous LiCl and extracted with EtOAc. The final compound was then purified by prep. HPLC to give 2-(dimethylamino)-N-(3-(N-(3-(3-(2- (dimethylamino)acetamido)-5-methoxy-phenylamino)-quinoxalin-2- yl)sulfamoyl)phenyl)acetamide. Ή NMR (400 MHz, CD₃OD) δ 8.45 (t, 1H), 7.93 (t, 1H), 7.85-7.88 (m, 1H), 7.70-7.74 (m, 1H), 7.65-7.68 (m, 1H), 7.58-7.62 (m, 1H), 7.58 (t, 1H), 7.34-7.42 (m, 3H), 7.0 (t, 1 H), 4.05 (d, 2H), 3.8 (s, 3H), 2.9-3.0 (d, 12H). MS (EI) m/z for C₂9H34N_g0₅S: 607.2 (MH⁺).

[00230] The following title compounds were prepared using procedures similar to those in Example 153.

Example 154: A^f-(3-(2,5-dimethoxyphenylamino)-7-methylquinoxalin-2- yl)benzenesulfonamide. MS (EI) m/z for C₂3H₂₂N₄0₄S: 451.0 (MPT*^").

Example 155a and Example 155b

V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-3- (methylamino)benzenesulfonamide and iV-(3-(3,5-dimethoxy-phenylamino)quinoxaIin- -yl)-3-(dimethylamino)benzenesulfonamide.

[00231] To a solution of 3-amino-N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)benzenesulfonamide (414 mg) in DMF (4.5 mL) was added iodomethane ( 1 14 uL). The reaction mixture was heated at 35-50 °C until the formation of both mono-methylated and di-methylated products was detected by LC MS. The mixture was diluted with EtOAc, washed with water, 10% LiCI (2 x) and brine. After removal of solvent in vacuo, the crude mixture was purified by flash silica column chromatography eluting with 15% EtOAc in hexanes, affording the mono-methylated and di-methylated products. Product A: N-(3-(3,5- dimethoxyphenylamino)quinoxalin-2-yl)-3-(methylamino)-benzenesulfonamide (35 mg). Ή NMR (400 MHz, DMSO) δ 12.2 (s, 1H), 8.93 (s, 1H), 7.85 (d, 1H), 7.58 (d, 1H), 7.40- 7.20 (m, 7H), 6.76 (m, 1H), 6.24 (m, 1H), 6.16 (br s, 1H), 3.77 (s, 6H), 2.71 (s, 3H). MS (EI) for C₂₃H₂₃N₅0 S: 466.05 (MH+). Product B: N-(3-(3,5- dimethoxyphenylamino)quinoxalin-2-yl)-3-(dimethylamino)benzenesulfonamide (33 mg). Ή NMR (400 MHz, DMSO) δ 1220 (s, 1H), 8.98 (s, 1H), 7.98 (d, 1H), 7.56 (d, 1H), 7.42- 7.32 (m, 7H), 6.74 (m, 1H), 6.24 (m, 1H), 3.77 (s, 6H), 2.97 (s, 6H). MS (EI) for

C₂₄H₂₅N₅0₄S: 480.04 (MH+). Example 156

N-(3-{[(2-{[3,5-bis(methoxy)phenyl]amino}pyrido[2,3-b]pyrazin-

[00232] To a THF suspension ( 1.3 mL) of 3-amino-N-(3- { [3,5-(dimethoxy)- phenyl]amino}-quinoxalin-2-yl)benzenesulfonamide (126 mg, 0.28 mmol), prepared using procedures similar to those described for Example 15, was added 0.143 mL of 2M aqeuos Na₂C0₃. To this yellow suspension is added dropwise 33 pL (0.42 mmol) of chlororacetyl chloride. The reaction mixture turns clear after a few minutes and is allowed to stir at 23°C for lh. To the reaction is added a DMSO (1 mL) solution containing 180 pL ( 1.4 mmol) of /ν,Λ ,ΛΓ trimethylethelyenediamine. The reaction is then warmed to 60°C and stirred for 18h. The product is isolated by preparative RP-HPLC (NH₄OAC/ACN) gradient, the appropriate fractions were pooled and lyophilize to give a solid yellow as the acetic acid salt: 59 mg (51 %). Ή-NMR (400 MHz, CDCL₃): 5 10.1 (br s, 1H), 8.37 (br s, 2H), 8.18 (d, 1H), 7.97 (d, 1H), 7.60 (br d, 1H), 7.27 (s, 2H), 7.20 (br s, 3H), 6.15 (s, 1H), 3.82 (m, 2H), 3.65 (s, 6H), 3.20 (br m, 2H), 2.82 (br s, 8H), 2.42 (s, 3H), 2.02 (s, 3H). MS (EI) m/z for C^HMNSOSS: 595.84 (MH⁺).

[00233] The following title compounds were prepared using similar procedures to those in Example 156.

Example 157: iV-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyI)-2-((3-(dimethylamino)propyl)(methyl)amino)acetamide. MS

(EI) m/z for C₃₀H₃₇N₇O₅S: 608.1 (MH⁺).

Example 158: 2-(l,4'-bipiperidin-l'-yl)-N-(3-(iV-(3-(3,5-dimethoxy- phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide. MS (EI) m/z for C3₄H₄iN₇0₅S: 660.1 (MH⁺).

Example 159: tert-butyl 2-(3-( V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenylcarbamoyl)piperidine-l-carboxylate. MS (EI) m/z for C₃₃H38N60₇S: 663.1 (MH⁺). Example 160: 3-( -(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)- iV-(l-(dimethylamino)propan-2-yl)benzamide. MS (EI) m z for C₂₇H₂₉ C1N₆0₄S: 569.0 (MH⁺).

Example 161: -(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-3- ureidobenzenesulfonamide. MS (EI) m/z for C23H22 6O5S: 495.40 (MET).

Example 162: 2-(dimethylamino)-AK3-(-V-(3-(5-methoxy-

2-methylphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide. MS (EI) m/z for C₂6H₂₈N₆0₄S: 521.69 (MIT).

Example 163: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yI)sulfamoyl)phenyl)-2-(4-methylpiperazin-l-yl)acetamide. MS (EI) m z for

C₂<,H₃₃N₇0₅S: 592.61 (MtF).

Example 164: 2-acetarnido-N-(3-(N-(3-(3,5-dimethoxyphenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)acetamide. MS (EI) m/z for C₂6H₂₆N₆0₆S: 550.59 (MH^1").

Example 165: terf-butyl 2-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxaIin-2- yl)sulfamoyl)phenylamino)-2-oxoethylcarbamate. MS (EI) m/z for C₂9H₃₂Ne0₇S:

609.32 (Mif).

Example 166

A^r-(2-(3,5-dimethoxy-phenylamino)pyrido[2,3-b]pyrazin-3-yl)-3- nitrobenzenesulfonamide

[00234] To a xylene suspension (15 mL) of N-(2-chloropyrido[2,3-b]pyrazin-3-yl)-

3-nitrobenzenesulfonamide (1 g, 2.7 mmol) (prepared using procedures similar to those in

Asier, et al /. Org Chem 2005, 70(7), 2878 and Leeson, et al J. Med.Chem 1991, 34, 1243) was added 420 mg (2.7 mmol) of 3,5 dimethoxyaniline. After refluxing the reaction for lh, the reaction is cooled , the precipitate is collected by filtration and dried under vacumn to give 830 mg of the product as a ~6: 1 mixture of isomers with the major being N-(2-(3,5- dimethoxy-phenylamino)pyrido[2,3-b] pyrazin-3-y l)-3-nitrobenzenesulfonamide which was assigned by known chemical reactivity. Analytical HPLC, ret. time = 3.3 min (14%), 3.05 min (86%), (conditions: Phenomenex Gemini C18 50x4.6 column, gradient 5% to 95% MeCN/H₂0, in the presence of 0.1% TFA, 5 min run at 3.5 ml/min flow rate, λ =254 nm). Ή-NM (400 MHz, DMSO-d6): major isomer 8 9.14 (br s, 1H), 8.69 (dd, 1H), 8.60 (dd, 1H), 8.33 (dt, 2H), 7.77 (t, 1H), 7.49 (dd, 1H), 7.37 d, 2H), 7.05 (s, 1H), 6.26 (t, IH), 3.77 (s, 6H); MS (EI) m/z for C₂iHi₈N₆0₆S: 483.08 (MH*).

Example 167

3-amino-jV-(2-(3,5-dimethoxy-phenylamino)pyrido[2,3-b]pyrazin-3- y benzenesulfonamide.

[00235] To a 1 : 1 THF/EtOH suspension (1 mL) of N-(3-(3,5-dimethoxyphenylamino)- pyrido[3,2-b]pyrazin-2-yl)-3-nitrobenzenesulfonamide (190 mg, 0.21 mmol) (prepared using procedures similar to those in Examples 166) was added 47 μ]_. (1.26 mmol) of formic acid plus 99 mg (1.17 mmol) of potassium formate and 50 mg of 10% palladium on charcoal. After refluxing the reaction for lh, hot filtration through celite (washing with a small portion of DMF), dilution with 30 mL of water, the pH was adjusted to 5.5 with 5% NaHC0₃, the product is isolated as a precipitate 140 mg (80%) of white powder. Analytical HPLC, ret. time = 2.6 min (90%), 3.05 min (10%), 100% pure (conditions: YMC C18 5x4.6 column, gradient 10% to 90% MeCN/H₂0, in the presence of 0.1 % TFA, 9 min run at 1 ml/min flow rate, λ =254 nm). Ή-NMR (400 MHz, CDCL₃): 5 8.48 (br s, 1H), 8.34 (dd, 1H), 7.92 (dd, 1H), 7.41 (dd, 1H), 7.15 (m, 3H), 7.13 (d, 2H), 6.86 (dd, 1H), 6. 28 (t, 1 H), 3.83 (s, 6H); MS (EI) m/z for C₂,H₂₀N₆O₄S: 453.03 (MH⁺).

Example 168

3-ainino- -(3-{[3,5-bis(niethoxy)phenyl]amino}pyrido[2,3-b]pyrazin- -yl)benzenesulfonamide

[00236] To a 1 : 1 THF/EtOH suspension (1 mL) of 3-nitro-N-(3-{ [3,5-bis(methoxy)- phenyl]amino}pyrido[2,3-b]pyrazin-2-yl)benzenesulfonamide (100 mg, 0.21 mmol)

(prepared using procedures similar to those used in Example 166) was added 46 μL· (0.63 mmol) of formic acid plus lOOmg (0.63 mmol) of potassium formate and 100 mg of 10% palladium on charcoal. After refluxing the reaction for Ih, hot filtration through celite, and concentration, the product is isolated by preparative RP-HPLC (AffiUOAc/ACN) gradient. The appropriate fractions were pooled and lyophilize to give solid yellow product: 3.2 mg (4%). Ή-NMR (400 MHz, CDC1₃): 58.62 (d, IH), 8.52 (s, IH), 7.62 (d, IH), 7.3 (m, 4H), 7.18 (d, 2H), 6.88 (d, I H), 6.27 (t, IH), 3.96 (br s, 2H), 3.83 (s, 6H). MS (EI) m/z for

C₂iH₂oN₆0₄S: 453.22 (MlT).

Example 169

iV-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-(l-{[2-(dimethylamino)- ethyl]amino}ethyl)benzenesulfonamide trifluoracetic acid salt

[00237] To a dichloroethane solution (0.6 mL) of 3-acetyl-N-(3- { [2-chloro-5-(methoxy)- phenyl]amino }quinoxalin-2-yl)benzenesulfonamide (150 mg, 0.3 1 mmol), prepared using procedures similar to those in Example 1 15, and 51 (0.37 mmol) of

N,N-dimethylethyIenediamine was added 19 μί. of acetic acid followed by 132 mg (0.62 mmol) of sodium cyanoborohydride. The reaction mixture was refluxed for 18h under a nitrogen atmosphere. After concentration (in vacuo), the product is isolated by preparative RP-HPLC (0.1 % TFA/ACN) gradient, followed by lyophilization of appropriate fractions to give solid yellow solid: 189 mg (90%). Ή-NMR (400 MHz, i/₃-MeOD): δ 8.74 (s, IH), 8.18 (s, IH), 8.12 (d, I H), 7.71 (m, 3H), 7.48 (m, 4H), 7.28 (d, IH), 6.63 (d, IH), 4.38 (q, IH), 3.80 (s, 3H), 3.30 (m, 3H), 3.12 (m, IH), 2.84 (s, 3H), 1.60 (d, 3H). MS (EI) m/z for C₂₇H₃iClN₆0₃S: 555.56 (MH⁺).

Example 170

N^-{[(3-{[(3-{[2-cUoro-5-(methoxy)phe^

nieth lphen l)amiiio](diineth lamiiio)methvlidene}-V-methylmethananiinium

[00238] To a dimethylformamide solution ( 1 mL) of 3-amino-N-(3- { [2-chloro-5- (methoxy)-phenyl]amino}quinoxalin-2-yl)2-methylbenzenesulfonamide (200 mg, 0.40 mmol), prepared using procedures similar to those described in Example 1 15, is added 312 pL ( 1.8 mmol) of D1EA and 122 mg (0.6 mmol) of HATU. After stirring for 18h at 60 °C, the product was precipitated from a 1 : 1 mixture of hexane/ethyl acetate, filtered and dried to afford 60 mg (26%). Ή NMR (400 MHz, DMSO- ): δ 9.26 (b rs, 1H), 8.96 (br s, 1H), 7.80 (s, 1H), 7.51 (br s, IH), 7.45 (d, 1H), 7.18 (brm, 4H), 6.91 (br s, 1H), 6.60 (br d, 1H), 3.82 (s, 3H), 3.36 (s, 3H), 2.85 (s, 6H), 2.58 (s, 3H). MS (EI) m/z for C₂₇H₃,CIN₇0₃S⁺: 569.32 (MH⁺).

Example 171

2-Bromo-N-(3-(N-(3-(3,5-dimethoxyphenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)acetamide

[00239] In a 50 mL round-bottom flask was added 2-bromoacetic acid ( 1.87 g, 13.5 mmol), N,N-diisopropylcarbodiimide (860 mg, 6.8 mmol) and 10 mL DCM. To this mixture was added 3-amino-N-(3-(3,5-dimethoxyphenylamino) quinoxalin-2-yl)

benzenesulfonamide (2.03 g, 4.5 mmol), prepared using procedures similar to those in Example 168. The reaction was stirred overnight at room temperature. Complete consumption of the starting aniline was confirmed by LCMS. The solvent was evaporated off to yield the crude product (2-bromo-N-(3-(N-(3-(3,5-dimethoxyphenylamino) quinoxalin-2-yl)sulfamoyl) phenyl) acetamide). This was used directly in the next step without purther purification.

General Alkylation Procedure 1

[00240] Into a 2-dram vial was placed 2-bromo-N-(3-(N-(3-(3,5-dimethoxy- phenylamino)quinoxalin-2-yl) sulfamoyl) phenyl) acetamide (86 mg, 0.15 mmol), prepared using procedures similar to those in Example 171.along with 2 mL of acetonitrile. Eight equivalents (1.2 mmol) of the desired amine, aniline, hydrazine or alkoxyamine were added followed by the addition of Hunig's Base (41 uL, 0.25 mmol). The reaction then was stirred at 50 °C for one hour (overnight for aniline reagents). Preparative reverse-phase HPLC was used to isolate the desired product directly from the crude reaction mixture. A Waters Fractionlynx preparative reverse-phase HPLC - equipped with a Waters SunFire Prep CI 8, OCD 5 μΜ, 30 X 70 mm column and running a 5-100 % gradient with a binary solvent system of 25 mM ammonium acetate in water/acetonitrile - was used to carry out the purification.

[00241] The following title compounds were prepared according to General Library Alkylation Procedure 1.

Example 172: V-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxaIin-2- yl)sulfamoyl)phenyl)-2-(methylamino)acetamide. Ή-NMR (400MHz, de-DMSO): 8.81 (s, 1H), 8.23 (t, 1H), 7.75 (d, 1 H), 7.66 (d, 1H), 7.41-7.38 (m, 1H), 7.35 (m, 1H), 7.32 (d, 2H), 7.29-7.27 (m, 1H), 7.14-7.1 1 (m, 2H), 6.14 (t, 1H), 3.80 (s, 1H), 3.78 (s, 6H), 2.58 (s, 3H), 1.91 (s, 2H); MS (EI) m z C₂5H26N₆0₅S: 523.6 (MH⁺).

Example 173: 2-(cyclopropylmethylamino)-A^r-(3-(-V-(3-(3,5- dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide. Ή-NMR (400MHz, d₆-DMSO): 10.58 (s, 1H), 8.81 (s, 1H), 8.20 (t, 1H), 7.76 (d, 1H), 7.67 (d, 1H), 7.42-7.36 (m, 2H), 7.32 (d, 2H), 7.27 (s, 1H), 7.14-7.12 (m, 2H), 6.15 (t, 1H), 3.93 (s, 2H), 3.78 (s, 6H), 2.89 (s, 1H), 2.88 (s, 1H), 1.05-1.00 (m, 1H), 0.59 (d, 1H), 0.57 (d, 1 H), 0.35 (d, 1H), 0.34 (d, 1H); MS (EI) m/z C₂₈H₃oN₆0₅S: 563.6 (MH⁺). Example 174: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(2-hydroxy-propylamino)acetamide. Ή-NMR (400MHz, <¼- DMSO): 10.49 ppm (s, I H), 8.81 ppm (s, IH), 8.23 ppm (t, IH), 8.13 ppm (s, IH), 7.76 ppm (d, IH), 7.765-7.763 (dd, IH), 7.41-7.37 ppm (m, 2H), 7.33-7.32 ppm (d, IH), 7.30- 7.28 ppm (m, IH), 7.16-7.09 ppm (m, 2H), 6.55 ppm (s, IH), 6.14 ppm (t, IH), 5.49 ppm (d, 2H), 5.25 ppm (s, IH), 3.85 ppm (s, IH), 3.78 ppm (s, 6H) 3.67-3.59 ppm (m, IH), 3.00- 2.89 ppm (dd, IH), 2.79-2.76 ppm ( m, IH), 1.10 ppm (d, IH), 1.01-0.99 ppm (d, IH); MS (EI) m z C₂₇H3oN₆06S: 566.6 (MH⁺).

Example 175: iV-(3-(N-(3-(3^-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(3-fluorobenzylamino)acetamide. Ή-NMR (400MHz, d₆- DMSO): 10.42 ppm (s, IH), 8.82 ppm (s, IH), 8.23 ppm (s, IH), 8.14 ppm (s, IH), 7.75 ppm (d, IH), 7.65 ppm (d, IH), 7.49-7.32 ppm (m, 6H), 7.25-7.20 ppm (m, IH), 7.14-7.12 ppm (m, 2H), 6.55 ppm (s, IH), 6.15 ppm (t, IH), 4.14 ppm (s, 2H), 3.78 ppm (s, 6H), 3.74 ppm (s, 2H); MS (EI) m/z C₃|H₂₉FN₆0₅S: 616.7 (MH⁺).

Example 176: 2-(benzylamino)-iV-(3-(JV-(3-(3^-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)acetamide. MS (EI) m/z C₃iH3oN₆0₅S: 599 (MH⁺).

Example 177: 2-(diethylamino)-N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)acetamide. MS (EI) m/z C₂₈H₃₂N60₅S: 565 (ΜΗ*).

Example 178: 2-(4-(3,4-dichlorophenyl)piperazin-l-yl)-iV-(3-( V-(3-(3,5- dimethoxyphenylaimno)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide. MS (EI) m/z

C3₄H₃₃C1₂N₇0₅S: 722 (MH⁺).

Example 179: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyI)phenyl)-2-(2,2-dimethylhydrazinyl)acetamide. MS (EI) m/z C₂6H_{2 7}0₅S: 552 (MH⁺).

Example 180: V-(3-(iV-(3-(3,5-dimethoxy-phenylamino)qumoxalin-2- yl)sulfamoyl)phenyI)-2-(p-tolylamino)acetamide. MS (EI) m/z C₃iH₃o ₆0₅S: 599 (MtT).

Example 181: 2-(benzyloxyamino)--V-(3-(-V-(3-(3,5-dimethoxy- phenyiamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide. MS (EI) m/z C₃iH₃oN₆06S: 615 (MH⁺).

Example 182: 2-(2-chlorophenylamino)--V-(3-(-V-(3-(3,5- dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide. MS (EI) m/z C₃oH₂₇ClN₆0₅S: 619 (MH⁺). Example 183: N-(3-(N-(3-(3,5-diraethoxyphenylamino)quinoxaIin-2- yl)suIfamoyl)phenyl)-2-(isopropylamino)acetamide. MS (EI) m/z C^HoNeOsS: 551 (MH⁺).

Example 184: 2-(4-cyclopentylpiperazin-l-yl)- V-(3-(/V-(3-(3,5- dimethoxyphenylamino)quinoxalin-2-yl)sidfamoyl)phenyI)acetamide. MS (EI) m z C₃3H39 ₇0₅S: 646 (MH⁺).

Example 185: /V-(3-(/V-(3-(3,5-dimethoxy-p enylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(4-propylpiperidin-l-yl)acetamide. MS (EI) m/z C32H38N6O5S: 619 (MIT).

Example 186: N-(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(isobutoxyamino)acetamide. MS (EI) m/z C28H32N6O6S: 581 (MH⁺).

Example 187: 2-(3-tert-butylphenylamino)-A-(3-(.V-(3-(3^- dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide. MS (EI) m/z C₃4H36 ₆0₅S: 641 (MH⁺).

Example 188: V-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(2-phenylpropan-2-ylamino)acetamide. MS (EI) m/z

C₃3H34N₆0₅S: 627 (MH⁺).

Example 189: N-(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yI)sulfamoyl)phenyl)-2-(3-fluoro-4-hydroxyphenylamino)acetamide. MS (EI) m/z C3oH₂₇FN₆0₆S: 619 (MH⁺).

Example 190: N-(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxaIin-2- yl)sulfamoyl)phenyl)-2-(2-(methylthio)benzylamino)acetamide. MS (EI) m z

C3₂H3₂N₆0₅S2: 645 (MH⁺).

Example 191: ^-(3 /V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(5-fluoro-2-methylbenzylamino)acetamide. MS (EI) m/z

C3₂H3,FN₆0₅S: 631 (MH⁺).

Examplel92: -(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(2-phenylpyrrolidin-l-yl)acetamide. MS (EI) m/z C34H34N6O5S: 639 (MIT).

Example 193: 2-(2-benzylpyrrolidin-l-yl)-_i/V-(3-(/V-(3-(3,5-dimethoxy- phenylamino)quinoxaIin-2-yl)sulfamoyl)phenyl)acetamide. MS (EI) m/z C35H₃₆N₆0₅S: 653 (MH⁺). Example 194: A^r-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)suIfamoyl)phenyl)-2-(2-phenylmorpholino)acetamide. MS (EI) m/z C₃₄H3₄N₆0₆S: 655 (MH⁺).

Example 195: ^-(3^N-(3 3,5-dimethoxy-phenylamino)quinoxalin-2- yl)suIfamoyl)phenyl)-2-(2-(pyridm-4-yl)piperidin-l-yl)acetamide. MS (EI) m/z

C^sN-^OsS: 654 (MH⁺).

Example 196: V-(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfaraoyl)phenyl)-2-(o-tolyIamino)acetamide. MS (EI) m/z C31H30N6O₅S: 599 (MH⁺). Example 197: iV-(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yI)sulfamoyl)phenyl)-2-(2,4-dimethylbenzylamino)acetamide. MS (EI) m z

C₃₃H₃4 ₆0₅S: 627 (MH*).

Example 198: A^-(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(methyl(pyridin-3-ylmethyl)amino)acetamide. MS (EI) m/z C₃iH₃|N₇0₅S: 614 (MH⁺).

Example 199: 2-(3-chloro-4-methylbenzylamino)-iV-(3-(N-(3-(3,5- dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide. MS (EI) m/z C₃2H₃,CIN₆0₅S: 647 (MH⁺).

Example 200: iV-(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-((2-(dimethylamino)-ethyl)(methyl)amino)acetamide. MS (EI) m/z C₂9H₃₅N₇0₅S: 594 (MH⁺).

Example 201: 2-(4-acetylpiperazin-l-yl)-.V-(3-( V-(3-(3,5- dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide. MS (EI) m/z C₃oH₃3N70₆S: 620 (MH⁺).

Example 202: iV-(3-(N-(3 3,5-dimethoxyphenylamino)quinoxalin-2- yl)sulf amoyl)pheny l)-2-(methy 1( 1-methylpy rrolidin-3-yl)amino)acetamide. MS (EI) m z C₃oH₃5N₇05S: 606 (NUT).

Example 203: N-(3-(iV-(3-(3,5-dimethoxyphenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(4-methyl-l,4-diazepan-l-yl)acetamide. MS (EI) m/z

C₃oH₃₅N₇0₅S: 606 (MH⁺).

Example 204: 2-(4-allylpiperazin-l-yl)-N-(3-( V-(3-(3,5- dimethoxyphenylamino)qumoxalin-2-yl)sulfamoyl)phenyl)acetamide. MS (EI) m/z C₃iH₃₅N₇0₅S: 618 (MH⁺). Example 205: V-(3-(N-(3-(3,5-dimethoxyphenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(4-isopropylpiperazin-l-yl)acetamide MS (EI) m/z

C₃₁H₃₇N₇0₅S: 620 (MH⁺).

Example 206: V-(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(3-(dimethyIamino)pyrrolidin-l-yl)acetamide. MS (EI) m/z C₃₀H₃₅N₇O₅S: 606 (MH⁺).

Example 207: iV-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)suIfamoyl)phenyI)-2-(3-(dimethylamino)azetidin-l-yl)acetamide. MS (EI) m z C₂9H33N₇0₅S: 592 (MH⁺).

Example 208: N-(3-( -(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyI)-2-(4-oxopiperidin-l-yl)acetamide. MS (EI) m/z C₂9H₃oN₆0₆S: 591 (MIT).

Example 209 : N-(3-(N-(3-(3,5-dimethoxy-phen lamino)quinoxalin-2- yl)sulfamoyI)phenyl)-2-((2-methoxyethyl)(methyl)amino)acetamide. MS (EI) m/z C₂₈H₃₂N₆0₆S: 581 (MH⁺).

Example 210: ^V-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(4-methylbenzyloxyamino)acetamide. MS (EI) m z

C₃₂H₃₂N₆0₆S: 629 (MH⁺).

Example 211: V-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(2-methoxybenzyloxyamino)acetamide. MS (EI) m/z

C₃2H32N60₇S: 645 (MH⁺).

Example 212: N-(3-(A^f-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yI)sulfamoyl)phenyl)-2-(propylamino)acetamide. MS (EI) m/z C₂₇H₃oN₆0₅S: 551 (MHT).

Example 213: N-(3-(N-(3-(3,5-dimethoxy-phenyIamino)quinoxalin-2- yl)sulfamoyI)phenyl)-2-(ethyl(methyl)amino)acetamide. MS (EI) m/z C₂₇H₃₀N₆O₅S: 551 (MIT).

Example 214: 2-(allyI(methyl)amino)- V-(3-( V.(3-(3,5-dimethoxy- phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide. MS (EI) m/z C₂₈H₃₀N₆O₅S: 563 (MH⁺).

Example 215: 2-(fert-butylamino)- V-(3-(A^f-(3-(3,5-dimethoxy- phenylamino)quinoxalin-2-yI)sulfamoyl)phenyl)acetamide. MS (EI) m/z C28H₃₂N₆0₅S: 565 (MH⁺). Example 216: N-(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxaIin-2- yl)sulfamoyl)phen l)-2-(isobut lamino)acetamide. MS (EI) m/z C28H32N6O5S: 565

(Ma ).

Example 217: 2 butylamino)-A^-(3-(.V-(3-(3,5-dimethoxy^henylaniino)qumoxalin-2- yl)sulfamoyl)phenyl)acetamide. MS (EI) m/z C₂8H3₂N60₅S: 565 (MH⁺).

Example 218: V-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(isopropyl(methyl)amino)acetamide. MS (EI) m/z C₂₈H₃₂N60₅S: 565 (MH^1").

Example 219: A^r-(3-(/V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)suIfamoyl)phenyl)-2-(4-formyIpiperazin-l-yI)acetamide. MS (EI) m/z C₂9H3iN₇0₆S: 606 (MH⁺).

Example 220: V-(3-(/V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(4-ethylpiperazin-l-yI)acetamide. MS (EI) m/z C30H35N7O5S: 606 (MH^1").

Example 221: /V-(3-(/V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yI)sulfamoyl)phenyl)-2-(4-formyl-l,4-diazepan-l-yl)acetamide. MS (EI) m/z

C₃oH₃3N₇0₆S: 620 (MH*).

Example 222: N-(3-(-V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sidfamoyl)phenyl)-2-(ethyl(2-hydroxyethyl)amino)acetamide. MS (EI) m/z

C₂8H₃₂N₆0₆S: 581 (MH⁺).

Example 223: (S)-A^-(3-( V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(3-hydroxypyrrolidin-l-yl)acetamide. MS (EI) m/z

C₂₈H3oN₆0₆S: 579 (MH*).

Example 224: /V-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxaIin-2- yl)sulfamoyl)phenyl)-2-(2,6-dimethylmorpholino)acetamide. MS (EI) m z

C30H3_{4 6}O6S: 607 (MH⁺).

Example 225: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)suIfamoyl)phenyl)-2-(2-methylbenzylamino)acetamide. MS (EI) m/z C₃₂H3₂N60₅S: 613 (MH*).

Example 226: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(2-methoxy-ethylainino)acetamide. MS (EI) m/z C₂₇H3oN₆0₆S: 567 (MH⁺). Example 227: N-(3-(iV-(3-(3,5-dimethoxyphenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(thiazolidin-3-yl)acetamide. MS (EI) m/z C₂7H_{28 6}0₅S₂: 581 (MH⁺).

Example 228: ^V-(3-(^V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(3-(hydroxymethyl)piperidin-l-yl)acetamide. MS (EI) m/z C₃oH34N₆0₆S: 607 (MH⁺).

Example 229: iV-(3-( V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(2-phenylpropylamino)acetamide. MS (EI) m/z C33H34 6O5S: 627 (MH⁺).

Example 230: -(3-( -(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(isobutyl(methyl)amino)acetamide. MS (EI) m/z C2 H34N6O5S: 579 (MH⁺).

Example 231: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(phenylamino)acetamide. MS (EI) m/z CSOH^NGOSS: 585 (MH⁺).

Example 232: N-(3-(jV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(2-propylphenylamino)acetamide. MS (EI) m/z C33H34N6O5S: 627 (MH⁺).

Example 233: N-(3-(jV-(3-(3,5-dimethoxy-phenyIamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(2-isopropylphenylamino)acetamide. MS (EI) m/z

C₃3H₃₄N₆0₅S: 627 (MH⁺).

Example 234: V-(3-(A^r-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(2-fluoro-4-methylphenylamino)acetamide. MS (EI) m/z C3iH₂₉FN60₅S: 617 (MH⁺).

Example 235: 2-(4-chlorophenylamino)- V-(3-(N-(3-(3,5-dimethoxy- phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide. MS (EI) m z

Example 236: N-(3-(yV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yI)suIfamoyl)phenyI)-2-(2-methoxyphenylamino)acetamide. MS (EI) m/z C3iH₃o ₆0₆S: 615 (MH⁺).

Example 237: 2-(3-chlorophenylamino)--V-(3-(N-(3-(3,5-dimethoxy- phenyIamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide. MS (EI) m z

C3oH₂₇ClN₆0₅S: 619 (MH⁺). Example 238: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(2,3-dimethylphenylamino)acetamide. MS (EI) m/z

C₃₂H3₂N₆0₅S: 613 (MH⁺).

Example 239: N-(3-(iV-(3-(3,5-dimethox -phenylamino)quinoxalin-2- yl)sulfamoyI)phenyl)-2-(2-fluorophenylamino)acetamide. MS (EI) m/z C₃oH₂₇FN60₅S: 603 (MH⁺).

Example 240: N-(3-(-V-(3-(3,5-dimethoxy-phenyIamino)quinoxalin-2- yl)sulfamoyl)phenyI)-2-(3-fluorophenylamino)acetamide. MS (EI) m/z C₃₀H₂₇FN6O₅S: 603 (MH⁺).

Example 241: A^r-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(thiophen-2-ylmethylamino)acetamide. MS (EI) m z

C₂₉H₂8N₆0₅S₂: 605 (MH⁺).

Example 242: 2-(cyclohexyl(ethyl)amino)-.V-(3-( V-(3-(3,5- dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide. MS (EI) m/z C₃₂H₃₈N₆0₅S: 6 I9 (MH⁺).

Example 243: 2-((cyclopropylmethyl)(propyl)amino)-iV-(3-(-V-(3-(3,5- dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide. MS (EI) m/z C₃₁H₃₆N₆0₅S: 605 (MH⁺).

Example 244: 2-(aUyl(cyclopentyI)amino)-N-(3-(iV-(3-(3,5- dimethoxyphenylaimno)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide. MS (EI) m/z C₃₂H₃₆N₆0₅S: 617 (MH⁺).

Example 245: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxaIin-2- yI)sulfamoyl)phenyl)-2-(ethyl(isopropyl)amino)acetamide. MS (EI) m/z C^H^eOsS: 579 (MH*).

Example 246: V-(3-(-V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(ethyl(phenyl)amino)acetamide. MS (EI) m/z C₃₂H32N60₅S: 613 (NOT).

Example 247: Af-(3-(N-(3 3,5-dimethoxy-phenylaniino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(2-methylpyrrolidin-l-yI)acetamide. MS (EI) m/z C₂9H₃₂N₆0₅S: 577 (MET).

Example 248: V-(3-(/V-(3-(3,5-dimethoxy-phenyIamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(2-methylpiperidin-l-yI)acetamide. MS (EI) m/z C₃oH₃4N60₅S: 591 (MH⁺). Example 249: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyI)phenyl)-2-(pyridin-2-yImethylainino)acetamide. MS (EI) m/z

C₃oH₂9 ₇0₅S: 600 (MH⁺).

Example 250: 2-(benzyl(methyl)amino)-iV-(3-(N-(3-(3,5-dimethoxy- phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide. MS (EI) m/z C32H3₂N₆O5S: 613 (MH⁺).

Example 251: A^r-(3-(A^-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(l-phenylethyIamino)acetamide. MS (EI) m/z C32H32N6O5S: 613 (MIT).

Example 252: iV-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyI)phenyl)-2-(3-methylpiperidin-l-yl)acetamide. MS (EI) m/z C30H34N6O5S: 591 (MH ^").

Example 253: iV-(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(4-methylpiperidin-l-yl)acetamide. MS (EI) m/z Csoth+NeOsS: 591 (MH⁺).

Example 254: 2-(3,4-dihydroisoquinolin-2(lH)-yl)-iV-(3-(N-(3-(3,5- dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide. MS (EI) m/z C3₃H₃2N₆0₅S: 625 (MH⁺).

Example 255: N-(3-(jV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(2,6-dimethylpiperidin-l-yl)acetamide. MS (EI) m/z

C _IH3₆N₆0₅S: 605 (MH⁺).

Example 256: N-(3-(N-(3-(3,5-dimethoxy-phenyIamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(3-hydroxybenzylamino)acetamide. MS (EI) m/z C31H30N6O6S: 615 (MH⁺).

General Library Acylation Procedure 1

[00242] Into a 2-dram vial were added 3-amino-N-(3-(3,5-dimethoxy- phenylamino)quinoxalin-2-yl)benzenesulfonamide (54 mg, 0.12 mmol), prepared using procedures similar to those described in Example 15, DMA (2 mL) and the desired carboxylic acid (0.17 mmol). DIEA (70 μΐ., 0.4 mmol) followed by HATU (53 mg,0.14 mmol) were added to the vial and the reaction mixture stirred at 50 °C overnight.

Preparative reverse-phase HPLC was used to isolate the desired product directly from the crude reaction mixture. A Waters Fractionlynx preparative reverse-phase HPLC; equipped with a Waters SunFire Prep CI 8, OCD 5 μΜ, 30 X 70 mm column and running a 5-100 % gradient with a binary solvent system of 25 mM ammonium acetate in water/acetonitrile; was used to carry out the purification.

[00243] The following title compounds were prepared according to General Library Acylation Procedure 1.

Example 257: N-(3-(N-(3-(2-chIoro-5-methoxy-phenylamino)quinoxalin-2- yl)suIfamoyl)phenyl)morpholine-4-carboxamide: MS (EI) m/z for C^H^ClNeOsS: 567 (MH ).

Example 258: iV-(3-(^V-(3-(3^-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(dimethylamino)acetamide. MS (EI) m/z for C₂6H28 60₅S: 535.1 (MH^").

Example 259: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyI)propionamide. Ή-NMR (400MHz, de-DMSO): 12.37 (s, lH), 10.20 (s, IH), 8.88 (s, IH), 8.37 (s, IH), 7.93 (s, IH), 7.77 (t, 2H), 7.59 (t, IH), 7.51 (t, IH), 7.41- 7.34 (m, 4H), 6.24 (t, IH), 3.76 (s, 6H), 2.36-2.31 (dd, 2H), 1.10 (s, IH), 1.08 (s, IH), 1.06 (s, IH); MS (EI) m/z C^sNsOsS: 508.6 (MH^1").

Example 260: A^r-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)pyridazine-4-carboxamide. Ή-NMR (400MHz, d₆-DMSO): 1 1.01 (s, IH), 9.66 (dd, IH), 9.52 (dd, IH), 8.90 (s, IH), 8.55 (s, IH), 8.13 (dd, IH), 7.99 (d, IH), 7.93 (d, IH), 7.65-7.58 (m, 2H), 7.42-7.35 (m, 4H), 6.24 (t, IH), 3.75 (s, 6H); MS (EI) m/z C₂7H₂₃N₇0₅S: 558.6 (MH⁺).

Example 261: N-(3-(^V-(3-(3,5-dimethoxy-phenylamino)quinoxaliii-2- yl)sulfamoyl)phenyl)-2-methyImcotinamide. Ή-NMR (400MHz, d₆-DMSO): 10.78 ppm (s, IH), 8.90 ppm (s, IH), 8.58-8.57 ppm (dd, 2H), 7.90-7.86 (m, 4H), 7.60-7.56 ppm (m, 2H), 7.42-7.34 (m, 5H), 6.23 ppm (t, IH), 3.74 ppm (s, 6H), 2.57 ppm (s, 3H); MS (EI) m/z CaHjeNjOsS: 570.60^).

Example 262: N-(3-(-V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(o-tolyloxy)acetamide. 'H-NMR (400MHZ, d₆-DMSO): 12.37 ppm (s, IH), 10.41 ppm (s, IH), 8.90 ppm (s, IH), 8.41 ppm (s, IH), 7.93 ppm (s, IH), 7.90-7.8 (m, 2H), 7.59-7.53 ppm (m, 2H), 7.42-7.33 ppm (m, 4H), 7.17-7.12 ppm (m, 2H), 6.89-6.85 ppm (m, 2H), 6.24 ppm (t, IH), 4.74 ppm (s, 2H), 3.76 ppm (s, 6H), 2.33 ppm (s, 2H); MS (EI) m/z C_3IH₂9N₅0₆S: 599.7 (MH⁺).

Example 263: A^f-(3-( -(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-3-methoxy-4-methyIbenzamide. MS (EI) m/z C3iH₂9N₅0₆S: 600 (MIT).

Example 264: N-(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-3-methoxy-4-methylbenzamide. MS (EI) m/z C28H24N6O5S: 557 (MH⁺).

Example 265: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)suIfamoyl)phenyl)thiazole-4-carboxamide. MS (EI) m/z C26H22N6O5S2: 563 (MH⁺). Example 266: 2-bromo-N-(3-(/V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yI)sulfamoyI)phenyl)thiophene-3-carboxamide. MS (EI) m/z C₂7H2₂BrN₅0₅S₂ 640 (MH⁺).

Example 267: V-(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)pivalamide. MS (EI) m/z C27H29N5O5S: 536 (MH⁺).

Example 268: /V-(3-(A^-(3-(3,5-dimethoxy-phenyIamino)quinoxalin-2- yl)sulfamoyl)phenyl)pent-4-enamide. MS (EI) m/z C27H27N5O5S: 534 (MHT).

Example 269: .V-(3-( V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)benzamide. MS (EI) m/z C29H₂₅N₅0₅S: 556 (MH⁺).

Example 270: N-(3-(iV-(3-(3,5-dimethoxy-phenyIamino)quinoxalin-2- yl)sulfamoyl)phenyl)butyramide. MS (EI) m/z C26H27N5O5S: 522 (MH⁺).

Example 271: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-methoxyacetamide. MS (EI) m/z C^H^NsOeS: 524 (MH⁺). Example 272: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)suIfamoyl)phenyl)cyclobutanecarboxamide. MS (EI) m/z C27H27N5O5S: 534 (MH⁺). Example 273: iV-(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-methylcyclopropanecarboxamide. MS (EI) m/z

534 (MH⁺).

Example 274: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyi)-l-methylcyclopropanecarboxamide. MS (EI) m/z C27H27N5O5S: 534 (MH⁺).

Example 275: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)suIfamoyI)phenyl)-3-methylbutanamide. MS (EI) m z C27H29N5O5S: 536 (MH*). Example 276: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-ethoxyacetamide. MS (EI) m/z

538 (MH⁺).

Example 277: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-3-methoxypropanamide. MS (EI) m/z C26H₂₇N50₆S: 538 (MH⁺). Example 278: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyI)-2-hydroxyacetamide. MS (EI) m/z C₂₄H₂3N₅06S: 510 (MH⁺). Example279: .V-(3-(A^-(3-(3,5-dimethoxy-plienylamino)quinoxalin-2- yl)sulfamoyl)phenyl)isobutyramide. MS (EI) m/z C₂₆H₂7N₅0₅S: 522 (MH⁺).

Example 280: iV-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)suIfamoyl)phenyl)-l-hydroxycyclopropanecarboxamide. MS (EI) m/z C₂6H₂₅N₅0₆S: 536 (MH⁺).

Example 281: .V-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)furan-3-carboxamide. MS (EI) m/z C₂7H₂₃N50₆S: 546 (MH*). Example 282: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)suIfamoyl)phenyl)tetrahydrofuran-3-carboxamide. MS (EI) m/z C₂₇H₂₇N₅0₆S: 550 (MH⁺).

Example 283: iV-(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)tetrahydrofuran-2-carboxamide. MS (EI) m/z C₂ H₂₇N₅06S: 550 (MH⁺).

Example 284: A^r-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)furan-2-carboxamide. MS (EI) m/z C₂7H₂3N₅O6S: 546 (ΜΗ ). Example 285: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)isonicotinamide. MS (EI) m/z C₂8H2₄N6O5S: 557 (MPT).

Example 286: V-(3-(-V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-lH-pyrrole-2-carboxamide. MS (EI) m/z C2₇H₂₄N6O5S: 545 (ΜΗ*).

Example 287: iV-(3-( V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)pyrazine-2-carboxamide. MS (EI) m/z C₂7H23 ₇0₅S: 558 (MH^1"). Example 288: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-l-methyl-lH-pyrrole-2-carboxamide. MS (EI) m/z C₂8H₂₆N6O5S: 559 (MH⁺).

Example 289: N-(3-( V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-5-methyIisoxazole-3-carboxamide. MS (EI) m/z C2₇H2₄ 6O6S: 561 (MPT). Example 290: -(3-( V-(3-(3,5-dimethoxy-phenylaiiiino)quinoxalin-2- yl)sulfamoyl)phenyl)thiophene-2-carboxaraide. MS (EI) m/z C₂₇H23N₅0₅S₂: 562 (MtT). Example 291: (S)-AT-(3-(A^r-(3-(3,5-dimethoxy-phenyIamino)quinoxalin-2- yl)sulfamoyl)phenyl)-l-methylpyrrolidine-2-carboxamide. MS (EI) m/z C28H30N6O5S: 563 (MH⁺).

Example 292: /V-(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-methyIbenzamide. MS (EI) m/z C₃oH27 ₅0₅S: 570 (MIT).

Example 293: AH3-(^3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-phenylacetamide. MS (EI) m/z C₃oH₂7N50₅S: 570 (MH*).

Example 294: A^-(3-( V-(3-(3,5-dimethoxy-phenylamino)quinoxaIin-2- yl)sulfamoyl)phenyI)-3-methylpicoIinamide. MS (EI) m/z C₂9H₂₆Ne0₅S: 571 (MH^1"). Example 295: AI'-(3-(A^f-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(pyridin-3-yI)acetamide. MS (EI) m/z C₂₉H₂₆N₆0₅S: 571 (MH*). Example 296: iV-(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-6-hydroxypicolinamide. MS (EI) m/z C₂₈H₂₄N₆0₆S: 573 (MH⁺). Example 297: /V-(3-(/V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-fluorobenzamide MS (EI) m/z C₂₉H₂₄FN₅0₅S: 574 (MH⁺).

Example 298: -(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-4-fluorobenzamide. MS (EI) m/z C₂₉H₂₄FN₅05S: 574 (MH⁺). Example 299: jV-(3-(N-(3-(3,5-dimethoxy-phenyIamino)quinoxalin-2- yl)sulfamoyl)phenyl)-3-fluorobenzamide. MS (EI) m/z C₂₉H₂₄FN₅0₅S: 574 (MH⁺). Example 300: 2-cyclohexyl-N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yI)sulfamoyl)phenyl)acetamide. MS (EI) m/z C30H33N5O5S: 576 (MH⁺).

Example 301 : iV-(3-(N-(3-(3,5-dimethoxy-phen lamino)quinoxaIin-2- yl)sulfamoyl)phenyi)-2-(2-oxocyclopentyl)acetamide. MS (EI) m/z C₂₉H_{29 5}0₆S: 576 (MH⁺).

Example 302: 4-cyclopropyl-^V-(3-(^-(3-(3,S-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-4-oxobutanamide. MS (EI) m/z C₂9H₂9N₅06S: 576 (MH⁺).

Example 303: A^r-(3-(A^f-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-3-oxocycIohexanecarboxamide. MS (EI) m/z C₂9H₂9N₅06S: 576 (MH⁺).

Example 304: iV-(3-(/V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yI)sulfamoyl)phenyl)-3-(pyridin-3-yI)propanamide. MS (EI) m/z C30H28N6O5S: 585 (MH⁺). Example 305: -V-(3-(N-(3 3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-methoxybenzamide. MS (EI) m/z C₃oH2₇N₅0₆S: 586 (MH⁺). Example 306: N-(3-(.V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-3-methoxybenzamide. MS (EI) m/z C₃oH₂₇N₅0₆S: 586 (MH*). Example 307: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-phenoxyacetamide. MS (EI) m/z C3oH₂₇N₅06S: 586 (MH⁺). Example 308: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxaIin-2- yl)sulfamoyl)phenyl)-4-methoxybenzamide. MS (EI) m/z C30H27 5O6S: 586 (MH⁺). Example 309: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yI)sulfamoyl)phenyl)-2-(4-fluorophenyI)acetamide. MS (EI) m/z C30H26FN5O5S: 588 (MH⁺).

Example 310: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(2-fluorophenyl)acetamide. MS (EI) m/z C30H26FN5O5S: 588 (MET^1").

Example 311: iV-(3-(-V-(3-(3,5-dimethoxy-phenyIamino)quinoxaIin-2- yl)sulfamoyl)phenyI)-2-(3-fluorophenyl)acetamide. MS (EI) m/z C30H26FN5O5S: 588 (MIT).

Example 312: 2-chIoro-A^?-(3-(A^r-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyI)benzamide. MS (EI) m/z C₂9H₂₄C1N₅0₅S: 590 (MHP).

Example 313: 4-chloro- V-(3-( V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yI)sulfamoyl)phenyl)benzamide. MS (EI) m/z C29H24CIN5O5S: 590 (MKT).

Example 314: 3-chloro-iV-(3-(A^r-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)benzamide. MS (EI) m/z C₂₉H₂₄C1N₅0₅S: 590 (MH⁺).

Example 315: (lR,2R)-N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-phen lcyclopropanecarboxamide. MS (EI) m/z C3₂H_{29 5}0sS: 596 (MH⁺).

Example 316: iV-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-l-phenylcyclopropanecarboxamide. MS (EI) m/z C32H29N5O5S: 596 (MH⁺).

Example 317: N-(3-(iV-(3-(3,5-dimethoxy-phenylamino)qumoxalin-2- yl)sulfamoyI)phenyl)-2-(lH-imidazol-4-yl)acetamide. MS (EI) m/z C₂₇H₂₅N₇0₅S: 560 (MtT). Example 318: V-iS-iV-tS-iS^-dimethox -phen laminoJquinoxalin-l- yl)sulfamoyl)phenyl)-4-methoxy-2-methylbenzamide. MS (EI) m/z C31H29 5O6S: 600 (MH⁺).

Example 319: iV-(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(4-fluorophenoxy)acetamide. MS (EI) m/z C₃oH₂₆FN50₆S: 604 (MH⁺).

Example 320: iV-(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-5-fluoro-2-methoxybenzamide. MS (EI) m/z C30H26FN5O6S: 604 (MH⁺).

Example 321 : 2-(4-chlorophenyl)-iV-(3-( V-(3-(3,5-dimethoxy-phenylamino)quinoxaIin- 2-yl)sulfamoyl)phenyl)acetamlde. MS (EI) m/z C30H26CIN5O5S: 604 (MH⁺).

Example 322: 2-(2-chlorophenyl)-N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin- 2-yl)sulfamoyl)phenyl)acetamide. MS (EI) m/z C₃oH₂₆ClN₅05S: 604 (MH⁺).

Example 323: 2-(3-chlorophenyI)-A^r-(3-(A^r-(3-(3,5-dimethoxy-phenylamino)quinoxalin- 2-yI)sulfamoyl)phenyl)acetamide. MS (EI) m/z C30H26CIN5O5S: 604 (MH⁺).

Example 324: l-acetyl-A^r-(3-(A^r-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)piperidine-4-carboxamide. MS (EI) m/z C30H32N6O6S: 605 (MH⁺). Example 325: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(pyridin-4-yl)acetamide. MS (EI) m/z C₂9H₂6N₆05S: 571 (MH⁺). Example 326: N-(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(pyridin-2-yl)acetamide. MS (EI) m/z C₂9H₂6N₆0₅S: 571 (MIT). Example 327: 2,4-dichloro-/V-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyI)phenyl)benzamide. MS (EI) m/z C₂₉H23C1₂N₅0₅S: 624 (MH⁺).

Example 328: 3,4-dichloro-N-(3-(N-(3-(3,5-dimethoxy-phenylainino)quinoxalin-2- yl)sulfamoyl)phenyl)benzamide. MS (EI) m/z C29H23CI2N5O5S: 624 (MH⁺).

Example 329: 2,5-dichIoro-A^r-(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)benzamide. MS (EI) m/z C29H23C1₂N₅0₅S: 624 (MH⁺).

Example 330: 3,5-dichloro-N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)benzamide. MS (EI) m/z

624 (MH^1").

Example 331: 2,3-dichloro- V-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)suIfamoyl)phenyl)benzamide. MS (EI) m/z C29H23CI2N5O5S: 624 (MH⁺).

Example 332: A⁷-(3-(A^r-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)pentanamide. MS (EI) m/z C₂₇H₂₉N₅0₅S: 536 (MH⁺). Example 333: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyI)-2-methylbutanainide. MS (EI) m/z C27H_{29 5}05S: 536 (MIT). Example 334: .V-(3-(N-(3-(3,5-dimethoxy-plienylamino)quinoxalm-2- yl)sulfamoyl)phenyl)-lH-imidazole-2-carboxamide. MS (EI) m/z C₂6H23N₇0₅S: 546 (MH⁺).

Example 335: AT-(3-(-V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-lH-imidazoIe-4-carboxamide. MS (EI) m/z C26H23N7O5S: 546 (MH*).

Example 336: N-(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yI)sulfamoyl)phenyl)isoxazole-5-carboxamide. MS (EI) m/z C₂₆H₂₂N₆06S: 547 (MH*). Example 337: iV-(3-(N-(3-(3,S-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-3,3-dimethylbutanamide. MS (EI) m/z C28H₃|N₅0₅S: 550 (MH⁺). Example 338: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-methylpentanamide. MS (EI) m/z C28H31N5O5S: 550 (MKT). Example 339: V-(3-(.V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2,2-dimethylbutanamide. MS (EI) m/z C28H31 5O5S: 550 (MH⁺). Example 340: N-(3-(A^r-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-4-methylpentanamide. MS (EI) m/z C₂₈H3iN50₅S: 550 (MH⁺). Example 341: V-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yI)sulfamoyl)phenyI)pyrimidine-5-carboxamide. MS (EI) m/z C27H23N7O5S: 558 (ΜΗ*). Example 342: iV-(3-(A^f-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-3-methylfuraii-2-carboxamide. MS (EI) m/z C₂gH₂5N506S: 560 (MH⁺).

Example 343: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)thiophene-3-carboxamide. MS (EI) m/z C₂₇H₂3N₅0₅S₂: 562 (MH⁺). Example 344: N-(3-(iV-(3-(3,5-dimethoxy-phenyIamino)quinoxalm-2- yl)sulfamoyI)phenyl)-3-oxocyclopentanecarboxamide. MS (EI) m/z C28H27N5O6S: 562 (Mtf).

Example 345: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(2-methoxyethoxy)acetamide. MS (EI) m/z C₂7H₂9N₅0₇S: 568 (MPT).

Example 346: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyI)phenyl)-4-methylbenzamide. MS (EI) m/z CsoH^NsOsS: 570 (MH⁺). Example 347 : iV-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(3-methylisoxazol-4-yl)acetamide. MS (EI) m/z C₂₈H₂6N₆0₆S: 575 (MH⁺).

Example 348: 3-cyclopentyl-/V-(3-(A^r-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)propanamide. MS (EI) m/z C30H33N₅O5S: 576 (MH⁺).

Example 349: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-o-tolylacetamide. MS (EI) m/z C3iH₂₉N50₅S: 584 (MH⁺). Example 350: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-methoxynicotinamide. MS (EI) m/z C^eNeOeS: 587 (MH^1"). Example 351 : ^V-(3-(iV-(3-(3,5-dimethoxy-pheny lamino)quinoxalin-2- yl)sulfamoyl)phenyl)-4-fluoro-3-methylbenzamide. MS (EI) m/z C30H₂6FN₅O5S: 588 (MH⁺).

Example 352: iV-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyI)phenyl)-3-fluoro-2-methylbenzamide. MS (EI) m z C₃₀H₂₆FN5O5S: 588 (MH⁺).

Example 353: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-3-fluoro-4-methylbenzamide. MS (EI) m/z C30H26FN₅O5S: 588 (MH⁺).

Example 354: /V-(3-(/V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yI)sulfamoyl)phenyl)-2-fluoro-5-methylbenzamide. MS (EI) m/z C30H₂6FN₅O₅S: 588 (MIT).

Example 355 : N-(3-(N-(3-(3,5-dimethoxy-pheny Iamino)quinoxalin-2- yl)sulfamoyl)phenyl)-5-fluoro-2-methylbenzamide. MS (EI) m/z C3oH₂6FN₅0₅S: 588 (MH⁺).

Example 356: 6-chloro-jY-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)nicotinamide. MS (EI) m/z C₂₈H₂₃C1N₆0₅S: 591 (MH⁺).

Example 357: 2-chloro-N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)nicotinamide. MS (EI) m/z C₂8H23CIN6O₅S: 591 (MH⁺).

Example 358: 2-chloro-iV-(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyI)phenyl)isonicotinamide. MS (EI) m/z C₂8H₂3CIN6O5S: 591 (MH⁺).

Example 359: N-(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yI)sulfamoyl)phenyl)-4-(dimethylamino)benzamide. MS (EI) m/z C₃|H₃oN₆05S: 599 (MH⁺). Example 360: N-(3-( -(3-(3,5-dimethoxy^henylamino)quinoxalin-2- l)sulfamoyl)phen l)-3-(dimeth laniino)benzamide. MS (EI) m/z C₃₁H3oN₆0₅S: 599 (MH⁺).

Example 361: -V-(3-(-V-(3-(3,5-dimethoxy-phenylamino)quinoxaIin-2- yl)sulfamoyl)phenyl)benzo[d][l,3]dioxole-5-carboxamide. MS (EI) m/z C3oH₂₅N₅0₇S: 600 (MH⁺).

Example 362: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(m-tolyloxy)acetamide. MS (EI) m/z C3iH₂9N₅0₆S: 600 (MH^"). Example 363: N-(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(4-methoxyphenyl)acetamide. MS (EI) m/z C31H2 N5O6S: 600 (MIT).

Example 364: N-(3-(iV-(3-(3,5-dimethoxy-phenyIamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(2-methoxyphenyl)acetamide. MS (EI) m z CsiH^NsOeS: 600 (MKT).

Example 365: V-(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-(3-methoxyphenyl)acetamide. MS (EI) m/z C31H29N5O6S: 600 (MH⁺).

Example 366: iV-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-methoxy-4-methylbenzamide. MS (EI) m/z CsiH^NsOeS: 600 (MIT).

Example 367: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-3-fluoro-4-methoxybenzamide. MS (EI) m/z C30H₂6FN5O6S: 604 (MIT).

Example 368: N-(3-(N-(3-(3,5-dimethoxy-phenyIamino)quinoxalin-2- yl)sulfamoyl)phenyl)-2-fluoro-6-methoxybenzamide. MS (EI) m/z C₃₀H26F ₅O6S: 604 (MH⁺).

Example 369: /V-(3-(iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)suIfamoyl)phenyl)-3-(4-methoxyphenyl)propanamide. MS (EI) m/z C32H31N5O6S: 614 (MIT).

Example 370: V-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yI)sulfamoyl)phenyl)-3-(2-methoxyphenyI)propanamide. MS (EI) m/z C32H31N5O6S: 614 (MH⁺). Example 371: N-(3-(A^-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-3-(3-methoxyphenyl)propanamide. MS (EI) m/z C3₂H₃iN₅0₆S: 614 (MH⁺).

Example 372

.V-(3 ^-(3-(3,5-dimethoxy^henylainino)quinoxalm-2-yl)sulfamoyl)phenyl)azetidine-3- carboxamide.

[00244] Into a 20 mL vial was added 3-amino-N-(3-(3,5-dimethoxy- phenylamino)quinoxalin-2-yl)benzenesulfonamide (0.24 mmol, 1 equiv), prepared using procedures similar to those described in Example 15, DMA ( 5 mL) and \ -{tert- butoxycarbonyl)azetidine-3-carboxylic acid (0.336 mmol, 1.4 equiv). Hunig's Base (0.792 mmol, 3.3 equiv) and HATU (0.288 mmol, 1.2 equiv) were added to the vial and the reaction mixture was then stirred at room temperature overnight. Completion of the reaction was indicated by LCMS. The solvent was removed by rotary evaporation. The crude mixture was carried forward without further purification. The residue was suspended in 5 mL ethyl acetate and chilled in an ice bath. A solution of 4 N HCI in dioxane ( 3 mL, 5 equiv) was added with stirring. The reaction mixture was then stirred at room temperature overnight. The solid materials were collected by filtration, washed with ethylacetate then purified further by preparative reverse-phase HPLC (ammonium acetate/ACN). A Waters Fractionlynx preparative reverse-phase HPLC; equipped with a Waters SunFire Prep CI 8, OCD 5 μΜ, 30 X 70 mm column and running a 5-100 % gradient with a binary solvent system of 25 raM ammonium acetate in water/acetonitrile; was used to carry out the purification. N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)azetidine-3-carboxamide was obtained (26 mg, 20%). Ή-NMR

(400MHz, d₆-DMSO): 10.26 (s, 1H), 8.81 (s, 1H), 8.25 (t, 1H), 8.14 (s, 1H), 7.74 (d, 1H), 7.69 (d, 1H), 7.41-7.39 (m, 1H), 7.36 (d, 1H), 7.32 (d, 2H), 7.30-7.28 (dd, 1H), 7.14-7.1 1 (m, 2H), 6.14 (t, 1H), 4.09 (d, 4H), 3.78 (s, 6H); MS (EI) m/z

535.6 (MH⁺). Example 373

N-(3-(4-fluorophenylamino)quinoxalm-2-yl)beiizenesulfonamide

[00245] A flask was charged with 2,3-dichloroquinoxaline (3.5 g, 18 mmol), 85 mL of dimethylsulfoxide, benzene sulfonamide (2.8 g, 18 mmol), and cesium carbonate (5.8 g, 18 mmol). The reaction mixture was stirred under an N₂ atmosphere for 15 h at 150 °C, after which time, it was transferred to a separatory funnel and 100 mL of water were added. Concentrated HC1 was then added in order to acidify the reaction mixture to pH<2. The aqueous layer was subsequently washed three times with 90 mL ethyl acetate. The ethyl acetate layers were then washed two times with 150 mL water, three times with 100 mL brine and then dried over sodium sulfate. The ethyl acetate was removed on a rotary- evaporator. A slurry was formed by adding ethyl acetate and dichloromethane to the dried crude product, filtration yielded N-(3-chloroquinoxalin-2-yl)-benzenesulfonamide which was used without further purification. MS (EI) m/z

319.9 (MET).

[00246] A CEM microwave reaction vessel was charged with N-(3-chloroquinoxaIin-2- y benzenesulfonamide (52 mg, 0.16 mmol), prepared using procedures similar to those described in the above step, 4-fluoroaniline (36 mg, 0.32 mmol), and 0.8 mL of

dimethylacetamide. The vessel was sealed and the reaction mixture was heated under microwave radiation for 25 m at 120 °C in a CEM Discover microwave instrument.

Methanol (1 mL) was added to the reaction mixture and after 20 minutes the product precipitated out of the solution. Filtration yielded N-(3-(4-fluorophenylamino)quinoxalin-2- yl)benzenesuIfonamide (39 mg, 62 %). Ή-NMR (400MHz, de-DMSO): δ 12.30 (s, 1H), 9.11 (s, 1H), 8.16-8.10 (d, 2H), 8.02-7.90 (m, 3H), 7.68-7.58 (m, 3H), 7.55-7.51 (m, 1H), 7.41-7.32 (m, 2H), 7.25-7.16 (m, 2H); MS (EI) m/z C₂oH,₅FN₄0₂S: 395.0 (MlT). Example 374

AK3-(AK3-chloroquinoxalin-2-yl)sulfam

Scheme A

[00247] A flask was charged with 3-aminobenzene sulfonamide (3.3 g, 19 mmol), and 20 mL of 1 : 1 acetone :H₂0. The solution was stirred at room temperature until the

aminobenzene sulfonamide had dissolved. The flask was then cooled in an ice bath and dimethylamino-acetyl chloride HCl (4.6 g, 29 mmol) was added. To the resulting slurry sodium bicarbonate (4.8 g, 57 mmol) was added over a 15 m period. After 30 min the reaction was removed from the ice bath and allowed to stir at room temperature for 15 h. The reaction mixture was then filtered and washed with methanol and acetonitrile. The filtrate was dried on a rotary evaporator to yield 2-(dimethylamino)-N-(3-sulfamoyl- pheny acetamide, which was submitted to the next step without further purification. MS (EI) m/z C,oH,₅N₃03S: 258.0 (MH⁺).

Scheme B

[00248] A flask was charged with dichloroquinozaline ( 1.0 g, 5.8 mmol), 10 mL of dimethylacetamide, 2-(dimetyhlamino)-N-(3-sulfamoylphenyI)acetamide (0.70 g, 2.7 mmol), and cesium carbonate ( 1.8 g, 5.5 mmol). The reaction mixture was stirred for 3 h at 140 °C and then filtered. The solvent was evaporated from the filtrate on a rotary- evaporator to yield (N-(3-(N-(3-chloroquinoxalin-2-yl)sulfamoyl)phenyI)- 2-(dimethylamino)acetamide) which was submitted to the next step without further purification. MS (EI) m/z C|₈Hi8ClN₅0₃S: 420.0 (MH⁺).

[00249] A CEM microwave reaction vessel was charged with N-(3-(N-(3- chloroquinoxalin-2-yl)sulfamoyl)phenyl)-2-(dimethylamino)acetamide (30 mg, 0.071 mmol), prepared using procedures similar to those described in Example 374, the desired aniline ( 16 mg, 0.14 mmol, 2 eq), and 0.5 mL of dimethylacetamide. The vessel was sealed and the reaction mixture was heated under microwave radiation for 70 min at 140 °C in a CEM Discover microwave instrument. The solvent was then removed by rotary- evaporation. Purification of the final product was accomplished by preparatory reverse- phase HPLC with the eluents 25 mM aqueous NI^OAc/ACN to the desired product.

[00250] The following compounds were prepared according to the above General Amination Procedure la.

Example 375: 2-(dimethylamino)-N-(3-(iV-(3-(3-fluorophenylaniino)quinoxalin-2- yl)suIfamoyl)phenyl)acetamide. Ή-NMR (400MHz, CDC1₃): 9.40 ppm (s, 1H), 8.43 ppm (s, 1H), 8.22 ppm (s, 1H), 8.07-8.02 ppm (d, 1H), 7.97-7.93 ppm (d, 1H), 7.76-7.71 (m, 2H), 7.53-7.48 ppm (t, 1H), 7.45-7.36 ppm (m, 4H), 7.35-7.28 ppm (m, 2H), 6.84-6.77 ppm (t, 1H), 3.10 ppm (s, 2H), 2.38 ppm (s, 6H); MS (EI) m/z C₂₄H₂₃FN₆0₃S: 495 (MH⁺). Example 376: 2-(dimethyIamino)--V-(3-(-V-(3-(4-fluorophenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)acetamide. MS (EI) m/z C₂4H₂₃FN₆03S: 495 (MH⁺).

Example 377: N-(3-(iV-(3-(4-chloro-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2- (diniethylamino)acetamide. MS (EI) m/z C₂4H₂₃C1N₆0₃S: 51 1 (MrT).

General Amination Procedure lb

[00251] A CEM microwave reaction vessel was charged with N-(3-(N-(3- chloroquinoxalin-2-yl)sulfamoyl)phenyl)-2-(dimethylamino)acetamide (62 mg, 0.147 mmol), prepared using procedures similar to those in Example 374, the desired aniline (0.567 mmol, 4 eq), and 1.0 mL of toluene. The vessel was sealed and the reaction mixture was heated under microwave radiation for 60 min at 180 °C in a CEM Discover microwave instrument. The solvent was removed on a rotary-evaporator. Purification of the final product was done by preparatory HPLC with NH₄OAC/ACN as eluent to yield the desired product.

[00252] The following compounds were prepared according to the above General Amination Procedure lb.

Example 378 : N-(3-(V-(3-(3-chloro-pheny lamino)quinoxalin-2-yl)sul amoyl)phenyl)-2- (dimethylamino)acetamide. MS (EI) m/z C₂₄H₂3C1N₆0₃S: 51 1 (MET^1").

Example 379: 2-(dimethylamino)- V-(3-(-V-(3-(4-fluoro-3- methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide. 2-

(dimethylamino)-N-(3-(N-(3-(4-fluoro-3-methoxyphenylamino)quinoxalin-2- yl)sulfamoyl)phenyl). ^!H-NMR (400MHz, CDC1₃): δ 9.47 (s, I H), 8.36 (s, IH), 8.29 (s, IH), 7.91-7.87 (d, IH), 7.80-7.73 (m, 2H), 7.66-7.63 (d, IH), 7.53-7.47 (t, IH), 7.43-7.30 (m, 4H), 7.10-7.04 (t, IH), 6.55-5.95 (br s, IH), 3.96 (s, 3H), 3.12 (s, 2H), 2.39 (s, 6H), 2.08 (s,3H(Ac0H); MS (EI) m/z C₂5H2₅FN₆0₄S: 525 (MH⁺).

Example 380

N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-4-isopropoxybenzenesulfonamide

[00253] / -(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-4-isopropoxy- benzenesulfonamide. A solution of 2,3-dichloroquinoxaline (2.0 mL, 0.38 M) was combined with K₂C0₃ (105 mg, 0.76 mmol) in a glass vial. A solution of

4-isopropoxybenzene sulfonamide ( 1.75 mL, 0.43 M) was added and the solution was stirred overnight at 125 °C. After cooling, acetic acid (45 mL, 0.79 mmol) and

3,5-dimethoxyaniline (230 mg, 1.5 mmol) were added. The reaction mixture was stirred again at 125 °C overnight. Upon cooling, the reaction mixture was diluted with 8 mL of methanol and then 8 mL of water. The precipitate was collected by filtration and recrystallized from N,N-dimethylacetamide/water to give N-(3-(3,5-dimethoxy- phenylamino)quinoxalin-2-yl)-4-isopropoxy-benzenesulfonamide (45 mg, 12%). ^lH-NMR (400MHz, d₆-DMSO): 12.16 (bs, IH), 8.93 (s, IH), 8.03 (d, 2H), 7.92 (bs, IH), 7.56 (d, IH), 7.36 (m, 4H), 7.07 (d, 2H), 6.24 (s, IH), 4.72 (m, IH), 3.76 (s, 6H), 1.27 (d, 6H); MS (EI) m/z C₂₅H26N₄0₅S: 495 (MIT).

[00254] Examples 381-41 1 were synthesized proceeding as above in Example 423. In the cases where the product did not precipitate, the mixture was purified by reverse phase HPLC.

Example 381 : 3-chloro-A^f-(3-(3^-dimethoxy-phenyIamino)quinoxalin-2- l)-4- methyIbeiKenesulfonam.de. Ή-NMR (400MHz, d₆-DMSO): 12.31 (bs, lH), 8.96 (s, IH), 8.18 (s, IH), 7.98 (d, IH), 7.92 (bs, IH), 7.58 (d, 2H), 7.43-7.33 (m, 4H), 6.24 (t, IH), 3.76 (s, 6H), 2.39 (s, 3H); MS (EI) m/z C₂₃H₂₁C1N₄0₄S: 485 (MIT).

Example 382: V-(3-(3,5-dimethoxy-phenyIamino)quinoxalin-2-yl)naphthalene-l- sulfonamide. MS (EI) m/z C₂6H₂₂N₄0₄S: 487 (ΜΗΓ).

Example 383: V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-4- fluorobenzenesulfonam.de. MS (EI) m/z C₂₂Hi₉FN₄0₄S: 455 (MH⁺).

Example 384: A^-(3-(3,5-dimethoxy-phenylaniino)quinoxalm-2-yl)-3- fluorobenzenesulfonamide. MS (EI) m/z C2₂H₁₉FN₄0₄S: 455 (MH⁺).

Example 385: N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-3- (trifluoromethyl)benzenesulfonamide. MS (EI) m/z C₂₃Hi₉F₃N₄0₄S: 505 (MH⁺).

Example 386: N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-4- (trffluoromethyl)benzenesulfonamide. MS (EI) m/z C₂₃H₁₉F₃N₄0₄S: 505 (MH⁺).

Example 387: iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-4- (trifluoromethoxy)benzenesulfonamide. MS (EI) m/z C₂₃Hi₉F₃N₄0sS: 521 (MtT). Example 388: .V-(4-(/V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)suIfamoyl)phenyl)acetamide. MS (EI) m/z C₂4H23N₅0₅S: 494 (MH⁺).

Example 389: AT-(3-(3,5-dimethoxy^henylamino)quinoxalin-2-yl)-4-fluoro-2- methylbenzenesulfonamide. MS (EI) m/z C₂₃H₂iFN₄0₄S: 469 (MH*).

Example 390: V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-2- methylbenzenesulfonamide. MS (EI) m/z C₂₃H₂₂N₄0₄S: 451 (MH⁺).

Example 391 : 2-chloro-.V-(3-(3,5-dimethoxy-plienylamino)quinoxalin-2- yl)benzenesulfonamide. MS (EI) m/z C₂₂Hi₉ClN₄0₄S: 471 (MH⁺).

Example 392: Af-(3^3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-3,5- difluorobenzenesulfonamide. MS (EI) m/z C₂₂H₁₈F₂N₄0₄S: 473 (MH*). Example 393: 3,5-dichloro-iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)benzenesulfonamide. MS (EI) m/z C₂₂H₁₈C1₂N₄04S: 505 (MH⁺).

Example 394: iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-3-fluoro-4- methylbenzenesulfonamide. MS (EI) m/z C₂₃H₂iFN₄0₄S: 469 (MH⁺).

Example 395: ^-(3-(3,5-dimethoxy-phenylamino)quinoxaIin-2-yI)-2- (trifluoromethyl)benzenesulfonamide. MS (EI) m/z C23H|₉F₃N₄0₄S: 505 (MH⁺). Example 396: 4-cyano-N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)benzenesulfonamide. MS (EI) m/z C₂₃H_!9N50 S: 462 (MIT^1").

Example 397: iV-(3-(3,5-dimethoxy-phenyIamino)quinoxalin-2-yl)-l- phenylmethanesulfonamide. MS (EI) m/z C₂₃H₂2N₄0₄S: 451 (MH⁺).

Example 398: 4,5-dichIoro-A'-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)thiophene-2-sulfonamide. MS (EI) m/z C₂₀H,₆Cl₂N₄O₄S₂: 5 1 1 (MH*).

Example 399: l-(3-chlorophenyl)-iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- y methanesulfonamide. MS (EI) m/z C₂₃H₂₁C1N₄0₄S: 485 (MH⁺).

Example 400: N-(3-(3,S-dimethoxy-phenylamino)quinoxalin-2-yl)-2,5- dimethylthiophene-3-sulfonamide. MS (EI) m/z C₂2H₂₂N₄0₄S₂: 471 (MH⁺).

Example 401: -V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yI)-3,5- bis(trifluoromethyl)benzenesulfonamide. MS (EI) m/z C₂4Hi₈F₆N₄0₄S: 573 (MH⁺). Example 402: ^V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-4-fluoro-3- (trifluoromethyl)benzenesulfonamide. MS (EI) m/z C₂₃Hi8F₄N₄0₄S: 523 (MH⁺). Example 403: 5-chloro-iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-l,3- dimethyl-lH-pyrazoIe-4-sulfonamide. MS (EI) m/z C₂,H₂,C1N₆0₄S: 489 (MH⁺). Example 404: 5-cldoro-N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-2- methoxybenzenesulfonamide. MS (EI) m/z C₂₃H2|C1N₄0₅S: 501 (MH⁺).

Example 405: 5-bromo-A^,-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-2- methoxybenzenesulfonamide. MS (EI) m/z C₂₃H₂iBrN₄0₅S: 545 (MH⁺).

Example 406: 2,5-dichloro-/V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yI)thiophene-3-suIfonamide. MS (EI) m/z C₂oH₁₆Cl₂N₄0 S₂: 51 1 (MH⁺).

Example 407: N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-3,5- dimethylisoxazole-4-sulfonamide. MS (EI) m/z C₂iH₂₁N₅05S: 456 (MH⁺).

Example 408: iV-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-2,5- dimethoxybenzenesuIfonam.de. MS (EI) m/z C₂₄H₂₄N₄0₆S: 497 (MH⁺).

Example 409: 3-chloro--V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-4- fluorobenzenesulfonamide. MS (EI) m/z C₂₂Hi₈ClFN 0₄S: 489 (MH⁺). Example 410: 4-(difluoromethoxy)-/V-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yI)benzenesulfonamide MS (EI) m/z C₂3H₂oF2N₄0₅S: 503 (MlF).

Example 411: N-(3-(3,5-dimethoxy-phenylamino)qumoxalin-2-yl)-3- (methylsulfonyl)benzenesulfonamide. MS (EI) m/z C₂3H₂2N₄0₆S₂: 515 (MH").

General Acylation Procedure 2

[00255] N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)- sulfamoyl)phenyl)azetidine-3-carboxamide (125 mg, 0.23 mmol), prepared using procedures similar to those described in Example 372, was dissolved into 5 mL DCE in a 10 mL round-bottom flask. DIEA (1.17 mmol, 5.0 equiv.) was then added with stirring followed by acid chloride (0.47 mmol, 2.0 equiv.). The reaction was then stirred at room temperature for 1 hour or until complete as indicated by LCMS. The solvent was subsequently removed under reduced pressure on a rotary evaporator. The crude material was then redissolved in methanol. Purification of the final product was accomplished by preparatory reverse-phase HPLC with the eluents 25 mM aqueous NH₄OAC/CAN. A Waters Fractionlynx preparative reverse-phase HPLC; equipped with a Waters SunFire Prep CI 8, OCD 5 μΜ, 30 X 70 mm column and running a 5-100 % gradient with a binary solvent system of 25 mM ammonium acetate in water/acetonitrile; was used to carry out the purification.

[00256] The following compounds were prepared according to General Acylation Procedure 2.

Example 412: N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-l-propionylazetidine-3-carboxamide. 'H-NMR (400MHz, <¼-

DMSO): 12.40 (s, IH), 10.45 (s, IH), 8.88 (s, IH), 8.40 (s, IH), 7.93 (s, IH), 7.82 (d, IH), 7.77 (d, IH), 7.60-7.45 (m, 2H), 7.41-7.30 (m, 4H), 6.24 (s, I H), 4.26 (t, IH), 4.22-4.17 (m, IH), 3.99 (t, IH), 3.95-3.89 (m, IH), 3.76 (s, 6H), 3.59-3.45 (m, IH), 2.05 (dd, 2H), 0.95 (t, 3H); MS (EI) m/z C29H30N6O6S: 591 (MH⁺). Example 413: l-acetyl-N-(3-{[(3-{[3,5-bis(methoxy)-phenyl]amino}quinoxalin-2- yI)amino]sulfonyl}phenyl)azetidine-3-carboxamide. MS (EI) m/z C₂8H28N₆0₆S: 577 (MIT).

Example 414: l-(cyclopropanecarbonyl)-^V-(3-(N-(3-(3,5-dimethoxy- phenylamino)quinoxaIin-2-yl)sulfamoyl)phenyl)azetidine-3-carboxamide. MS (EI) m/z CsoHsoNeOeS: 603 (MH⁺).

General Reductive Amination Procedure 1

[00257] To a solution of N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)azetidine-3-carboxamide ( 1 10 mg, 0.19 mmol), prepared using procedures similar to those described in Example 372, in 3 mL of DCE and 200 μΐ- of DMF, aldehyde (0.77 mmol, 4.0 eq.)was added slowly followed by tetramethylammonium triacetoxyborohydride ( 1. 16 mmol, 6.0 eq). The reaction was stirred at room temperature overnight. LC/MS indicated the reaction was completed. The solvent was subsequently removed under reduced pressure on a rotary evaporator. The crude material was then redissolved in methanol. Purification of the final product was accomplished by preparatory reverse-phase HPLC with the eluents 25 mM aqueous NFLjOAc/CAN. A Waters

Fractionlynx preparative reverse-phase HPLC; equipped with a Waters SunFire Prep CI 8, OCD 5 μΜ, 30 X 70 mm column and running a 5- 100 % gradient with a binary solvent system of 25 mM ammonium acetate in water/acetonitrile; was used to carry out the purification.

[00258] The following title compounds were prepared according to General Reductive Amination Procedure 1.

Example 415: N-(3-(AH3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyI)phenyl)-l-ethylazetidine-3-carboxamide. Ή-NMR (400MHz, de-DMSO): 10.29 (s, IH), 8.82 (s, IH), 8.25 (t, IH), 7.75-7.68 (m, 2H), 7.43-7.38 (m, IH), 7.375-7.340 (m, IH), 7.338-7.310 (d, 2H), 7.305-7.262 (m, IH), 7.15-7.08 (m, 2H), 6.56 (s, I H), 6.15 (t, 1H), 4.15-4.08 (m, 2H), 4.06-3.95 (m, 2H), 3.78 (s, 6H), 3.65-3.56 (m, 1H), 3.12-3.04 (m, 2H), 1.03 (t, 3H); MS (EI) m/z C₂₈H₃oN₆0₅S: 563 (MH⁺).

Example 416: l-(cyclopropylmethyl)-AK3-(N-(3-(3,5-dimethoxy- phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)azetidine-3-carboxamide. MS (EI) m/z C₃oH₃₂N₆0₅S: 589 (MH⁴).

Example 417: l-benzyl^-(3 N-(3-(3,5-dimethoxy-phenylamino)quinoxaIin-2- yl)sulfamoyl)phenyl)azetidine-3-carboxamide. MS (EI) m z C₃₃H₃₂N₆0₅S: 625 (MH⁺). Example 418: A^r-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)phenyl)-l-(furan-2-ylmethyl)azetidine-3-carboxamide. MS (EI) m/z C₃₁H₃₀N₆O₆S: 615 (MH⁺).

Example 419: l-((lH-imidazol-5-yl)methyl)-iV-(3-(^-(3-(3,5-dimethoxy- phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)azetidine-3-carboxamide. MS (EI) m/z C₃₀H₃oN₈0₅S: 615 (MH⁺).

General Amide Formation Procedure la

[00259] Into a small 1 dram vial was added 3-(N-(3-(2-chloro-5-methoxy-phenylamino)- quinoxalin-2-yl)sulfamoyl)benzoic acid (61 mg, 0.13 mmol, 1.1 equiv), prepared using procedures described for Example 100. The acid was dissolved in DMA (1 mL) and DIEA (42 pL, 0.24 mmol, 2 equiv) was added then added to the solution. The amine reagent ( 1 mL of 0.12 M solution in DMA) was added to solution with stirring followed by HATU (64 mg, 0.17 mMol, 1.4 equiv). The reaction was stirred overnight at room temperature. Upon completion as indicated by LCMS analysis, 2 mL of methanol was added to the solution. Preparative reverse-phase HPLC was used to isolate the desired product. A Waters

Fractionlynx preparative reverse-phase HPLC - equipped with a Waters SunFire Prep C I 8, OCD 5 uM, 30 X 70 mm column and running a 5-100 % gradient with a binary solvent system of 25 mM ammonium acetate in water/acetonitrile - was used to carry out the purification.

[00260] The following compounds were prepared according to General Amide Formation Procedure 1. Example 420: 3-(N-(3-(2-chIoro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfaraoyl)- iV-(3-(dimethylamino)propyl)benzamide. 3-(N-(3-(2-chloro-5- memoxyphenylamino)quinoxalin-2-yl)sulfamoyl)-N 3^

Ή NMR (400 MHz, de-DMSO): 9.44 (s, I H), 8.94 (s, IH), 8.79 (t, IH), 8.54 (s, IH), 8.24 (d, IH), 7.87 (d, IH), 7.48 (m, 3H), 7.33 (d, IH), 7.18 (m, 2H), 6.60 (dd, IH), 3.82 (IH), 3.04 (m, 3H), 2.51 (m, 5H), 1.91 (s, IH), 1.86 (m, 3H); MS (EI) m/z for C₂₇H₂c>ClN₆0₄S: 569 (MH*).

Example 421 : 3-(N-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)- iV-(l-methylazetidin-3-yl)benzamide. 3-(N-(3-(2-chloro-5- methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)-N-(l -memylazetidin-3-yl)benzamide: Ή NMR (400 MHz, de-DMSO): 9.43 (s, IH), 9.23 (d, IH), 8.94 (d, IH), 8.58 (s, IH), 8.29 (d, IH), 7.89 (d, IH), 7.56 (t, I H), 7.47 (d, IH), 7.44 (d, IH), 7.33 (d, IH), 7.18 (m, 2H), 6.60 (dd, IH), 4.81 (m, IH), 4.33 (m, 2H), 4.19 (m, 2H), 3.82 (s, IH), 2.51 (s, 3H); MS (EI) m/z for C₂₆H2₅C1N₆0₄S: 553 (MH*).

Example 422: 3-(N-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)- N-(pyridin-4-ylmethyl)benzamide. MS (EI) m/z C₂₈H₂₃C1N₅0₄S: 575 (MH⁺).

Example 423: 3-(/V-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyI)- W-(3-(dimethylamino)propyl)benzamide. MS (EI) m/z C₂₈H₂₆C1N₇0₄S: 592 (MH*). Example 424: iV-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)-3-(2,2- dimethylhydrazinecarbonyl)benzenesulfonamide. MS (EI) m/z C₂₄H23CIN60₄S: 527 (MH*).

Example 425: 3-(N-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yI)sulfamoyl)- W-(2-methoxyetbyl)benzamide. MS (EI) m/z C₂₅H₂ C1N₅0₅S: 542 (MH⁺).

Example 426: A^r-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)-3-(4- methyipiperazine-l-carbonyI)benzenesulfonamide. MS (EI) m/z C₂₇H₂₇C1N₆0 S: 567 (MH⁺).

Example 427: 3-(A^?-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)- V-(2-(pyrrolidin-l-yl)ethyl)benzamide. MS (EI) m/z C₂₈H₂₉C1N₆0₄S: 581 (MH*).

Example 428: 3-(/V-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)- N-(2-(pyridin-4-yl)ethyl)benzamide. MS (EI) m/z C₂9H₂5C1N₆0₄S: 589 (MH*).

Example 429: N-(2-(lH-imidazol-4-yl)ethyl)-3-( V-(3-(2-chloro-5- methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)benzamide. MS (EI) m z

C₂₇H₂₄C1N₇0₄S: 578 (MH*). Example 430: 3-(N-(3^2 Woro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyI)- N-(piperidin-l-yl)benzamide. MS (EI) m/z C₂7H₂₇C1N₆0₄S: 567 (MH⁺).

Example 431 : 3-(N-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yI)sulfamoyl)- N-(2-hydroxyethyl)benzamide. MS (EI) m z C24H2₂C1N₅0₅S: 528 (MH⁺).

Example 432: 3-(iV-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)- N-(3-ethoxypropyl)beiizamide. MS (EI) m z

570 (MH+).

Example 433: 3-(-V-(3-(2-chloro-5-methoxy-phenyIamino)quinoxaIin-2-yl)sulfamoyI)- N-(3-(pyrrolidin-l-yl)propyl)benzamide. MS (EI) m/z C2₉H₃IC1N₆0₄S: 595 (MH*). Example 434: 3-(N-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)- iV-(3-(diethylamino)propyl)benzamide. MS (EI) m/z C₂9H33C1N₆0₄S: 597 (MH⁺).

Example 435: 3-(N-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)- /V-(3-(2-oxopyrrolidin-l-yl)propyI)benzamide. MS (EI) m/z C29H₂₉C1N₆0₅S: 609 (MH⁺) Example 436: 3-(N-(3-(2-cMoro-5-methoxy-phenylamino)quinoxalin-2-yI)suIfamoyl)- W-(pyridin-2-ylmethyl)benzamide. MS (EI) m/z C₂₈H2₃C1N₆0₄S: 575 (MH⁺).

Example 437: 3-(iV-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)- N-(2-cyanoethyl)-W-methylbenzamide. MS (EI) m/z C₂₆H₂3C1N₆0₄S: 551 (MET).

Example 438: 3-(N-(3-(2-chloro-5-methoxyphenylamino)quinoxalin-2-yl)siilfamoyl)- N.(2-cyanoethyl)-/V-ethylbeiizamide. MS (EI) m/z C2₇H₂₅C1N₆0₄S: 565 (MH⁺).

Example 439: 3-(iV-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)- N-(2-(ethylthio)ethyl)benzamide. MS (EI) m z C₂₆H₂₆C1N₅0₄S2: 572 (MH⁺).

Example 440: 3-( V-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-V-(3-propoxypropyl)benzamide. MS (EI) m/z C₂₈H₃oClN₅0₅S: 584 (MH⁺).

Example 441: 3-(N-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)- N-(5-(diethylamino)pentan-2-yl)benzamide. MS (EI) m/z C31H37CIN6O4S: 625 (MH⁺). Example 442: 3-(iV-(3-(2-chIoro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-V-(3-methoxypropyl)benzamide. MS (EI) m/z C26H26CIN5O5S: 556 (MH").

Example 443: 3-(-V-(3-(2-chloro-5-methoxy-phenyIamino)quinoxalin-2-yl)sulfamoyl)- N-(3-morpholinopropyl)benzamide MS (EI) m/z C₂₉H₃iClN₆0₅S: 61 1 (MH⁺).

Example 444: 3-(/V-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)- N-(pyridin-3-ylmethyl)benzamide MS (EI) m/z C₂₈H₂3C1N60₄S: 575 (MH⁺).

Example 445: 3-(/V-(3-(2-chloro-5-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)- W-(2-cyanoethyl)benzamide. MS (EI) m/z C₂₅H₂₁C1N₆0₄S: 537 (MH⁺).

Example 446: 3-(iV-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)- N-(l-methoxypropan-2-yl)benzamide. MS (EI) m/z C₂₆H26C1N₅0₅S: 556 (MH+). Example 447: 3 N-(3-(2-cWoro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)- iV-(2-(methylthio)ethyl)benzamide. MS (EI) m/z C₂5H24C1N₅0₄S2: 558 (MH+).

Example 448: 3-(^-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)- -V-(3-(dimethylamino)propyl)-Af-methylbenzamide. MS (EI) m z C₂₈H3iClN₆0₄S: 583 (MH⁺).

Example 449: 3-(iV-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)- iV-(3-isopropoxypropyl)benzamide. MS (EI) m z C^HboClNsOsS: 584 (MH^).

Example 450: 3-(iV-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)- N-(2-(dimethyIamino)ethyl)-iV-ethylbenzamide. MS (EI) m/z C28H₃iClN₆0₄S: 583 (MIT).

Example 451: V-(3-butoxypropyl)-3-(A^-(3-(2-chloro-5-methoxy- phenylamino)quinoxalin-2-yl)sulfamoyl)benzamide. MS (EI) m/z C^E^ClNsOgS: 598 (MH⁺).

Example 452: 3-(jV-(3-(2-chIoro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)- V-(2-(diethylamino)ethyl)benzamide. MS (EI) m/z C₂₈H₃iClN₆0₄S: 583 (MH⁺).

Example 453: methyl 3-(3-( V-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)betizamido)propanoate. MS (EI) m/z C26H₂₄C1N₅0₆S: 570 (MH⁺).

Example 454: 3-(iV-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)- /V-methyl-/V-propylbenzamide. MS (EI) m/z C₂6H2₆C1N₅0₄S: 540 (MH⁺).

Example 455: ethyl 3-(3-(N-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2- yl)sulfamoyl)benzamido)propanoate. MS (EI) m/z C₂7H₂6C1N₅0₆S: 584 (MH⁺).

Example 456: 3-(A^r-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)- ^V-(2-(piperidin-l-yl)ethyl)benzamide. MS (EI) m/z C₂₉H₃iClN₆0₄S: 595 (MH⁺).

Example 457: 3-(iV-(3-(2-chIoro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)- /V-((l-ethylpyrrolidin-2-yl)methyl)benzamide. MS (EI) m/z C₂₉H₃iClN₆0₄S: 595 (MH⁺). Example 458: V-(2-(bis(2-hydroxyethyl)amino)ethyl)-3-(N-(3-(2-chloro-5- methoxyphenyIamino)quinoxaIin-2-yl)sulfamoyI)benzamide. MS (EI) m/z

C₂₈H₃iClN₆0₆S: 615 (MET).

Example 459: N-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)-3-(3- (diethylamino)pyrrolidine-l-carbonyl)benzenesulfonamide. MS (EI) m/z

C₃oH₃₃ClN₆0₄S: 609 (MH⁺).

Example 460: 3-(/V-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)- V-methyI-/V-(l-methylpyrrolidin-3-yl)benzamide. MS (EI) m/z C₂₈H₂₉C1N₆0₄S: 581 (MH⁺). Example 461 : N-(3-(2-chloro-5-metho -phen lamino )quinoxalin-2- l)-3-(3- (dimethylamino)pyrrolidine-l-carbonyl)benzenesulfonamide. MS (EI) m/z

C28H29CIN6O4S: 581 (MH⁺).

Example 462: 3-(.V-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)siilfamoyl)- .V-(2-methyl-l-morpholinopropan-2-yl)benzamide. MS (EI) m/z C₃oH₃₃ClN₆05S: 625 (MKT).

Example 463: 3-(A^-(3-(2-chloro-5-methoxy^henylainino)quinoxalin-2-yl)sulfamoyl)- N-(lH-pyrrol-l-yl)benzamide. MS (EI) m/z C₂₆H₂IC1N₆0₄S: 549 (MH⁺).

Example 464: 3-( V-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)- N-(3-oxopyrazolidin-4-yl)benzamide. MS (EI) m z C₂5H₂₂C1N₇05S: 568 (MH⁺).

Example 465: N-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)-3-(2- ((dimethylamino)methyl)piperidine-l-carbonyl)benzenesulfonamide. MS (EI) m/z C₃oH₃₃ClN₆0₄S: 609 (MH*).

Example 466: /V-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)-3-(2- (piperidin-l-ylmethyl)piperidine-l-carbonyl)benzenesulfonamide. MS (EI) m/z C₃₃H3₇C1N₆0₄S: 649 (MH⁺).

Example 467: 3-(N-(3-(2-cMoro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)- iV-(l-ethylpiperidin-3-yl)benzamide MS (EI) m/z C₂₉H₃₁C1N₆0₄S: 595 (MH*).

General Amide Formation Procedure lb

[00261] The procedure outlined in General Amide Formation Procedure la was used to incorporate a number of amines that contained a second amine group protected as the tert-butylcarbamate (i.e. where R', within NHR'R", contained a Boc-protected amine group). The deprotection was carried out after HPLC purification of the Boc-protected precursor.

[00262] Into a small 1 dram vial was added 3-(N-(3-(2-chloro-5-methoxy- phenylamino)quinoxalin-2-yl)sulfamoyl)benzoic acid (61 mg, 0.13 mmol, 1 . 1 equiv). The acid was dissolved in 1 mL of DMA and DEEA (42 L, 0.24 mmol, 2 equiv) was added then added to the solution. The mono-Boc-protected diamine reagent ( 1 mL of 0.12 M solution in DMA, 1 equiv) was added to solution with stirring followed by HATU (64 mg, 0.17 mmol, 1.4 equiv). The reaction was stirred overnight at room temperature. Upon completion as indicated by LCMS analysis, 2 mL of methanol was added to the solution. Preparative reverse-phase HPLC was used to isolate the desired product directly from this crude reaction solution. A Waters Fractionlynx preparative reverse-phase HPLC; equipped with a Waters SunFire Prep C18, OCD 5 μΜ, 30 X 70 mm column and running a 5-100 % gradient with a binary solvent system of 25 mM ammonium acetate in water/acetonitrile; was used to carry out the purification. The product fractions were combined and concentrated to dryness under reduced pressure by rotary evaporation. A solution of 4 N HCl in dioxane (2 mL) was added. The solution was then stirred at room temperature until no starting material was detected. The deprotected product precipitated out of solution as an HCL salt and was collected by filtration, washed with ether and dried under vacuum.

[00263] The following compounds were prepared according to the above General Amide Formation Procedure lb.

Example 468: 3-(N-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)suIfamoyl)- N-(piperidin-3-yI)benzamide. 3-(N-(3-(2-chloro-5-methoxyphenylamino)quinoxalin-2- yl)sulfamoyl)-N-(piperidin-3-yl)benzamide: Ή NMR (400 MHz, d₆-DMSO): 12.82 (s, IH), 9.12 (s, I H), 9.04 (s, IH), 8.85 (d, IH), 8.65 (s, IH), 8.55 (s, IH), 8.18 (m, IH), 7.98 (s, IH), 7.69 (m, 2H), 7.43 (m, 2H), 6.69 (dd, IH), 4.21 (s, IH), 3.83 (s, 3H), 3.69 (m, IH), 3.48 (m, I H), 3.18 (s, IH), 2.84 (q, 2H), 1.91 (s, 2H); MS (EI) m/z for C₂₇H₂₇CIN₆0₄S: 567 (MH⁺).

Example 469: 3-(N-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)- V-(piperidin-2-ylmethyl)benzamide. 3-(N-(3 -(2-chloro-5- methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)-N-(piperidin-2-ylmethyl)benzamide: NMR (400 MHz, de-DMSO): 12.78 (s, IH), 9.16 (s, IH), 9.09 (s, IH), 8.79 (s, IH), 8.59 (d, 2H), 8.22 (t, 2H), 7.99 (s, IH), 7.74 (t, IH), 7.66 (s, IH), 7.42 (m, 2H), 6.69 (dd, IH), 3.82 (s, 3H), 3.69 (dd, IH), 3.57 (m, I H), 3.50 (m, 3H), 3.22 (s, 2H), 2.82 (d, IH), 1.68 (m, 5H); MS (EI) m/z for C₂₈H₂<,C1N₆0₄S: 581 (MH⁺).

Example 470: 3-(3-aminopyrrolidine-l-carbonyl)-N-(3-(2-chloro-5-methoxy- phenylamino)quinoxalin-2-yl)benzenesulfonamide. MS (EI) m/z C₂6H₂₅CIN₆0₄S: 553 (MH⁺).

Example 471: 3-(3-aminoazetidine-l-carbonyl)-/V-(3-(2-chloro-5-methoxy- phenylamino)quinoxalin-2-yl)benzenesulfonamide. MS (EI) m/z C₂₅H₂₃C1N₆0 S: 539 (MH⁺).

Example 472: 3-(3-aminopiperidine- 1 -car bonyl)-N-(3-(2-chloro-5-methoxy- phenylamino)quinoxalin-2-yl)benzenesulfonamide. MS (EI) m/z C₂₇H₂₇C1N₆0₄S: 567 (MH⁺).

Example 473: 3-(N-(3-(2-chIoro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)- W-(pyrrolidin-3-yl)benzamide. MS (EI) m/z C₂6H₂sClN₆0₄S: 553 (MtT). Example 474: N-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)-3-(3- (methylamino)pyrrolidine-l-carbonyl)beiizenesulfonaniide. MS (EI) m/z

C₂₇H₂₇C1N₆0₄S: 567 (MH⁺).

Example 475: N-(2-aminoethyl)-3-(N-(3-(2-chloro-5-methoxy- phenyIamino)qidnoxalin-2-yl)sulfamoyl)benzamide. MS (EI) m z C₂₄H₂₃C1N₆0₄S: 527 (MIT).

Example 476: 3-(4-amino-3-oxopyrazolidine-l-carbonyl)-N-(3-(2-chloro-5- methoxyphenylamino)quinoxalin-2-yl)benzenesulfonamide. MS (EI) m z

C₂₅H₂₂C1N₇0₅S: 568 (MH⁺).

Example 477

3-(jV-(3-(2-chloro-5-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)- N-((l-methylpiperidin-2-yl)methyl)benzamide

[00264] 3-(N-(3-(2-chloro-5-methoxyphenylamino)quinoxalin-2-yI)sulfamoyl)-N- (piperidin-2-ylmethyl)benzamide (299 mg, 0.51 mmol, 1 equiv), prepared using procedures similar to those described for Example 514, was dissolved in 2.3 mL of DMA. Formic acid (388 μΙ_, 10.28 mmol, 20 equiv) was added to solution with stirring followed by the addition of formaldehyde (508 μL· of 37% aq. solution). The reaction was then stirred at room temperature overnight. Analysis of an aliquot of the reaction mixture by LCMS indicated the complete consumption of starting material. The reaction was diluted with methanol (2 mL). Preparative reverse-phase HPLC was used to isolate the desired product directly from the crude reaction mixture. A Waters Fractionlynx preparative reverse-phase HPLC; equipped with a Waters SunFire Prep CI 8, OCD 5 μΜ, 30 X 70 mm column and running a 5-100 % gradient with a binary solvent system of 25 mM ammonium acetate in water/acetonitrile; was used to carry out the purification.Ή NMR (400 MHz, d₆-DMSO): 9.44 (s, IH), 8.94 (s, IH), 8.79 (t, IH), 8.57 (s, IH), 8.27 (d, IH), 7.90 (d, IH) 7.54 (t, IH), 7.46 (d, IH), 7.39 (d, IH), 7.33 (d, IH), 7.18 (m, 2H), 6.60 (dd, IH), 3.82 (s, 3H), 3.59 (m, 2H), 3.00 (s, IH), 2.90 (s, 3H), 1.62 (m, 7H); MS (EI) m/z for C₂₉H₃iClN₆0₄S: 595 (MH*).

Example 478

3-(iV-(3-(2-chloro-5-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)- AHl-methylpiperidin-3-yl)benzamide

[00265] The title compound was prepared using similar procedures to those used in Example 522. Ή NMR (400 MHz, de-DMSO): 9.43 (s, IH), 8.93 (s, IH), 8.59 (s, IH), 8.24 (d, IH), 7.87 (d, IH), 7.47 (m, 2H), 7.40 (d, IH), 7.33 (d, IH), 7.19 (m, 2H), 6.60 (dd, 1H), 4.21 (s, 1H), 3.82 (s, 1H), 2.76 (s, 1H), 2.50 (m, 7H), 1.91 (m, 2H), 1.63 (m, 2H); MS (EI) m/z for C^CIN^S: 581 (MH⁺).

Biological Examples

Biological Example 1

PDKalpha Luciferase-Coupled Chemiluminescence Assay Protocol

[00266] PI3Ka activity is measured as the percent of ATP consumed following the kinase reaction using luciferase-luciferin-coupled chemiluminescence. Reactions were conducted in 384-well white, medium binding microtiter plates (Greiner). Kinase reactions were initiated by combining test compounds, ATP, substrate (P1P2), and kinase in a 20 pL volume in a buffer solution. The standard PDKalpha assay buffer is composed 50 mM Tris, pH 7.5, 1 mM EGTA, 10 mM MgCl₂, 1 mM DTT and 0.03% CHAPS. The standard assay concentrations for enzyme, ATP, and substrate are 0.5-1.1 nM, ΙμΜ, and 7.5 μΜ, respectively. The reaction mixture was incubated at ambient temperature for approximately 2 h. Following the kinase reaction, a 10 pL aliquot of luciferase-luciferin mix (Promega Kinase-Glo) was added and the chemiluminescence signal measured using a Victor2 plate reader (Perkin Elmer). Total ATP consumption was limited to 40-60% and IC50 values of control compounds correlate well with literature references.

[00267] Certain compounds of the invention demonstrated the ability to bind to PI3K when tested in this assay. The following embodiments are directed to the compounds themselves as well as their use in a method of treating. For example, in one embodiment of the invention, the PI3K inhibitor is selected from the compounds in Table 1 having a PI3K- binding affinity of about 8 μΜ or less. In another embodiment, the PI3K inhibitor is selected from the compounds in Table 1 having a PI3K-binding affinity of about 4 μΜ or less. In another embodiment, the PI3K inhibitor is selected from the compounds in Table 1 having a PI3K-binding affinity of about 3 μΜ or less. In another embodiment, the PI3K inhibitor is selected from the compounds in Table 1 having a PI3K-binding affinity of about 2 μΜ or less. In another embodiment, the PI3K inhibitor is selected from the compounds in Table 1 having a PI3K-binding affinity of about 1.5 μΜ or less. In another embodiment, the PI3K inhibitor is selected from the compounds in Table 1 having a PI3K-binding affinity of about 1 μΜ or less. In another embodiment, the PI3K inhibitor is selected from the compounds in Table 1 having a PI3K-binding affinity of about 0.750 μΜ or less. In another embodiment, the PI3K inhibitor is selected from the compounds in Table 1 having a PI3K-binding affinity of about 0.5 μΜ or less. In another embodiment, the PI3K inhibitor is selected from the compounds in Table 1 having a PI3K-binding affinity of about 0.3 μΜ or less. In another embodiment, the PI3K inhibitor is selected from the compounds in Table 1 having a PI3K-binding affinity of about 0.2 uM or less. In another embodiment, the PI3K inhibitor is selected from the compounds in Table 1 having a PI3K-binding affinity of about 0.1 uM or less. In another embodiment, the PI3K inhibitor is selected from the compounds in Table 1 having a PI3K-binding affinity of about 0.075 jiM or less. In another embodiment, the PI3K inhibitor is selected from the compounds in Table 1 having a PI3K-binding affinity of about 0.050 μΜ or less.

Biological Example 2

Phospho AKT assay

[00268] PC3 cells were seeded on 6- well plates at 150,000 cells/well. Cells were cultured for 3 days, then treated with compounds in serum-free medium for 3 hr. EGF (100 ng/ml) was added for the last 10 min. Cells were lysed in TENN buffer. Phospho T308 Akt and total Akt were quantified by ELISA performed according to the Biosource assay protocol. The readings of phospho Akt were normalized to total Akt readings.

Biological Example 3

Phospho S6 assay

[00269] PC3 cells were seeded on 96-well plates at 8,000 cells/well. For each experiment, cells were seeded and treated in duplicated plates: one plate for phospho S6 CellELISA, and one plate for total S6 CellELISA. Cells were cultured on the plates for 3 days, then treated with compounds in serum-free medium for 3 hr in triplicate. Cells were fixed with 4% formaldehyde, quenched with 0.6% H202, blocked with 5% BSA, incubated with either phospho S6 antibody or total S6 antibody overnight, incubated with goat-anti- rabbit-IgG-HRP for 1 hr, and developed in chemiluminescent substrate.

Biological Example 4

PIP₃ assay

[00270] MCF-7 cells grown in 10-cm dishes were starved for 3 hours in DMEM, and then treated with compounds for 20 minutes. In the last 2 minutes of the incubation with the compounds, EGF (100 ng ml) was added to stimulate the production of PIP3. The medium was aspirated and the cells were scraped with 10% trichloroacetic acid. The lipids were extracted from the pellet after the cell lysates were centrifuged. PIP3 in the cellular lipid extraction was quantified with the AlphaScreen [Registered TM of PerkinElmer] assay in which Grpl-PH is used as the ΡΓΡ3 specific probe. The amount of cellular ΡΓΡ3 was calculated from the standard curve of diC_¾ PI (3,4,5) P3. Biological Example 5-10

In vivo models

[00271] Female and male athymic nude mice (NCr) 5-8 weeks of age and weighing approximately 20 g were used in the following model. Prior to initiation of a study, the animals were allowed to acclimate for a minimum of 48 h. During these studies, animals were provided food and water ad libitum and housed in a room conditioned at 70-75°F and 60% relative humidity. A 12 h light and 12 h dark cycle was maintained with automatic timers. All animals were examined daily for compound-induced or tumor-related deaths.

[00272] PC-3 human prostate adenocarcinoma cells were cultured in vitro in DMEM (Mediatech) supplemented with 20% Fetal Bovine Serum (Hyclone),

Penicillin-Streptomycin and non-essential amino acids at 37°C in a humidified 5% C0₂ atmosphere. On day 0, cells were harvested by trypsinization and 3xl0⁶ cells (passage 13, 99% viability) in 0.1 mL of ice-cold Hank's balanced salt solution were implanted subcutaneously into the hindflank of 5-8 week old male nude mice. A transponder was implanted in each mouse for identification, and animals were monitored daily for clinical symptoms and survival. Body weights were recorded daily.

[00273] U-87 MG human glioblastoma cells were cultured in vitro in DMEM

(Mediatech) supplemented with 10% Fetal Bovine Serum (Hyclone),

Penicillin-Streptomycin and non-essential amino acids at 37°C in a humidified 5% C0₂ atmosphere. On day 0, cells were harvested by trypsinization and 2xl0⁶ cells (passage 5, 96% viability) in 0.1 mL of ice-cold Hank's balanced salt solution were implanted intradermally into the hindflank of 5-8 week old female nude mice. A transponder was implanted in each mouse for identification, and animals were monitored daily for clinical symptoms and survival. Body weights were recorded daily.

[00274] A549 human lung carcinoma cells were cultured in vitro in DMEM (Mediatech) supplemented with 10% Fetal Bovine Serum (Hyclone), Penicillin-Streptomycin and non-essential amino acids at 37°C in a humidified 5% C0₂ atmosphere. On day 0, cells were harvested by trypsinization and lOxlO⁶ cells (passage 12, 99% viability) in 0.1 mL of ice-cold Hank's balanced salt solution were implanted intradermally into the hindflank of 5-8 week old female nude mice. A transponder was implanted in each mouse for identification, and animals were monitored daily for clinical symptoms and survival. Body weights were recorded daily.

[00275] A2058 human melanoma cells were cultured in vitro in DMEM (Mediatech) supplemented with 10% Fetal Bovine Serum (Hyclone), Penicillin-Streptomycin and non-essential amino acids at 37°C in a humidified, 5% C0₂ atmosphere. On day 0, cells were harvested by trypsinization and 3xl0⁶ cells (passage 3, 95% viability) in 0.1 ml ice-cold Hank's balanced salt solution were implanted intradermally in the hind-flank of 5-8 week old female athymic nude mice. A transponder was implanted in each mouse for identification, and animals were monitored daily for clinical symptoms and survival. Body weights were recorded daily.

[00276] WM-266-4 human melanoma cells were cultured in vitro in DMEM (Mediatech) supplemented with 10% Fetal Bovine Serum (Hyclone), Penicillin-Streptomycin and non-essential amino acids at 37°C in a humidified, 5% C0₂ atmosphere. On day 0, cells were harvested by trypsinization and 3xl0⁶ cells (passage 5, 99% viability) in 0.1 ml ice-cold Hank's balanced salt solution were implanted intradermally in the hind-flank of 5-8 week old female athymic nude mice. A transponder was implanted in each mouse for identification, and animals were monitored daily for clinical symptoms and survival. Body weights were recorded daily.

[00277] For subcutaneous or intradermal tumors, the mean tumor weight of each animal in the respective control and treatment groups was determined twice weekly during the study. Tumor weight (TW) was determined by measuring perpendicular diameters with a caliper, using the following formula:

tumor weight (mg) = [tumor volume = length (mm) x width² (mm²)]/2

[00278] These data were recorded and plotted on a tumor weight vs. days

post-implantation line graph and presented graphically as an indication of tumor growth rates. Percent inhibition of tumor growth (TGI) is determined with the following formula:

where Xo = average TW of all tumors on group day X_f = TW of treated group on Day f

Y_f = TW of vehicle control group on Day f

If tumors regress below their starting sizes, then the percent tumor regression is determined with the following formula:

( Xo - Xf ) 100

Xo Tumor size is calculated individually for each tumor to obtain a mean ± SEM value for each experimental group. Statistical significance is determined using the 2-tailed Student's t-test (significance defined as P<0.05).

Pharmaceutical Composition Examples

[00279] The following are representative pharmaceutical formulations containing a compound of Formula I.

Tablet Formulation

[00280] The following ingredients are mixed intimately and pressed into single scored tablets.

Ingredient Quantity per tablet, mg

compound of this invention 400

Cornstarch 50

croscarmellose sodium 25

Lactose 120

magnesium stearate 5

Capsule Formulation

[00281] The following ingredients are mixed intimately and loaded into a hard-shell gelatin capsule.

Ingredient Quantity per tablet, mg

compound of this invention 200

lactose, spray-dried 148

magnesium stearate 2

Suspension Formulation

[00282] The following ingredients are mixed to form a suspension for oral administration.

Ingredient Amount

compound of this invention 1.0 g

fumaric acid 0.5 g

sodium chloride 2.0 g

methyl paraben 0.15 g

propyl paraben 0.05 g

granulated sugar 25.5 g

sorbitol (70% solution) 12.85 g

Veegum K (Vanderbilt Co.) 1.0 g Flavoring 0.035 mL

Colorings 0.5 mg

distilled water q.s. to lOO mL

Injectable Formulation

The following ingredients are mixed to form an injectable formulation.

Ingredient Amount

compound of this invention 1-2 g

sodium acetate buffer solution 0.4 M 2.0 mL

HC1 (1 N) or NaOH (l M) q.s. to suitable pH

water (distilled, sterile) q.s.to 20 mL

[00284] All of the above ingredients, except water, are combined and heated to 60- 70.degree. C. with stirring. A sufficient quantity of water at 60.degree. C. is then added with vigorous stirring to emulsify the ingredients, and water then added q.s. to 100 g.

Suppository Formulation

[00285] A suppository of total weight 2.5 g is prepared by mixing the compound of the invention with Witepsol.RTM. H-15 (triglycerides of saturated vegetable fatty acid; Riches- Nelson, Inc., New York), and has the following composition:

Ingredient Quantity per tablet, mg

compound of this invention 500

Witepsol^®H-15 balance

[00286] The foregoing invention has been described in some detail by way of illustration and example, for purposes of clarity and understanding. It will be obvious to one of skill in the art that changes and modifications may be practiced within the scope of the appended claims. Therefore, it is to be understood that the above description is intended to be illustrative and not restrictive. The scope of the invention should, therefore, be determined not with reference to the above description, but should instead be determined with reference to the following appended claims, along with the full scope of equivalents to which such claims are entitled. All patents, patent applications and publications cited in this application are hereby incorporated by reference in their entirety for all purposes to the same extent as if each individual patent, patent application or publication were so individually denoted.

Claims

What is claimed is:

1. A method for treating a disease, disorder, or syndrome which method comprises administering to a patient a pharmaceutical composition comprising a therapeutically effective amount of Compound A

or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition comprising a therapeutically effective amount of a Compound A and a pharmaceutically acceptable carrier, excipient, or diluent, in combination with another agent.

2. The method of claim 1 , wherein the disease is selected from anaplastic thyroid cancer, chronic lymphocytic leukemia, mantel cell lymphoma, non-Hodgkins lymphoma, glioblastoma multiforme, pediatric brain tumors, pontine glioma, HPV-related head and neck cancer, Hormone Receptive positve (HR+) breast cancer, and HER-2 overexpressing breast cancer.

The method of claim 1, wherein Compound A is adminstered in combination with more agents selected from:

Agent Name

ch 14.18

Decitabine (5-aza-2'-deoxycytidine)

E7389 (Halichondrin B Analog)

EMD 121974 (Cilengitide)

Entinostat (MS-275, SNDX-275)

FK228 (Depsipeptide; Romidepsin)

Flavopiridol (alvocidib)

GDC-0449 ***

IMC-A12

MDX-010 (MDX-CTLA4; Hybridoma- derived and Transfectoma-derived)

K-2206

O-6-Benzylguanine

Obatoclax mesylate (GX15-070MS)

OSI-906

Pertuzumab

Rl 15777 (tipifarnib, Zarnestra)

Reolysin

RO4929097

SB-715992 (ispinesib)

SCH727965

SJG-136

Thalidomide (Thalomid)

Triapine

UCN-01

VEGF-Trap (aflibercept)

Vorinostat (suberoylanilide hydroxamic acid; SAHA)

XK469R

17-AAG

17-DMAG

Alemtuzumab (Campath)

AZD2171 (cediranib; Recentin™)

AZD6244

BAY 43-9006 tosylate (BAY 54-9085; sorafenib tosylate)

Bevacizumab (rhuMAb VEGF, Avastin)

BMS-354825 (dasatinib, Sprycel)

CCI-779 (temsirolimus, Torisel)

Erlotinib (OSI-774; Tarceva)

Gefitinib (ZD 1839, Iressa)

GM-CSF (sargramostim, Leukine)

GW572016 (lapatinib)

GW786034 (pazopanib)

MLN 518

Oxalip atin (Eloxatin)

Perifosine

Rituximab (MoAb C2B8 anti CD20, Agent Name

chimeric)

STI571 (imatinib, Gleevec)

Sunitinib malate (SU01 1248 L-malate;

Sutent)

Trastuzumab (Herceptin)

4. The method of claim 3, wherein wherein Compound A is adminstered in combination with one or more agents selected from:

Agent Name

Triapine

UCN-01

VEGF-Trap (aflibercept)

Vorinostat (suberoylanilide hydroxamic

acid; SAHA)

XK469R

17-AAG

5. The method of claim 3, wherein wherein Compound A is adminstered in combination with one or more agents selected from ABT-888, AZD6244, CCI-779, erlotinib, gefitinib, GW572016, GW786034, pertuzumab, and sunitinib.

6. A tablet formulation of Compound A.

7. A capsule formulation of Compound A.